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Abstract
Aurora kinases play an essential role in orchestrating chromosome alignment,
segregation and cytokinesis during mitotic progression, with both aurora-A and B
frequently over-expressed in a variety of human malignancies including those of
leukaemic origin. Acute myeloid leukaemia (AML) is a heterogeneous clonal
disorder of haematopoietic progenitor cells whose prognosis is particularly poor
and where standard induction therapy has changed little over the past thirty years.
This thesis evaluated the effects of AZD1152-hQPA (barasertib-hQPA), a highly
selective inhibitor of aurora-B kinase, in AML cell lines and primary samples.
Inhibition of phospho-Histone H3 (pHH3) on serine 10 can be used as a biomarker
for AZD1152-hQPA activity and an assay was optimized to measure pHH3 in our
cell lines and primary samples. AZD1152-hQPA inhibited pHH3 in our cell lines
resulting in polyploid cells, apoptosis, and cell death, irrespective of cellular p53
status.
Over-expression of the ATP-binding cassette (ABC) drug transporter proteins P-
glycoprotein (Pgp) and Breast cancer resistance protein (BCRP) is a major
obstacle for chemotherapy in many tumour types with Pgp conferring particularly
poor prognosis in AML. A cell line which over-expresses Pgp was developed by
selecting for daunorubicin (DNR) resistance in OCI-AML3 cells. Pgp and also
BCRP expressing AML cell lines were found to be resistant to AZD1152-hQPA
and it was found that AZD1152-hQPA is effluxed by these transporters. pHH3
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inhibition by low dose AZD1152-hQPA was seen in all of the primary samples
tested with Pgp and BCRP positive samples being less sensitive. However, 50%
inhibition of pHH3 by AZD1152-hQPA was achieved in 94.6% of these samples.
The FLT3-ITD-expressing MOLM-13 and MV4-11 cell lines were particularly
sensitive to AZD1152-hQPA. Internal tandem duplications (ITDs) within the
FLT3 tyrosine kinase receptor are found in approximately 25% of AML patients
and are associated with a poor prognosis. It was demonstrated that AZD1152-
hQPA directly targets phosphorylated FLT3 in the FLT3-ITD cell lines along with
inhibiting its downstream target pSTAT5. FLT3-ITD primary samples were
particularly sensitive to clonogenic inhibition and pSTAT5 down-regulation after
treatment with AZD1152-hQPA compared with FLT3 wild-type (WT) samples.
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1.1 Background
The global burden of cancer continues to increase largely because of the aging and
growth of the world population alongside an increasing adoption of cancer-causing
behaviors, particularly smoking, in economically developing countries. In the
developed world cancer is considered as one of the leading causes of death, second
only to circulatory disorders such as heart disease and strokes, and is therefore a
major burden on public health services in these countries. Statistics from Europe in
2008 show there were an estimated 3.2 million new cases of cancer and 1.7 million
deaths (Ferlay et al., 2010). The most common cancers were colorectal cancers
(436,000 cases, 13.6% of the total), breast cancer (421,000, 13.1%), lung cancer
(391,000, 12.2%) and prostate cancer (382,000, 11.9%). The most common causes
of death from cancer were lung cancer (342,000 deaths, 19.9% of the total),
colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and
stomach cancer (117,000, 6.8%) (Ferlay et al., 2010). Cancer is considered an age-
dependent disease, with 64% of all cases occurring in patients aged 65 or over and
approximately 76% of all cancer mortalities occurring in patients from the same
age group (Jemal et al., 2010). The overall risk of an individual developing cancer
during their lifetime is one in three. For patients under the age of 50 however, this
risk is reduced to 1 in 27 (Ferlay et al., 2010). In the United States in 2010, there
are projected to be a total of 1,529,560 new cancer cases, and 569,490 deaths from
cancer (Jemal et al., 2010). Leukaemia ranks ninth in the list of most prevalent
cancers diagnosed, with 43,050 new cases estimated in 2010, with incidence and
mortality greater in males than females (Jemal et al., 2010). Approximately 29%
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Table 1.1 – Estimated new leukaemia cases and deaths, United States, 2010. (Data
from Jemal et al Ca Cancer J Clin 2010.)
ESTIMATED NEW CASES ESTIMATED DEATHS
Both
Sexes
Male Female Both
Sexes
Male Female
Leukaemia 43,050 24,690 18,360 21,840 12,660 9,180
Acute lymphocytic leukaemia 5,330 3,150 2,180 1,420 790 630
Chronic lymphocytic
leukaemia
14,990 8,870 6,120 4,390 2,650 1,740
Acute myeloid leukaemia 12,330 6,590 5,740 8,950 5,280 3,670
Chronic myeloid leukaemia 4,870 2,800 2,070 440 190 250
Other leukaemia 5,530 3,280 2,250 6,640 3,750 2,890
of these new cases will be acute myeloid leukaemia (AML) (Table 1.1). In
children ages birth to 14, leukaemia, particularly acute lymphocytic leukaemia, is
the commonest form of cancer and accounts for nearly one-third of the cases
diagnosed (Jemal et al., 2010).
1.2 Leukaemia
The term leukaemia comes from the Greek words for "white" (leukos) and "blood"
(haima) and is a broad term covering a spectrum of malignant diseases of the
blood and bone marrow. Unlike other cancers, leukaemia does not produce a
tumour mass, but results in a clonal, neoplastic over-proliferation of immature
cells of the haematopoietic system, which are characterized by aberrant or arrested
differentiation. Leukaemia is classified into four main types, acute and chronic
leukaemias, which are further subdivided by their lineage into lymphoid or
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myeloid. Acute leukaemias are usually aggressive diseases characterized by a
rapid accumulation of bone marrow progenitors called blast cells. They are
subdivided into AML and acute lymphoblastic leukaemia (ALL) depending on
whether the blasts are shown to be myeloblasts or lymphoblasts (Hoffbrand,
2006). Bone marrow failure, caused by accumulation of blast cells, and tissue
infiltration are the dominant clinical features of acute leukaemia, which if left
untreated is fairly rapidly fatal (Hoffbrand, 2006).
Chronic leukaemias are distinguished from acute leukaemias by their slower
progression. Again chronic leukaemia can be subdivided into myeloid (chronic
myeloid leukaemia; CML) and lymphoid (chronic lymphoid leukaemia; CLL)
groups. Typically taking months or years to progress, they are characterized by the
excessive build up of relatively mature, but still abnormal, white blood cells
(Hoffbrand, 2006).
1.3 Acute myeloid leukaemia
AML is a heterogeneous clonal disorder of haematopoietic progenitor cells where
cells lose the ability to differentiate normally, and to respond to normal regulators
of proliferation, resulting in accumulation of non-functional cells termed
myeloblasts (Stone et al., 2004). In the absence of treatment this can lead to fatal
infection, bleeding, or organ infiltration. AML can be diagnosed and classified
using the World Health Organisation (WHO) system, which supersedes the
previous French-American-British (FAB) classification (Table 1.2). The FAB
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Table 1.2 – Acute myeloid leukaemia and related precursor neoplasms, and acute
leukaemias of ambiguous lineage (WHO 2008). (From (Dohner et al., 2010)).
CATEGORIES
Acute myeloid leukaemia with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p22;q23); MLLT3-MLL
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
Acute myeloid leukaemia with myelodysplasia-related changes
Therapy-related myeloid neoplasms
Acute myeloid leukaemia, not otherwise specified (NOS)
Acute myeloid leukaemia with minimal differentiation
Acute myeloid leukaemia without maturation
Acute myeloid leukaemia with maturation
Acute myelomonocytic leukaemia
Acute monoblastic/monocytic leukaemia
Acute erythroid leukaemia
Pure erythroid leukaemia
Erythroleukaemia, erythroid/myeloid
Acute megakaryoblastic leukaemia
Acute basophilic leukaemia
Acute panmyelosis with myelofibrosis (syn.: acute myelofibrosis; acute myelosclerosis)
Myeloid sarcoma (syn.: extramedullary myeloid tumour; granulocytic sarcoma;
chloroma)
Myeloid proliferations related to Down syndrome
Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder)
Myeloid leukaemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukaemias of ambiguous lineage
Acute undifferentiated leukaemia
Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1
Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged
Mixed phenotype acute leukaemia, B/myeloid, NOS
Mixed phenotype acute leukaemia, T/myeloid, NOS
Provisional entity: Natural killer–cell lymphoblastic leukaemia/lymphoma
system classified AML by morphology but was relatively poor information in that
only a few subtypes, such as acute promyelocytic leukaemia (APL), could be
distinguished as having a distinct prognosis. Over the past 20 years, conventional
cytogenetic, flow cytometry, fluorescence in situ hybdidization, DNA sequencing,
and PCR have more precisely defined prognostically important subsets of AML.
M.Grundy
6
The WHO classification reflects the fact that an increasing number of acute
leukaemias can be categorized based upon their underlying cytogenetic or
molecular genetic abnormalities and recognizing these recurring genetic lesions
has prompted development of novel therapies to target them (Dohner et al., 2010).
AML is the most common myeloid leukaemia with a prevalence of 3.8 cases per
100,000 rising to 17.9 cases per 100,000 in adults aged 65 years and older. The
median age at presentation is about 70 years, and three men are affected for every
two women. Risk factors for acquiring AML include exposure to ionizing
radiation, benzene (most commonly through smoking) and cytotoxic
chemotherapy (Estey, 2006).
In terms of prognosis, there are a number of factors readily identifiable after
presentation that can be used to predict the risk of relapse in newly diagnosed
patients with AML. The most important are age, karyotype, FMS-like tyrosine
kinase (FLT3) status and response to induction chemotherapy. Age is one of the
strongest adverse prognostic factors in AML, with investigators defining cutoffs of
60 or 65 years beyond which the outcome is worse (Ravandi et al., 2007). This is
partly reflected by the higher proportion of cases with adverse cytogenetics and/or
overexpression of the MDR1 gene encoding the drug efflux pump P-glycoprotein
which leads to multidrug resistance in elderly patients (Leith et al., 1997). In
addition, older patients often do not tolerate chemotherapy and frequently present
with intercurrent medical conditions that are exacerbated by standard
antileukaemic treatment. Chromosomal abnormalities are detected in
approximately 55% of adult AML, and the importance of diagnostic cytogenetics
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Table 1.3 – Standardized reporting for correlation of cytogenetic and molecular
genetic data. (From Dohner et al Blood 2010, 115:453-474)
GENETIC GROUP SUBSETS
Favourable t(8;21)(q22;q22); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD (normal karyotype)
Mutated CEBPA (normal karyotype)
Intermediate-I Mutated NPM1 and FLT3-ITD (normal karyotype)
Wild-type NPM1 and FLT3-ITD (normal karyotype)
Wild-type NPM1 without FLT3-ITD (normal karyotype)
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL
Cytogenetic abnormalities not classified as favourable or adverse
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
t(6;9)(p23;q34); DEK-NUP214
t(v;11)(v;q23); MLL rearranged
íRUGHOTíDEQOSFRPSOH[NDU\RW\SH
as an independent prognostic factor in AML, was first highlighted by Grimwade et
al (Grimwade et al., 1998). They categorized patients into favourable,
intermediate, or poor prognostic groups depending on the presence of specific
cytogenetic abnormalities (Grimwade et al., 1998). More recently cytogenetic
examination at diagnosis has allowed patients to be stratified into four prognostic
groups with relapse risks varying from 35% (favourable) to 76% (adverse)
(Milligan et al., 2006). Anomalies associated with the favourable prognostic group
are more frequent in patients less than 60 years old whilst patients in the poor
prognosis group tend to be older and may have a preceding myelodysplastic or
myeloproliferative disorder (Dohner et al., 2010). The intermediate prognostic
groups encompass 50-60% of patients with AML and include patients with
specific chromosomal anomalies, such as trisomy 8 or 21, as well as normal
karyotype (NK), characterized by a variety of molecular abnormalities. Along with
cytogenetic data these groups have recently been updated to include information
from mutation analysis of the FLT3, NPM1, and CEBPA genes (Table 1.3)
(Dohner et al., 2010). Internal tandem duplications (ITDs) of FLT3 are present in
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25% to 30% of all AML patients (Kottaridis et al., 2001). They predict an
increased risk of relapse across all cytogenetic subgroups and will be discussed
further in section 1.4. A favourable prognostic factor is the presence of a
nucleophosmin (NPM1) mutation which is associated with a higher complete
remission (CR) and longer survival. NPM1 gene disruptions are seen in
approximately 35% to 50% of patients with AML, particularly those with NK, and
have been associated with FLT3 mutations (Cazzaniga et al., 2005; Ravandi et al.,
2007). When NPM and FLT3 mutations are co-expressed the negative influence of
the FLT3 mutation overcomes the benefit of NPM mutations on survival
(Schnittger et al., 2005). Mutations in the transcription factor CCAAT/enhancer-
ELQGLQJSURWHLQĮ&(%3$JHQHRFFXULQDERXWRI1.$0/5DYDQGL et al.,
2007). They are also associated with a favourable prognosis, particularly in
patients with double mutations and without a FLT3-ITD (Ravandi et al., 2007).
The prognostic effect of FLT3-ITD, NPM1 and CEBPA status on outcome,
particularly in NK AML, suggests that screening for these mutations should be
done routinely in newly diagnosed AML. The presence of c-kit mutations in AML
patients with the favourable risk cytogenetic markers, inv(16) and t(8;21), confers
higher relapse and worse overall survival rates (Paschka et al., 2006).
Approximately 85% of patients with NK AML have a mutation although the
prognostic significance of some of these is unclear (Marcucci et al., 2011).
Adverse outcome has been associated with over-expression of a number of other
genes including DNMT3A, IDH1, IDH2, TET2, WT1 and EVI1 (Milligan et al.,
2006; Ley et al., 2010; Shen et al., 2011). Mutations in DNA methyltransferase 3a
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(DNMT3a) occur in 25-35% of NK AML and are associated with mutations in
NPM1 and FLT3-ITD (Thol et al 2011). The clinical significance of mutations in
IDH1 and TET2 have been reported to be context dependent with their prognosis
depending on association with FLT3-ITD, or NPM1 and CEBPA respectively
(Estey, 2012).
1.4 FMS-like tyrosine kinase 3
FLT3 is a class 3 tyrosine kinase membrane bound receptor which is expressed
primarily in early haematopoietic progenitors and plays a major role in myeloid
differentiation (Gilliland, 2002). It is composed of an immunoglobulin-like
extracellular ligand binding domain, a transmembrane domain, a juxtamembrane
dimerization domain, and a highly conserved intracellular kinase domain
interrupted by a kinase insert (Figure 1.1). Binding of FLT ligand (FL) to FLT3
results in the unfolding of the receptor allowing receptor-receptor dimerization to
take place (Meshinchi, 2009). This receptor dimerization results in activation of
the tyrosine kinase enzyme leading to phosphorylation of numerous intracellular
sites and recruitment of a number of cytoplasmic proteins (Figure1.1).
The ITD mutation of FLT3 is a result of duplication of a fragment within the
juxtamembrane coding region encoded by exons 14 and 15 (Nakao et al., 1996).
The mutation results in spontaneous dimerization, and enzyme activation, without
the need for ligand binding, conferring growth-factor independence to AML cells.
Consequently, the ITD mutation constitutionally activates multiple downstream
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signalling pathways, including PI3K/AKT, MAPK and STAT resulting in
leukaemic cell survival and proliferation (Figure 1.1) (Gilliland, 2002; Meshinchi,
2009). In contrast to FLT3-ITD, the FLT3-WT receptor requires FL induced
activation to phosphorylate STAT5 during normal haematopoiesis (Zhang et al.,
2000; Choudhary et al., 2007). FLT3-ITD mutations are associated with a higher
diagnostic white cell count, lower remission rate, higher relapse rate, and worse
survival (Kottaridis et al., 2001). The presence of an ITD in conjunction with loss
of the second wild-type FLT3 allele confers a particularly poor prognosis
(Kottaridis et al., 2001). A study that sorted primary AML samples into stem cell
enriched CD34+/CD38- fractions found that FLT3-ITD mutations are present in
leukaemia stem cells and that FLT3 inhibitors may have activity against these cells
(Levis et al., 2005). Another FLT3 mutation is the FLT3 activation loop mutation
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membrane
Intracellular
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AT
FLT3 signal transduction pathway
ECD
Figure 1.1 FLT3 receptor monomer is composed of an extracellular domain (ECD), a trans-membrane
domain (TMD), a juxtamembrane domain (JMD), and a tyrosine kinase domain (TKD). Binding to FLT3
ligand leads to receptor dimerization and activation of the intracellular kinase. Adapted from Meshinchi
et al Clin Cancer Res 2009;15(13).
FL FL FL
TMD
JMD
TKD
ST
AT
H
SP
90
FL FL
PIP2 PIP3
AKT
P
ST
AT
ST
AT
P P
PP
H
SP
90
M
AP
K
P
AKT
P
FHKR BAD1)ț%MDM2
mTOR
p53
H
SP
90
Cell growthApoptosis
Cell survival, proliferation, differentiation Cell cycle arrest, DNA repair, Apoptosis
JAK
SHC
PI3K
GRB2
RAS
M.Grundy
11
(ALM) (also known as a tyrosine kinase domain point mutation) which occurs in
about 7% of AML patients. The majority of ALMs occur in codons 835 with a
change of an aspartic acid to tyrosine (Meshinchi, 2009). The presence of FLT-
ALMs and FLT3-ITDs are generally mutually exclusive and FLT3-ALMs are not
associated with higher diagnostic white cell count or adverse outcome (Meshinchi,
2009). Recent evidence shows that in contrast to FLT3-ALMs, FLT3-ITDs use the
Src family kinase SRC to activate STAT5 (Leischner et al., 2012). Therefore,
although FLT3-ALMs promote auto-phosphorylation, and FL independent
proliferation, similar to FLT3-ITDs, there are different biological responses
between the two mutations due to activation of different downstream effectors
(Meshinchi, 2009).
1.5 ABC binding cassette transporters
The development of multidrug resistance (MDR) is frequently observed in the
treatment of cancer, and is a phenomenon that allows tumour cells that have been
exposed to one cytotoxic agent to develop cross resistance to a range of
structurally and functionally unrelated compounds. Cells exposed to toxic agents
can develop resistance by a number of mechanisms including decreased uptake,
accelerated detoxification, defective apoptosis pathways, or increased efflux which
lowers the effective drug concentration inside the cell (Gottesman et al., 2002).
ATP-binding cassette (ABC) transporter-mediated active efflux of cytotoxic
agents is the most characterized mechanism by which cancer cells develop MDR,
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particularly after repeated cycles of chemotherapy (Gottesman et al., 2002). The
ABC transporters are an evolutionary extremely well conserved family of
transmembrane proteins expressed in most cells and involved in the ATP driven
transport of a huge variety of substrates including sugars, peptides, inorganic ions,
amino acids, proteins, vitamins and metallic ions (Schinkel, 2003). The family
currently consists of 49 members, 13 of which are associated with
chemotherapeutical drug transport and drug resistance (De Jonge-Peeters et al.,
2007). The genes can be divided into subfamilies based on similarity in gene
structure resulting in seven mammalian ABC gene subfamilies (ABCA, B, C, D, E
F and G family). The most widely studied members ABCB1 (MDR1/P-
glycoprotein), ABCC1 (multidrug resistance-associated protein 1, MRP1) and
ABCG2 (breast cancer resistance protein, BCRP) have the ability to export a wide
variety of structurally unrelated chemotherapeutic compounds from cancer cells,
thereby conferring MDR to these cells (Schinkel, 2003).
Permeability-glycoprotein (Pgp) was the first ABC transporter to be characterized,
discovered by Ling and co-workers in multidrug resistant Chinese hamster ovary
Extracellular
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ABC ABC
N-terminus
C-terminus
P-glycoprotein structure
Glycosylation site
ATP binding site ATP binding site
Figure 1.2 The basic structure of P-glycoprotein consisting of two similar six transmembrane spanning
regions and two intracellular binding sites.
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cells (Juliano, 1976). Pgp, the product of the MDR1 (ABCB1) gene, is a 170 kDa
polypeptide consisting of two very similar halves, each containing 6
transmembrane segments, and an intracellular binding site (Figure 1.2). MRP1 has
the same overall architecture as Pgp but has an additional N-terminal extension
consisting of 5 transmembrane segments (Figure 1.3). BCRP is considered a half
transporter as it consists of only one nucleotide binding domain (NBD) and 6
transmembrane segments (Figure 1.4) (Schinkel, 2003). Also, in contrast to Pgp
and MRP1, the NBD of BCRP is at the amino terminal end of the polypeptide
(Schinkel, 2003).
Pgp is normally expressed in the intestine, blood-brain barrier, kidney, liver, testes,
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ATP binding site ATP binding site
Figure 1.3 The basic structure of multidrug resistance-associated protein 1 (MRP1) consisting of three transmembrane
spanning regions and two intracellular binding sites.
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Figure 1.4 The basic structure of breast cancer resistance protein consisting of one six transmembrane
spanning region and one intracellular binding site.
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placenta and in healthy haematopoietic stem cells (Szakacs et al., 2006). The
transmembrane domains of Pgp interact with neutral and positively charged
hydrophobic substrates, which are then effluxed by hydrolysis of ATP, thus
conferring resistance against a wide spectrum of chemically diverse compounds.
These compounds include not only anticancer drugs such as vinca alkaloids,
anthracyclines and taxol, but also therapeutic agents such as HIV protease
inhibitors and many other exogenous compounds such as rhodamine 123 (R123)
(Table 1.4) (Ambudkar et al., 1999). The latter compound has been used
extensively in marker assays of Pgp function in normal and cancerous human cells
(Pallis, 2005). Also, in addition to drug efflux, Pgp has been reported to play a role
in mediating drug independent resistance to apoptosis in AML blasts (Pallis et al.,
2002). This resistance is thought to occur due to the physiological role of Pgp as a
lipid translocase, which enables it to modulate ceramide mediated apoptotic
Table 1.4 – Selected substrates of P-glycoprotein. (Adapted from (Ambudkar et
al., 1999)).
Anticancer Drugs Vinca Alkaloids (Vincristine, Vinblastine)
Anthracyclines (Doxorubicin, Daunorubicin, Epirubicin)
Epipodophyllotoxins (Etoposide, Teniposide)
Paclitaxel (Taxol)
Actinomycin D
Topotecan
Mylotarg
Imatinib
Other cytotoxic agents Colchicine
Ethidium bromide
Puromycin
Cyclic and linear peptides Gramicidin D
Valinomycin
HIV protease inhibitors Ritonavir
Idinavir
Saquinavir
Other compounds Rhodamine 123
Hoechst 33342
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pathways (Pallis et al., 2002). MRP1 is found on both the plasma membrane and
on membranes of intracellular compartments and has very similar substrates to
Pgp although its transport activity is dependent on the presence of glutathione (De
Jonge-Peeters et al., 2007). BCRP is the more recently discovered ABC transporter
that has been shown to play a role in multidrug resistance (Doyle et al., 1998).
BCRP is also a drug efflux pump which is associated with mitoxantrone and
anthracycline resistance along with substrates including flavopiridol and
camptothecin derivatives (Mao, 2005).
In vitro experiments with AML cells were amongst the first to establish the
concept of tumour stem cells. In these studies, it was demonstrated that a small
proportion of undifferentiated cells were able to reconstitute the tumour when
injected into non-obese diabetic with severe combined immunodeficiency disease
(NOD/SCID) mice. Along with potent tumour initiation, these cells also showed
both self-renewal and differentiation capacity (Bonnet, 1997). A study of 58 AML
patients found higher Pgp and MRP functional activities in less mature cells, as
defined by immune phenotype, with no consistent up-regulation in relapsed AML
(Van Der Kolk et al., 2001). In a smaller study by our group no difference in Pgp
protein levels between immature CD34+/CD38- and mature CD34+/CD38+
primary samples was observed (Jawad et al., 2009). A more recent gene
expression profiling study in patient samples showed that Pgp and BCRP were
preferentially expressed on CD34+/CD38- normal and leukaemic stem cells with
subsequent down-regulation upon differentiation to a more mature CD34+/CD38+
phenotype (De Grouw et al., 2006). Also, in contrast to the more mature cells,
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standard chemotherapeutic, and Pgp substrate, daunorubicin (DNR) (Costello et
al., 2000). A recent study in CML cell lines reported that the promoter regions of
the ABCB1, ABCG2 and ABCC1 genes contain binding sites for the Octamer-4
(Oct-4) transcription factor. Oct-4 is considered a marker of tumour stem cells and
their findings suggest that Oct-4 can regulate the expression of these ABC
transporters and that this is associated with the MDR phenotype of these cells
(Marques et al., 2010).
Normal human haemopoietic stem cells (HSCs) and leukaemic stem cells (LSCs)
are characterized by their ability to efflux the fluorescent dyes R123 and Hoechst
33342. Hoechst 33342-dull/R123-dull cells are a highly enriched stem cell fraction
called the side population (SP). Although both Pgp and BCRP have the capacity to
extrude Hoechst 33342, it has been established that this SP phenotype of HSCs in
mice is mainly conferred by the BCRP transporter with Pgp responsible for the
extrusion of R123 (Raaijmakers, 2007).
As well as multidrug resistance ABC transporters are known to play an important
role in the regulation of cellular cholesterol homeostasis (Gottesman, 2001). AML
cells, in contrast to normal mononuclear cells, often do not show efficient
feedback repression of cholesterol synthesis when exposed to high sterol media in
vitro, a feature that is associated with an increased cell survival (De Jonge-Peeters
et al., 2007). Also, indications for an active and dysfunctional cholesterol
metabolism have been found at the mRNA level in primitive CD34+ CD38- AML
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cells, protecting these cells by this critical cytoprotective lipid signalling pathway
(Peeters et al., 2006). It has therefore been suggested that a better understanding of
ABC transporter mediated drug resistance and cholesterol metabolism in the
primitive leukaemic cell population might lead to new therapeutic approaches and
better antileukaemic strategies (De Jonge-Peeters et al., 2007).
1.5.i ABC transporters in AML
Despite improvements accomplished in the last thirty years with the use of a
combination of cytarabine and intercalating agents, the overall prognosis of adult
AML remains poor (Lowenberg et al., 2003). A major issue in the treatment of
AML is MDR to chemotherapeutic drugs (Benderra et al., 2004; Damiani et al.,
2006). In patients with AML, MDR can be present intrinsically at diagnosis or can
arise during chemotherapy as well as at relapse. One of the most characterized
resistance mechanisms in AML is drug extrusion mediated by Pgp. Expression of
the MDR1 gene coding for Pgp is high in elderly patients with AML and is
associated with worse complete remission rates (Leith et al., 1997). Pgp protein is
expressed in 47% of elderly AML cases; (Burnett et al., 2009) compared to 34% in
younger patients (Pallis et al., 2011) and is involved in the transport of many drugs
used in the treatment of AML, including anthracyclines, etoposide and Mylotarg
(Szakacs et al., 2006). A study of 817 patients entered into the National Cancer
Research Network AML 14 and 15 trials found that age, low white blood cell
(WBC) count, high bcl-2, secondary AML and myelodysplastic syndrome, and
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adverse cytogenetics all correlated strongly with high Pgp protein expression
(Seedhouse et al., 2007).
BCRP has been shown to be overexpressed in 33% of AML patients with NK and
to significantly reduce the duration of CR (Damiani et al., 2006). In a study of 40
AML patients, high ABCG2 mRNA expression was a prognostic factor for poor
overall survival (OS) (Uggla et al., 2005). Another study showed BCRP
expression to be a poor prognostic factor for CR and OS in 149 AML patients
treated with DNR and mitoxantrone but not with idarubicin (Benderra et al.,
2004). This group also reported that AML patients co-expressing both Pgp and
BCRP had the poorest prognosis. The contribution of MRP1 to MDR in AML is
more controversial. One study of 352 younger AML patients found MRP1 to be
expressed in 10% of cases but found no relationship between MRP1 expression
and clinical outcome (Leith et al., 1999). Another study of 91 AML patients found
no association between MRP1 expression and response to chemotherapy or OS
(Borg et al., 1998). A further study of 104 AML patients found MRP1 functional
expression not to be prognostic in its own right but combined expression of MRP1
and Pgp had a strong negative impact on response and OS (Van Der Kolk et al.,
2000). Damiani et al also found that MRP1 expression alone did not influence
treatment outcome, but patients over-expressing more than one MDR protein had a
lower probability to achieve CR, as if there was an additive effect (Damiani et al.,
2007).
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Inhibiting Pgp as a way of reversing MDR has been intensively studied for more
than 20 years. Many agents that modulate the function of Pgp have been identified,
including calcium channel blockers, calmodulin antagonists, steroidal agents,
immunosuppressive drugs and antibiotics (Thomas, 2003). However, despite
promising theories, treatment results with first generation Pgp inhibitors such as
verapamil, cyclosporine A (CSA) and quinidine were poor with only CSA
showing any real clinical benefit in AML patients (List et al., 2001). These
disappointing results could be attributed to the low binding affinity and therefore
the high dosage leading to unacceptable toxicity with these compounds. Also
many of these agents are substrates for other transporters and enzyme systems
resulting in unpredictable pharmacokinetic interactions in the presence of
chemotherapy agents (Qadir et al., 2005).
To overcome these limitations, several novel analogues of the early
chemosensitizers were tested and developed, with the aim of finding Pgp
modulators with less toxicity and greater potency. These second generation Pgp
modulators include valspodar (PSC-833) and biricodar (VX-710) and are more
potent and less toxic than their predecessors (Thomas, 2003). PSC-833 is a CSA
analogue that does not have the immunosuppressive or nephrotoxic effect of CSA
and is 20 times more potent than CSA in increasing DNR retention in MDR cells
(Boesch et al., 1991). The cancer and leukaemia group B (CALGB) investigators
randomized 120 elderly patients with AML to receive 1 of 2 chemotherapy
regimens with PSC-833. Unfortunately the excessive mortality rates in one arm of
this trial led to its early closure (Baer et al., 2002). Another study comparing
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mitoxantrone, etoposide and cytarabine with or without PSC-833 in poor risk
AML patients showed no benefit in using PSC-833 compared to chemotherapy
alone (Greenberg et al., 2004). Also, results from the LRF AML14 trial reported
no improvement in outcome when combining PSC-833 with DNR in elderly
patients with AML and high-risk MDS (Burnett et al., 2009). Although PSC-833 is
an efficient Pgp inhibitor, it does have the complication that it is also an inhibitor
of cytochrome P450 3A4 (CYP3A4), one of the main drug metabolizing enzymes
in the body (Thomas, 2003). Many antileukaemic drugs that are Pgp substrates,
such as etoposide and doxorubicin, are also extensively degraded by CYP3A4.
Therefore, co-administration with PSC-833 can intensify the toxic side effects of
these drugs, necessitating a dose reduction for safe treatment. Third generation
molecules that potently and specifically inhibit Pgp and do not affect CYP3A4
have been developed including Elacridar (GF120918), tariquidar (XR9576) and
zosuquidar (LY335979) which are being tested in clinical trials (Abraham et al.,
2009; Lancet et al., 2009). In a Phase I study, zosuquidar was well tolerated given
as a 72-hour intravenous infusion together with induction therapy using cytarabine
(Ara-c) and DNR and the recommended dose of this agent for Phase II study was
established (Lancet et al., 2009). However a phase II randomized trial of 449
elderly AML or high-risk MDS patients found no benefit of zosuquidar when
given in combination with Ara-c and DNR (Cripe et al., 2010). It is hoped that pre-
selection of patients with Pgp-positive AML, by phenotyping at diagnosis, would
target those who are most likely to benefit from any future modulator trials.
Increased toxicity in Pgp negative patients could be masking any positive effects
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in Pgp positive patients in the early modulator trials without any pre-selection
criteria (Mahadevan, 2004).
More recently, newly developed microarray techniques, have enabled detection of
another ABC transporter, ABCA3, as a possible cause for drug resistance in
childhood AML (Steinbach et al., 2006). ABCA3 is a novel intracellular
transporter that is thought to confer cellular MDR by lysosomal drug sequestration
(Chapuy et al., 2008). In another study in adult AML patients, ABCC3 (MRP3)
was identified to have a possible role in chemoresistance, particularly in the M5
FAB AML subtype (Benderra et al., 2005). A study of 281 AML patients recently
demonstrated that the number of ABC transporters over-expressed had a profound
effect on the patient’s prognosis (Marzac et al., 2011). In this study complete
remission was achieved in 71%, 59%, 54% and 0% of patients over-expressing 0,
1, 2, or 3, ABC genes respectively. This could be a possible explanation as to why
only the broad spectrum inhibitor CSA showed any real clinical benefit in AML
patients compared to inhibitors such as PSC833 which are tailored against a
specific ABC transporter.
1.5.ii Analytical methods for measuring MDR in AML
There are several methods available to measure MDR1/ABCB1 expression in
AML samples; although they do not necessarily produce comparable results
(Sonneveld, 2001). Generally, bulk methods such as mRNA PCR or Northern blot
are not suitable for quantitative differences of MDR1 expression in subpopulations
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of AML cells with certain morphologies, and with these assays, it is not possible to
correlate MDR1 expression with maturation or differentiation markers (Sonneveld,
2001). Therefore, most investigators prefer to determine MDR1 expression at the
protein level (Pgp). Pgp specific antibodies such as C219 and JSB1 have been used
in immunocytochemistry, but these assays are not highly reproducible and they are
not quantitative (Lizard et al., 1995). Flow cytometry however, can be used to
determine Pgp expression in viable cells using monoclonal antibodies such as
MRK16 and UIC2, which bind to an extracellular epitope. The reactivity of the
UIC2 antibody with Pgp is increased by the addition of Pgp transported
compounds and is useful in the identification of Pgp substrates (Mechetner et al.,
1997). MRK16 is a monoclonal antibody generated against the human
myelogenous leukaemia K-562 cells resistant to adriamycin (K-562/ADM) and
this is the antibody of choice for quantifying Pgp in AML cells (Hamada, 1986).
Along with allowing the detection of Pgp in different subsets of cells, this
technique requires a limited amount of time and cellular material, particularly
important as Pgp expression is associated with low cell counts (Pallis et al., 2003b;
Seedhouse et al., 2007). This flow cytometric method is established and
reproducible within our group using CD45 staining to identify AML blasts (Pallis,
2005; Pallis et al., 2005).
It has been reported that a combination of phenotypic and functional Pgp analysis
may predict clinical outcome in AML (Schuurhuis et al., 1995; Broxterman et al.,
1996). R123 retention has been comprehensively studied as a method for
assessment of Pgp function and good correlation has been shown between R123
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efflux and MRK-16 expression (Broxterman et al., 1996). Again, this flow
cytometric method is established and reproducible within our group using CSA or
PSC-833 as a positive control modulator (Pallis, 2005; Pallis et al., 2005). Using
such a functional assay the effect of Pgp inhibition by a drug-resistance
modulating agent can also be evaluated.
Functional assays to determine BCRP function have been described using
BODIPY-prazosin retention and Fumitremorgin C (FTC) as the positive control
modulator (Van Der Kolk et al., 2000; Van Der Pol et al., 2003). We intend to use
this flow cytometric method to measure BCRP function in our cell lines. There is
some discordance in the literature between BCRP protein expression and function
in AML blasts (Suvannasankha et al., 2004). We were not convinced that existing
antibodies for BCRP, such as BXP-21 and BXP-34, were sufficiently
characterized, and decided to measure BCRP (ABCG2) message by realtime PCR
in our patient samples. High ABCG2 mRNA expression has been reported to be a
poor prognostic factor for overall OS in AML patients (Uggla et al., 2005).
As described in section 1.5.i the contribution of MRP1 to MDR in AML is more
controversial. Functional MRP can be studied by flow cytometry with calcein
acetoxymethyl ester (calcein-AM) or carboxyfluorescein diacetate retention with
MK-571 as a positive control modulator (Gekeler et al., 1995; Dogan et al., 2004).
However, data from such functional studies in AML patients is contradictory. For
example, one study found that MRP function correlated with low CR and poor OS
(Laupeze et al., 2002), whilst another found MRP function not to be prognostic in
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its own right but the combination of MRP and PGP efflux to be highly prognostic
(Van Der Kolk et al., 2000). Because of this and the lack of sufficiently
characterized antibodies we decided not to measure MRP expression in our patient
samples.
1.6 Therapy in AML
Intrinsic resistance or treatment-induced acquired resistance is one of the major
obstacles to the effective treatment of patients with AML. Although nearly 80% of
younger AML patients may initially achieve complete remission with current
therapy most will relapse with resistant disease (Lowenberg et al., 2003). Clinical
outcomes in the elderly have been even more modest as these patients do not tend
to tolerate intensive chemotherapy regimens and frequently have poor cytogenetics
(Leith et al., 1997). Less than 10% of older patients with AML will achieve long-
term disease free survival with conventional chemotherapy (Appelbaum et al.,
2001). This inability to successfully treat AML patients, particularly the elderly,
underlies the continuing need to develop new treatments for AML. During recent
years, considerable progress has been made in deciphering the molecular genetic
basis of AML in defining new diagnostic and prognostic markers. Such
developments prompted an international expert panel to provide recommendations
for the diagnosis and management of AML (Dohner et al., 2010). This excludes
acute APL whose recommendations are published separately (Sanz et al., 2009).
APL is the most curable subtype of AML with a dramatic improvement in survival
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with the introduction of all-trans retinoic acid (ATRA) and more recently arsenic
trioxide (ATO) into its therapy (Sanz et al., 2009).
Therapy for AML consists of two phases, with the first attempting to produce CR
and the second aiming to prolong that CR. The likelihood of relapse declines
sharply to less than 10% once a patient has been in remission for 3 years (Estey,
2006). However, current therapeutic strategies for AML, relying on remission
induction followed by postremission therapy with additional intensive
chemotherapy or stem-cell transplantation, have produced limited survival benefits
(Ravandi et al., 2007). Despite multiple clinical trials, examining combinations of
cytotoxic agents, remission induction therapy for patients with adult AML has
changed little over the past thirty years. Standard therapy for AML consists of a
combination of an anthracycline such as DNR and the nucleoside analogue Ara-c
(Figure 1.5). The cytotoxic activity of DNR is attributed to the formation of drug-
stabilized complexes between DNA and the nuclear enzyme topoisomerase II.
Topoisomerase II is essential for the maintenance of DNA integrity and the
survival of proliferating cells and topoisomerase II poisons such as DNR,
etoposide and doxorubicin, inhibit enzyme-mediated DNA ligation causing the
accumulation of double-stranded breaks. Other biological effects include free
radical formation, alkylation of DNA and interaction with components of the cell
membrane (Come et al., 1999). Nucleoside analogues such as Ara-c are taken into
the cell by nucleoside transporters and metabolized by intracellular enzymes,
before being incorporated into newly synthesized DNA, leading to chain
termination and inhibition of DNA synthesis (Ravandi et al., 2004). The standard
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induction regimen for newly diagnosed AML consists of three days of an
anthracycline (e.g. DNR, at least 60 mg/m2, idarubicin, 10-12 mg/m2, or
mitoxantrone, 10-12 mg/m
2
) intravenously and Ara-c, 100-200 mg/m
2
by
continuous infusion for seven days. With such (“3 + 7”) regimens 60% to 80% of
young adults and 40% to 60% of older adults can achieve CR (Dillman et al.,
1991; Zhu et al., 2009). Clinical outcomes in the elderly are more modest as these
patients do not tend to tolerate intensive chemotherapy and frequently have
cytogenetic abnormalities (as discussed in section 1.3). Less than 10% of older
patients with AML will achieve long-term disease free survival with conventional
chemotherapy (Appelbaum et al., 2001). The fact that the majority (more than
75%) of newly diagnosed AML patients are 60 years or older, clearly indicates the
need for development of less toxic and specific therapies to improve the cure rates
in this large patient group (De Jonge-Peeters et al., 2007). New drugs being
Figure 1.5 The chemical structure of the anthracycline DNR and
the nucleoside analogue Ara-c.
Chemical structure of Daunorubicin and Cytarabine
Daunorubicin
Cytarabine
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Table 1.5 – Examples of novel agents being tested in AML. (Adapted from
(Robak, 2009)).
DRUG CLASS AGENTS MECHANISM OF ACTION
Tyrosine kinase
inhibitors (FLT3
inhibitors)
Lestaurtinib (CEP701)
Tandutinib (MLN518)
PKC412
AC220
Sorafenib
Inhibition of FLT3 phosphorylation,
induction of apoptosis
Newer nucleoside
analogues
Clofarabine (Evoltra®)
Troxacitabine Troxatyl®)
Sapacitabine (CYC682,
CS-682)
Inhibition of ribonucleotide
reductase and DNA polymerase;
induction of apoptosis
Immunotoxins Gemtuzumab ozogamicin
(Mylotarg®)
CD33 binding, toxin
internalization, and double strand
DNA breaks
Hypomethylating
agents
Azacitidine (Vidaza®)
Decitabine (Dacogen®)
Inhibition of DNA methylation
Farnesyltransferase
inhibitors
Tipifarnib (Zarnestra)
lonafarnib (Sarasar®)
Inhibition of farnesyltransferase,
inhibition of angiogenesis, and
induction of cellular adhesion
Alkylating agents Laromustine (Onrigin®) DNA alkylation and DNA cross-
linking
Haematopoietic stem
cell mobilizing agent
Plerixafor (AMD3100) Antagonist of CXCR4 binding to
CXCL12
evaluated in clinical studies include FLT3 inhibitors, nucleoside analogues,
immunotoxins, hypomethylating agents, farnesyltransferase inhibitors, alkylating
agents and haematopoietic stem cell mobilizing agents (Table 1.5). FLT3
inhibitors and the immunotoxin Gemtuzumab ozogamicin will be discussed in the
next section.
The newer second-generation purine nucleoside analogue clofarabine has recently
been extensively studied in patients with AML and is reviewed by (Tran, 2012).
Clofarabine was synthesized to combine the most favourable pharmacokinetic
properties of fludarabine and cladribine, and acts by inhibiting ribonucleotide
reductase and DNA polymerase, as well as by inducing apoptosis. Clofarabine,
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response rates and median OS were higher for clofarabine combined with Ara-c
when compared to single agents alone in untreated elderly AML (Tran, 2012). The
authors concluded that clofarabine may be a useful alternative in AML patients
who may not tolerate standrard therapy with anthracyclines.
Two demethylating agents, the cytosine analogues decitabine and azacitidine are
currently in phase III clinical trials and are reviewed by (Garcia-Manero, 2008).
DNA methylation is the addition of a methyl group to specific stretches of DNA
sequences often located in or near promoter regions. DNA methylation occurs
when a methyl group is attached to a cytosine by 1 of the 3 known active DNA
methyltransferases (DNMTs). DNA methylation causes loss of gene function
induced by epigenetic gene silencing. Such changes may be reversible using
DNMT inhibitors and both decitabine and azacitidine have been approved for the
treatment of myelodysplastic syndromes (MDS). MDS are clonal disorders of
haematopoietic stem cells, characterized by an ineffective haematopoiesis
associated with cytopenias, functional abnormalities of bone marrow lineages, and
by high incidence of progression to AML. In a trial with high-risk MDS, 2 year
overall survival with azacitidine was 50%, compared with 16% with conventional
treatment (Fenaux et al., 2010).
Tipifarnib is a farnesyltransferase inhibitor currently under development for the
treatment of AML. Farnesyltransferase is an enzyme involved in cell signalling,
proliferation, and differentiation. It catalyzes the transfer of the farnesyl moiety to
the cysteine terminal residue of a substrate protein on Ras and farnesylated protein
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products of the Ras gene family are frequently activated in MDS and AML. Karp
et al recently reported the results of a phase II trial where a CR of 25% was
achieved in AML patients >70 years receiving tipifarnib and etoposide in
combination (Karp et al., 2012). The results of this study are encouraging in that
they highlight the therapeutic progress in a population of poor-risk, older AML
patients who are very difficult to treat. Another phase I/II study found tipifarnib in
combination with idarubicin and Ara-c to cause better CR duration and higher CR
rates in AML patients with chromosome 5/7 abnormalities (Jabbour et al., 2011).
1.7 Targeted therapy
Cancer chemotherapy can be limited by a lack of specificity, resulting in damage
to normal cells as well as cancer cells. Targeted therapy aims to reduce toxicity in
normal tissues and thereby improve quality of life for the cancer patient. AML is a
highly heterogeneous disease that lacks efficient markers needed in clinical
diagnosis to incorporate more novel risk-adapted therapeutic strategies. However,
diagnostic studies, including immunophenotyping, cytogenetic evaluation, and
molecular genetic studies, are aiding development of a more targeted approach to
treat specific subtypes of AML. Acute promyelocytic leukaemia (APL) became
the first subtype of AML to be treated with an agent targeting a specific genetic
mutation. High complete remission rates for APL, which is characterized by a
t(15:17) translocation resulting in a fusion transcript of promyelocytic leukaemia-
UHWLQRLFDFLGUHFHSWRUĮ30/5$5ĮDUHQRZDFKLHYDEOHWKURXJKWUHDWPHQWZLWK
ATRA and ATO (Tallman et al., 2002; Sanz et al., 2009). Further confidence that
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small-molecule inhibitors of specific kinases may prove to be highly effective
anticancer agents comes from the success of imatinib in the treatment of chronic
myelogenous leukaemia (CML). CML is characterized by the presence of a t(9:22)
translocation resulting in a constitutively active tyrosine kinase encoded by the
breakpoint cluster region-abelson (BCR-ABL) fusion gene. Imatinib is a selective
tyrosine kinase inhibitor which competes with ATP binding in the BCR-ABL
protein kinase and inhibits tyrosine phosphorylation of the downstream proteins
involved in BCR-ABL signal transduction (Crossman, 2004). Whilst imatinib
treatment is beneficial in the majority of CML cases it is becoming apparent that
some patients are resistant to imatinib and other patients experience relapse after
initial success with the drug. Recent evidence demonstrates that Pgp may play a
role in this resistance and there is also evidence that imatinib is a BCRP substrate
(Burger et al., 2004; Thomas et al., 2004).
Therapeutic targets such as the human epidermal growth factor receptor 2 (HER2)
in breast cancer and the KRAS mutation in colon cancer can be used to optimize
patient selection for Herceptin and Erbitux treatment respectively (Saijo, 2011).
Markers required for stratifying patients with AML according to risk levels and for
assigning certain subtypes of this disease to appropriate molecular targeted
therapies is complex. However, new targeted molecular approaches in AML are
being developed on the basis of the progress made in deciphering the molecular
pathogenesis of AML.
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FLT3-ITD mutations are among the most frequently detected molecular
abnormalities in AML patients and cause constitutive activation of the receptor
kinase (Gilliland, 2002). This makes them an attractive target for tyrosine kinase
inhibition by small molecule inhibitors and there has been considerable interest in
the development of FLT3 inhibitors. A number of these are in phase II/III clinical
trials, and include CEP-701 (Lestaurtinib) and PKC-412 (Midostaurin), both of
which demonstrate activity in experimental models of FLT3-ITD positive
leukaemia (Levis et al., 2002; Weisberg et al., 2002; Smith et al., 2004; Stone et
al., 2005; Knapper et al., 2006). CEP701 is part of the international phase 3
AML17 study for young adults with newly diagnosed AML. The use of CEP-701
and PKC-412 as single agents in high risk AML patients has shown only limited
benefit with no increase in complete remission observed (Smith et al., 2004; Stone
et al., 2005; Knapper et al., 2006). However, studies which combined CEP-701 or
PKC-412 with conventional chemotherapy, suggested a possible therapeutic
benefit (Fischer et al., 2010; Levis et al., 2011). A study by our research group
confirmed that AML samples with a FLT3-ITD are more susceptible to PKC-412
and another FLT3 inhibitor, AG1296, than wild type samples (Hunter et al., 2004).
Also, expression of Pgp in the FLT3-ITD cells reduced their sensitivity to AG1296
and the authors concluded that Pgp expression should be assessed in clinical trials
of FLT3 inhibitors. Recently, more potent FLT3 inhibitors such as AC220 and
sorafenib are being investigated and are reviewed by (Knapper, 2011). They
possess the ability to achieve more sustained in vivo inhibition of FLT3 and have
shown highly promising activity in early clinical studies (Rollig et al., 2011).
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AC220 is currently part of the AML18 study in combination with conventional
chemotherapy in older patients with AML and high risk MDS.
Gemtuzumab ozogamicin/GO (Mylotarg) is a humanized anti-CD33 antibody
chemically linked to the cytotoxic agent calicheamicin that inhibits DNA synthesis
and induces apoptosis. CD33 antigen is present on the surface of AML cells in
80% to 90% of patients with AML. Combinations of GO with chemotherapy as
induction or post-remission therapy are promising, and phase III trials are ongoing
(Stasi et al., 2008). In the medical research council (MRC) AML 15 trial, younger
AML patients (under 60 years) with favourable cytogenetics who were treated
with GO in combination with induction chemotherapy showed a significant
survival benefit, and a trend was also documented for patients with intermediate
risk (Burnett et al., 2011b). Results from the MRC AML 16 trial suggest that older
patients, including those with intermediate risk cytogenetics, also benefit from the
addition of GO to remission induction therapy (Burnett et al., 2011a).
Targeted therapy is a rapidly evolving and expanding topic and recently drugs
targeting the aurora kinase family of proteins have come to prominence as being of
potential benefit in tumour therapy (Carvajal et al., 2006).
1.8 The aurora kinase family
The mammalian aurora kinases aurora-A, aurora-B and aurora-C comprise a
family of serine/threonine kinases that are essential for mitotic progression
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(Andrews et al., 2003). Amongst their many functions the auroras act to establish
mitotic spindles by regulating the spindle checkpoint, centrosome duplication and
separation, as well as microtubule-kinetochore attachment and cytokinesis
(Andrews et al., 2003). The expression levels, as well as the kinase activity of all
three aurora kinases is cell cycle dependent, with the activity increasing at the S
phase, reaching a peak level at the G2/M phase (Bischoff, 1999). Recently the
auroras have been linked to tumourigenesis, and the fact that that they are kinases,
amenable to small molecule inhibition, makes them attractive targets for
anticancer drug development (Carvajal et al., 2006). The first homologue of the
aurora kinase family, Increase-in-ploidy 1 (Ipl1), was identified in budding yeast
using a genetic screen for mutants that were defective in chromosome segregation
(Chan, 1993). In 1995 the original eukaryotic aurora allele was identified in a
screen for Drosophila melanogaster mutants that were defective in spindle-pole
behaviour and termed aurora after the phenomenon aurora borealis, of the night
skies Polar Regions (Glover et al., 1995). By 1998 three human aurora kinase
homologues had been identified and their nomenclature simplified to aurora-A,
aurora-B and aurora-C (Carmena, 2003). Interest in the auroras has intensified
since the observation that aurora-A over-expression is oncogenic (Bischoff et al.,
1998). The aurora kinases are nuclear proteins and although the carboxyl terminus
catalytic domains of the auroras are highly conserved (71% between aurora-A and
aurora-B), the three members exhibit strikingly different sub-cellular localizations
and functions during mitosis interacting with a distinct set of proteins (Carmena,
2003). The auroras play multiple roles during mitotic progression and their
distribution correlates strongly with their functions (Carmena, 2003).
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Aurora-A is localized primarily on spindle poles and transiently along the spindle
microtubules as cells progress through mitosis and is considered orthologous to the
initial aurora discovered in Drosophila (Carmena, 2003; Katayama, 2010). The
kinase functions primarily in mitotic entry, centrosomal regulation, mitotic spindle
formation, alignment of metaphase chromosomes and is also known to
phosphorylate numerous centrosomal proteins (Carmena, 2003). Loss of aurora-A
function leads to monopolar mitotic spindles, cell cycle arrest, accumulation of
cells in the G2/M phase and apoptosis (Carmena, 2003).
Aurora-B is a chromosomal passenger protein whose kinase activity peaks during
mitosis. Chromosomal passenger proteins are characterized by their unique
property of translocation from the chromosomal inner centromeric region to the
central mitotic spindle and cell cortex during mitotic progression (Carmena, 2003).
As such aurora-B undergoes dynamic localization, associating first to the
kinetochores from prophase to metaphase, and then to the spindle midzone and
midbody during late anaphase, telophase and cytokinesis (Andrews et al., 2003; Fu
et al., 2007). This kinase was first associated with cancer in 1998 when it was
found to be overexpressed in colon tumours (Bischoff et al., 1998). Inhibition of
aurora-B results in abnormal cell division, polyploidy and apoptosis (Ditchfield et
al., 2003).
Aurora-C is the least studied of the aurora family and its expression was originally
thought to be restricted to the testis where it has a specific role in the regulation of
chromosome segregation during male meiosis (Hu et al., 2000). More recently,
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aurora-C has been identified at low levels in sixteen other tissues including bone
marrow, with studies suggesting that it has a similar intracellular distribution and
complementary role to aurora-B along with survivin as a chromosomal passenger
protein (Sasai et al., 2004; Yan et al., 2005).
Aurora-B is the catalytic component of the chromosomal passenger complex
(CPC), which is composed of three additional non-catalytic subunits that direct its
activity: survivin, inner centromere protein (INCENP) and borealin. Survivin and
INCENP have both regulatory and targeting functions and are phosphorylated by
aurora-B in vitro whilst borealin is thought to target aurora-B to centromeres
(Gassmann et al., 2004). The CPC orchestrates the spindle checkpoint and ensures
the accurate segregation of chromatids and correct microtubule/kinetochore
attachment during mitosis and cytokinesis (Andrews et al., 2003). Aurora-B is
required for cleavage furrow ingression (Fuller et al., 2008), and inhibition of
aurora-B function results in premature exit from mitosis without undergoing
chromosome segregation and cytokinesis, and continued re-entry into the cell
cycle (a process referred to as endoreduplication), resulting in multi-nucleated
cells and ultimately cell death (Ditchfield et al., 2003). This increase-in-ploidy
phenotype makes aurora-B orthologous to Ipl1 in budding yeast (Carmena, 2003)
where it is required for spindle checkpoint function in response to a lack of tension
across attached kinetochores (Lampson, 2010). In higher eukaryotic cells, catalytic
activity of aurora-B is required for recruitment of checkpoint protein BubR1 to
kinetochores and sustained mitotic arrest in the absence of tension (Ditchfield et
al., 2003). In mitotic chromosomes, kinetochore-microtubule attachments can be
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found in many states; monotelic (one kinetochore attached to a microtubule from
only one pole), syntelic (each kinetochore attached to microtubules emanating
from one pole), merotelic (both kinetochores attached to microtubules derived
from both poles) and amphitelic (bi-polar bi-oriented attachment). Aurora-B is
essential for the generation of the correct amphitelic attachment state required for
accurate chromosome segregation (Figure 1.6) (Andrews et al., 2003). Aurora-B is
also known to phosphorylate Histone H3 (pHH3) at the serine 10 (Ser
10
) position
during mitosis (Hsu et al., 2000; Giet, 2001; Bhaumik et al., 2007). Inhibition of
pHH3 reflects aurora-B inhibition and as such can be considered a biomarker for
aurora-B activity. There is some confusion about the actual definition of what a
biomarker is and what its characteristics are. However, the most widely accepted
definition of a biomarker is “a characteristic that is objectively measured and
Aurora B
Survivin Borealin
INCENP
Syntelic Monotelic Merotelic
CPC
Figure 1.6 Functions of the CPC in kinetochore–
microtubule attachment. Adapted from Andrews
et al Curr Opin Cell Biol 2003.
Amphitelic
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evaluated as an indicator of normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention” (Atkinson et al., 2001).
Inhibition of Histone H3 phosphorylation has been reported to prevent initiation of
chromosome condensation and entry into mitosis (Van Hooser et al., 1998).
Aurora-B has also been reported to directly phosphorylate the retinoblastoma
tumour suppressor protein (Rb), a function which regulates the postmitotic
checkpoint to prevent endoreduplication after aberrant mitosis (Nair et al., 2009).
Both Aurora-A and B have been shown to be over-expressed in a wide variety of
tumour types (Katayama et al., 1999; Han et al., 2002; Tong et al., 2004; Chieffi
et al., 2006) including those of haematological origin (Ikezoe et al., 2007; Yang et
al., 2007; Careta et al., 2012) and are therefore thought to represent promising
targets for anticancer drug development.
1.9 Aurora kinase inhibitors
Anti-mitotic drugs such as the taxanes (e.g. paclitaxel, docetaxel) and the vinca
alkaloids (e.g. vincristine, vinblastine) block tumour cell division and are used
routinely in the clinic to treat cancer (Jordan, 2004). A major drawback of these
drugs is the collateral damage caused to non-dividing cells, including clinical
neuropathy, caused by the inhibition of microtubule dependent processes in axons
and glial cells. The common feature of the anti-mitotic drugs is that they all bind
tubulin, leading to the suppression of microtubule dynamics, inhibition of spindle
assembly and activation of the spindle assembly checkpoint (SAC). SAC
activation induces mitotic arrest and tumour cells typically die directly in mitosis
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or following mitotic exit. This mechanism of action is distinct to that seen with
aurora-B inhibition which results in inactivation of the SAC, leading to aborted
cell division without mitotic arrest. Continued suppression of aurora-B activity
leads to further rounds of genome replication without division, a process referred
to as endoreduplication, which ultimately results in tumour cell death (Ditchfield
et al., 2003). Therefore, compounds that inhibit aurora-B and prevent spindle
assembly without affecting micotubules in non dividing cells should in principle
have anti-tumour activity without the neuropathies associated with the classical
antimitotic drugs.
Success of agents such as imatinib in the treatment of CML has increased
confidence that small-molecule inhibitors of specific kinases may prove to be
highly effective anticancer agents (Crossman, 2004). The implication of the
auroras in tumourigenesis and the fact that that they are kinases, amenable to small
molecule inhibition, makes them attractive targets for anticancer drug
development. In particular, both aurora-A and aurora-B have been shown to be
aberrantly expressed in freshly isolated leukaemia cells from individuals with
AML, compared with bone marrow mononuclear cells from healthy volunteers
(Ikezoe et al., 2007). A growing number of aurora kinase inhibitors have been
described that show anti-tumour activity in vivo. Whether aurora-A or aurora-B is
the better anticancer drug target is a matter of debate. One study compared the
effects of aurora-A and aurora-B antisense oligonucleotides in pancreatic cells and
found that aurora-A targeted therapy may be preferable to aurora-B (Warner et al.,
2006). However, most of the evidence points to aurora-B as the target of choice.
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Three non-specific aurora kinase inhibitors ZM447439, Hesperadin and VX-680
all induce similar phenotypes when tested in cell based assays (Ditchfield et al.,
2003; Hauf et al., 2003; Harrington et al., 2004). Specifically, all three inhibit
phosphorylation of Histone H3 on Ser10 and induce DNA endoreduplication in the
absence of cytokinesis, results that suggest that their cellular effects are largely
due to the inhibition of aurora-B (Keen, 2004). Another study compared the effects
of RNA interference and small molecules targeting aurora-A versus aurora-B in
colon cancer cells and found that the cells tested were extremely sensitive to
aurora-B inhibition (Girdler et al., 2006). Recently a group using RNA
interference experiments showed that inactivation of aurora-B bypasses the
requirement for aurora-A leading to polyploidy, indicating that aurora-B is
responsible for mitotic arrest in the absence of aurora-A (Yang et al., 2005). More
recently a study of 297 ALL and 237 newly diagnosed paediatric AML patient
samples reported an increase in expression of both aurora-A and aurora-B proteins
when compared to normal bone marrow samples (Segers et al., 2011). The group
used a short hairpin RNA system to silence aurora-A and aurora-B in both ALL
and AML cell lines and found that only silencing of aurora-B resulted in
proliferation arrest and apoptosis. With this in mind more specific inhibitors for
aurora-B are being developed, one of which is AZD1152, and is discussed later.
1.10 Aurora kinase inhibitors in AML
There are pre-clinical data on several aurora kinase inhibitors with promising
results in AML cells. ZM447439 was the first aurora kinase inhibitor to be
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developed (Ditchfield et al., 2003). It is an inhibitor of both aurora-A and aurora-B
that causes growth inhibition in colony forming assays and apoptosis in AML cells
(Ditchfield et al., 2003; Ikezoe et al., 2007). Importantly, ZM447439 did not
inhibit clonogenic growth of myeloid stem cells from healthy donors (Ikezoe et al.,
2007). PHA-680632 is a potent inhibitor of all three aurora kinases that has shown
tumour growth inhibition in nude mice bearing a human leukaemia (HL-60)
xenograft (Soncini et al., 2006). VX-680 is another selective inhibitor of all three
aurora kinases which inhibits Histone H3 phosphorylation and demonstrates anti-
tumour activity in mouse xenograft models (Gizatullin et al., 2006). When VX-
680 was delivered to nude mice bearing a human leukaemia (HL-60) xenograft it
resulted in a 98% reduction in tumour volume compared with controls.
Interestingly, VX-680 also exhibits cross-inhibitory activity against the receptor
tyrosine kinase FLT3 and ablated colony formation in primary AML cells with
FLT3-ITD (Harrington et al., 2004; Carvajal et al., 2006). The non-specific aurora
kinase inhibitor AS703569 is also a potent inhibitor of FLT3 and has shown anti-
tumour activity in AML cell lines and primary blasts (Sarno et al., 2007). VX-680
has also been shown to increase Bax/Bcl-2 expression ratio in primary AML cells,
a favourable proapoptotic predictor for drug response and survival in AML, and to
enhance the cytotoxic effect of the chemotherapeutic agent etoposide on AML
cells (Huang et al., 2008).
M.Grundy
41
1.11 AZD1152-hQPA (Barasertib-hQPA)
AZD1152 is a novel pyrazoloquinazoline prodrug developed by AstraZeneca that
has good solubility, making it suitable for parenteral administration, which is then
converted rapidly to the active drug AZD1152 hydroxy-QPA (AZD1152-hQPA)
in human plasma (Figure 1.7) (Mortlock et al., 2007). It is the more active
AZD1152-hQPA that has been supplied by AstraZeneca for the purpose of this
study. AZD1152-hQPA is a highly potent sub-micromolar selective inhibitor of
aurora-B (Ki, 0.36nM/L) compared with aurora-A (1369nM/L) and aurora-C
(17nM/L) and has a high specificity versus a panel of 50 other serine/threonine
and tyrosine kinases (Keen et al., 2005). A study investigating the activity of
AZD1152 in AML cells found anti-proliferative and apoptotic activity in cell lines
AZD1152 prodrug
AZD1152-hQPA
Plasma
Figure 1.7 The chemical structure of AZD1152 prodrug and the
active moiety AZD1152-hQPA (C26H30FN7O3, m.w. 507.57)
after de-phosphoryation in plasma. (Adapted from D.Pluim et al.
J. Chromatogr 2009)
Chemical structure of AZD1152 prodrug and
de-phosphorylated AZD1152-hQPA
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and primary cells at concentrations associated with changes in the phosphorylation
status of the aurora-B substrate Histone H3 (Joel et al., 2005). AZD1152-hQPA
has also been shown to significantly inhibit the growth of human colon, lung and
haematologic tumour xenografts in immunodeficient mice, with phenotypes
indicative of aurora-B inhibition such as, chromosome misalignment, loss of cell
division, suppression of Histone H3 phosphorylation and subsequent apoptosis
(Mortlock et al., 2007; Wilkinson et al., 2007).
AZD1152 has also shown tumouricidal activity against a panel of tumour cell lines
including those of AML origin (Joel et al., 2005; Walsby et al., 2005; Oke et al.,
2009). Recently AZD1152 has been reported to reduce aurora-B protein stability
in breast cancer cell lines by enhancing proteasome mediated polyubiquitination
and degradation (Gully et al., 2010). Therefore AZD1152 is the first aurora kinase
inhibitor shown to be negatively regulating both activity and stability of the
protein. A study on the potential of AZD1152 as a new treatment for multiple
myeloma found high levels of aurora-B kinase mRNA and protein expression in a
panel of human myeloma cell lines and primary myeloma cells (Evans et al.,
2008). AZD1152 induced apoptotic death in myeloma cell lines at nanomolar
concentrations and combination of AZD1152 with dexamethasone showed
increased anti-myeloma activity compared with the use of either agent alone.
Another study, investigating the effects of AZD1152 administration on human
leukaemic cell lines has recently been reported (Yang et al., 2007). The compound
inhibited the proliferation of AML, Acute lymphocytic leukaemia (ALL), and
CML cell lines with an IC50 ranging from 3nM to 40nM. The cells all had 4N/8N
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DNA content followed by apoptosis. Of note, AZD1152 synergistically enhanced
the anti-proliferative activity of vincristine, a tubulin depolymerizing agent, and
DNR, a topoisomerase II inhibitor. The authors concluded that AZD1152 is a
promising new agent for the treatment of individuals with leukaemia and that the
combined administration of AZD1152 with conventional chemotherapeutic agents
warrants further investigation.
Data on results from the first phase I clinical trial in advanced pretreated solid
malignancies has been reported (Boss et al., 2006). AZD1152 was well tolerated
when administered as a 2 hour intravenous infusion at doses up to 300mg.
Neutropenia was the dose limiting toxicity at 450mg with no other clinically
significant toxicities reported. They reported significant disease stabilization
suggesting a promising clinical future development for the drug. More recently
another phase I/II clinical trial provided information on the safety and efficacy of
AZD1152 in patients with advanced AML showing that the drug had an acceptable
tolerability profile in patients with AML (Lowenberg et al., 2009).
AZD1152 is currently being tested in phase II clinical trials as a single agent or in
combination with low dose Ara-c for the treatment of elderly patients with AML
who are unsuitable for standard induction treatment.
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1.12 Project objective
This study investigates the efficacy of the novel aurora-B kinase inhibitor
AZD1152-hQPA in a panel of AML cell lines and primary samples. Down-
regulation of phosphorylation of Histone H3 on Ser10 (pHH3) can be used to
measure aurora-B inhibition and will be used as a biomarker for AZD1152-hQPA
activity. Initially it was planned to investigate the specificity of AZD1152-hQPA
in AML cell lines and primary samples in relation to their ABC transporter status.
In response to some of the initial observations further work was undertaken
including biomarker assay optimisation, development of a new MDR cell line and
investigation of FLT3-ITD as possible secondary target of AZD1152-hQPA.
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Chapter Two
MATERIALS AND
METHODS
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2.1 Materials
Materials were from Sigma (Poole, Dorset UK) unless otherwise stated. AZD1152-
hQPA (active drug) was supplied by AstraZeneca in powdered form. A 10mM stock
solution was prepared in DMSO, aliquoted and then frozen. Further dilutions were
made in cell culture/assay medium. Radio-labelled [14C]-AZD1152-hQPA was also
supplied by AstraZeneca for use in the drug accumulation assays.
2.2 Cell lines and cell culture
OCI-AML3, MOLM-13 and M-07e myeloid leukaemia cell lines were obtained
from the German Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). U937 and KG-1a cell lines were from the European
Collection of Animal Cell Cultures (Salisbury, UK). MV4-11 cell line was
obtained from the American Type Culture Collection (Manassas, VA, USA). HL-
60 cells were a gift from Dawn Bradbury (Nottingham University Hospitals, UK),
OCI-AML6.2 cells a gift from Dr. Jo Mountford (University of Glasgow, UK) and
HL-60ADR (Krishnamachary et al., 1994) cells a gift from Mark Center (Kansas
State University, USA). HL-60, U937, OCI-AML3, OCI-AML6.2, MOLM-13 and
MV4-11 cell lines were maintained in RPMI 1640 medium with 10% foetal calf
serum (FCS; First Link, Birmingham, UK), 2mM L-glutamine, 100 U/ml
penicillin and 10µg/ml streptomycin. The KG-1a and M-07e cell lines were
maintained as above with 20% FCS and the M-07e having the addition of 10ng/ml
GM-CSF (Novartis, Basel, Switzerland).
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Table 2.1 – Human leukaemic cell line panel used in the study. (Information taken
from<URL:http://www.dsmz.de/human_and_animal_cell_lines/cell_line_index.ph
p)
CELL LINE CELL TYPE ORIGIN
OCI-AML3 Human acute myeloid leukaemia Established from the peripheral blood of a 57-year-old man
with acute myeloid leukaemia (AML FAB M4) at diagnosis
OCI-AML6.2 Human acute myeloid leukaemia Derived within the St Jude Children's Research Hospital,
Memphis, USA (Abbott et al., 2002).
MOLM-13 Human acute myeloid leukaemia Established from the peripheral blood of a 20-year-old man
with acute myeloid leukaemia AML FABM5a at relapse
after initial MDS
MV4-11 Human acute monocytic leukaemia Established from a 10-year-old boy with acute monocytic
leukaemia (AML FAB M5) at diagnosis
M-07e Human acute megakaryoblastic
leukaemia
Established from the peripheral blood of a 6-month-old girl
with acute megakaryoblastic leukaemia (AMLM7) at
diagnosis; Subline of the growth factor-independent M-07
HL-60 Human acute myeloid leukaemia Established from the peripheral blood of a 35-year-old
woman with acute myeloid leukaemia (AML FAB M2)
HL-60ADR Human acute myeloid leukaemia Derived within Kansas State University, USA by isolating
HL-60 cells resistant to adriamycin.
U937 Human histiocytic lymphoma Established from the pleural effusion of a 37-year-old man
with generalized diffuse histiocytic lymphoma; Cells were
described to express markers and properties of monocytes
KG-1a Human acute myeloid leukaemia
(derivative of KG-1)
Established from the bone marrow of a 59-year-old man with
erythroleukaemia that developed into AML; KG-1a is a
subclone of the AML cell line KG-1
All cultures were kept at 37°C in 5% CO2 and all experiments were performed
with cell lines in log phase. The leukaemic cell lines that were used are shown in
table 2.1. Continued testing to authenticate these cell lines was initially performed
using a panel of monoclonal antibodies and later by STR fingerprinting (2.4). Cell
line FLT3-ITD status was confirmed using the protocol described in 2.16.
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2.3 Cell line validation and mycoplasma testing
2.3.i Cell line validation using monoclonal antibodies
Continued testing to authenticate these cell lines was performed using a panel of
monoclonal antibodies and FLT3 mutational analysis towards the final passage of
each batch thawed. CD38 FITC, CD33 PE, CD34 Percp (BD Biosciences), CD13
FITC (Dako) and CD42 PE (Pharmingen) mouse monoclonal antibodies along
with their isotype control were used to validate the cell line phenotype. 2x10
5
cells
were incubated with 2.5µl normal mouse serum and 2.5µl monoclonal antibody or
the isotype control followed by washing in PBSAA (PBS; Oxoid, Basingstoke,
UK/1% bovine serum albumin/0.5% sodium azide) and analysis by flow
cytometry. Cell line FLT3-ITD status was confirmed using the protocol described
in 2.16. The phenotypes and FLT3 status of the cell lines used in the study are
Table 2.2 – Cell line panel phenotype and FLT3 status.
CELL LINE CD13 CD33 CD38 CD34 CD42 FLT3
OCI-AML3 Positive Positive Positive Negative Negative WT
OCI-AML6.2 Positive Positive Positive Negative Negative WT
OCI-AMLDNR Positive Positive Positive Negative Negative WT
MOLM-13 Negative Positive Positive Negative Negative ITD
MV4-11 Negative Positive Positive Negative Negative ITD
M-07e Positive Positive Positive Negative Positive WT
HL60 Positive Positive Negative Negative Negative WT
U937 Positive Positive Positive Negative Negative WT
KG-1a Positve Negative Negative Positive Negative WT
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shown in table 2.2.
2.3.ii OCI-AML3/OCI-AML6.2 genetic analysis
DNA was prepared using a QIAamp DNA blood mini kit (Qiagen, Crawley, UK)
and 5ng DNA was amplified using the Powerplex 16 System (Promega,
Southampton, UK) to assess short tandem repeats (STR). The products were run
on a 3130 Genetic Analyzer and the data analyzed using GeneMapper ID v3.2
software. The STR analysis of the OCI-AML6.2 cell line was shown to be
identical to the parent OCI-AML3 cell line indicating that there were no
significant genetic changes.
2.3.iii Mycoplasma testing
Mycoplasma testing was carried out at a similar time to cell phenotyping using a
mycoalert mycoplasma detection kit (Lonza, Rockland, USA) and following the
manufacturer’s instructions. Briefly, cells were centrifuged and 100µl of
supernatant removed to a 96 well luminescent plate (Costar) and mixed with 100µl
mycoalert reagent. After 5 minutes incubation, luminescence was read on a
POLARstar Optima plate reader (BMG Labtech, UK) (Reading A) followed by a
further 10 minute incubation with 100µl mycoalert substrate. A second
luminescence reading was then taken (Reading B) and the ratio of Reading
B/Reading A calculated. A ratio of >1.0 indicated the presence of mycoplasma.
Positive and negative controls were supplied for validation.
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2.4 Primary patient samples
Multi-centre presentation peripheral blood (PB) or bone marrow (BM) samples
were obtained at diagnosis from patients with AML (excluding M3 subtype) and
taken into preservative-free heparin or into EDTA tubes. All samples were pre-
treatment and only samples received within 48 hours of being removed from the
patient were analyzed. Use of these samples was approved by the Nottingham 1
Research Ethics Committee (reference number 06/Q2403/16).
2.5 Isolation of mononuclear cells from peripheral blood
and bone marrow
Peripheral blood or bone marrow was diluted 1 in 2 in RPMI before being layered
onto an equal volume of Histopaque and centrifuged at 600g for 20 minutes (Fig.
2.1). Using a sterile pipette the mononuclear cells were carefully removed from
the plasma-histopaque interface and placed into RPMI before being centrifuged at
600g for 10 minutes. At this stage any contaminating red blood cells were
removed by the addition of 6mls ice cold 0.89% Ammonium chloride (For 500ml:
4.495g NH4Cl, 18.5mg EDTA, 0.5g KHCO3 + 500ml dH2o) and incubation on ice
for 10 minutes. Cells were then centrifuged at 400g for 10 minutes, re-suspended
in fresh RPMI and then centrifuged at 200g for a final 10 minutes before counting.
2.6 Cryopreservation and thawing of cell lines and patient
cells
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For cryopreservation, cells were counted and re-suspended at 1x107/100µl
(1x10
6
/100µl for cell lines) in cold RPMI. Cryovials were labelled with sample
code, cell concentration, and date and placed on ice before the addition of 700µl
freeze solution (For 35ml: 5ml DMSO (Origen Biomedical, Sweden), 10ml FCS +
20ml RPMI). 300µl cells were added to each cryovial (the final concentration in
each vial is 10% DMSO and 20% FCS) before being placed in a freezing chamber
and frozen at -80°c for at least 2 hours followed by transfer to liquid nitrogen for
long term storage. To thaw, samples were removed from liquid nitrogen, placed
into a water bath at 37°C for about 2 minutes and then transferred drop wise to
cold thaw solution (RPMI containing 10% FCS and 1% heparin (Hospital
pharmacy) – heparin only used when thawing patient samples). Cell lines were re-
suspended in the appropriate media, placed into flasks and incubated directly at
Centrifuge
600g
20 mins
Blood/Marrow
HistopaqueTM
Plasma
Red cells
Mononuclear cells
Separation of PB/BM over Histopaque
Figure 2.1 Mononuclear cells migrate during centrifugation,
forming a distinct, opaque layer at the plasma Histopaque
interface. After carefully removing the plasma phase, the
lymphocyte/monocyte layer is collected by aspiration.
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37°C/5% C02. Patient cells were then centrifuged at 250g for 5 minutes and re-
suspended in rest medium (RPMI containing 20% FCS and 1% L-glutamine) for
90 minutes at 37°C/5% C02. Thawed and rested samples were then subjected to
viability analysis using trypan blue exclusion and only samples with > 85% post-
rest viability were used.
2.7 Suspension culture of primary patient samples
Primary AML samples were cultured at 1x10
6
/ml in RPMI 1640 with 10% FCS,
2mM L-glutamine, supplemented with 20ng/ml interleukin (IL)-3 (gift from
Novartis, Surrey, UK), 20ng/ml stem cell factor (SCF) (R+D Systems, Abingdon,
UK), 20ng/ml IL-6 (R+D Systems) + 25ng/ml granulocyte colony-stimulating
factor (G-CSF) (R+D Systems) + 0.07µl/ml beta-mercaptoethanol.
2.8 Cell viability assays
2.8.i Preparation of fixed stained cells
Peripheral blood mononuclear cells from healthy volunteers were prepared by a
standard density gradient technique. Cells in PBSAA were incubated with CD45
FITC antibody for 20 minutes, washed twice, and resuspended in fresh 2%
Paraformaldehyde (VWR International). The final cell concentration was
determined using a haemocytometer and trypan blue exclusion.
2.8.ii 7-AAD/fixed stained cell viability assay
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This was done by a previously published in-house method which allows rapid
evaluation of viable cells by flow cytometric counting (Pallis et al., 1999a). 100µl
cells were cultured at 2x10
5
ml in 96-well plates in triplicate. 7-Amino-
actinomycin D (7-AAD), which detects dead cells, was diluted in PBS as a
50µg/ml stock solution and mixed with harvested AZD1152-hQPA treated or
control cells to give a final concentration of 12.5µg/ml. Samples were incubated in
the dark for 20 minutes before being analyzed by flow cytometry. The number of
viable cells remaining was quantified by excluding dead cells and calculating a
ratio with reference to an internal standard of fixed, pre-labelled cells.
2.9 Histone H3 phosphorylation status and cell cycle
analysis by intracellular flow cytometry
Cells were harvested by centrifugation washed in PBSAA and 3x10
5
cells treated
with fixation medium (Abd Serotec, Oxford, UK) at room temperature (RT) for 15
minutes. Ice cold methanol was added and after 10 minutes incubation on ice, cells
were washed in PBSAA, re-suspended in permeabilization medium (Abd Serotec)
and 5µg/ml of anti-phospho-histone H3 (Ser 10) mouse monoclonal antibody
(Upstate; now part of Millipore, Livingstone, UK) or mouse isotype control (Dako,
Ely, UK) was added. After 2 hours incubation at RT, cells were washed twice in
PBSAA, re-suspended with 3µl of secondary antibody (goat anti-mouse IgG FITC
F(ab`)2; Dako), and incubated for 1 hour in the dark. Cells were then washed twice
in PBSAA and re-suspended in 25µg/ml 7-AAD for 20 minutes in the dark.
Samples were collected using a FACScalibur. Isotype controls were used for
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cytometer set up and doublets were gated out before fluorescence data were
collected. Data were analyzed using Cellquest software with phosphorylation
status expressed as percentage of total cells gated.
2.10 Immunofluorescence analysis of Histone H3
phosphorylation status
Cells were treated identically as for Histone H3 flow cytometric analysis up until
the final wash step. Cells were then manually placed onto glass slides, mounted in
VECTASHIELD mounting medium containing DAPI (Vector laboratories, Inc),
and visualized with a fluorescent microscope (Olympus, UK).
2.11 Determination of Pgp and BCRP function
Functional Pgp expression was determined by modulation of rhodamine 123
(R123) efflux. Cells were re-suspended at 1x10
6
/ml in culture medium and
incubated (75 minutes, 37°C) with R123 (200ng/ml) with or without 2.5µg/ml
cyclosporine A (CSA; hospital pharmacy) or diluent control. Control tubes
containing R123 were placed on ice to halt the reaction. Functional BCRP
expression was measured similarly and was determined by modulation of
BODIPY-prazosin (BODIPY; Invitrogen) efflux. Cells were re-suspended at
1x106/ml in culture medium and incubated (75 minutes, 37°C) with BODIPY
(25nM) with or without 10µM FTC (Calbiochem) or diluent control. Control tubes
containing BODIPY were placed on ice. All tests were carried out in duplicate.
Patient samples had the added step of the addition of 5µl CD45 PerCP to identify
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the blast population before cells were washed twice in PBSAA at 4°c, collected
using a FACScalibur (Becton Dickson, UK) and analyzed using Cellquest
software. Mean fluorescence intensity (MFI) of each sample in the FL1 channel
was measured, since this corresponds to R123/BODIPY retention. The modulation
ratio is calculated as: (MFI with modulator – cold control MFI)/(MFI with diluent
control – cold control MFI). The average of the duplicate experiments was
calculated.
2.12 Pgp protein expression – MRK16 mAb
For Pgp protein expression cells were harvested, washed in PBSAA, and 2x10
5
cells incubated with 1µg MRK16 anti-Pgp antibody (Kamiya Biomedical) or
IgG2a isotype control (Dako) for 30 minutes at RT. Cells were washed x3 in
PBSAA and blocked in 80µl 20% normal rabbit serum for 30 minutes on ice. 5µl
FITC-conjugated rabbit anti-mouse secondary antibody (Dako) was added and
cells incubated for 30 minutes on ice. Cells were washed twice in PBSAA and cell
line data collected using a FACScalibur. Patient samples had the added step of the
addition of 5µl CD45 PerCP (Becton Dickinson) and 5µl Normal Mouse serum
before being washed twice in PBSAA and collected using a FACScalibur.
Labelling the patient samples with CD45 PerCP allowed the leukaemic blast
(CD45 low/side scatter low) cells to be gated.
2.13 Apoptosis assays
2.13.i Detection of apoptosis with Annexin V-FITC
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Detection of apoptosis was determined using the Annexin V-FITC apoptosis
detection kit according to the manufacturer’s instructions. Briefly, following
treatment for 48 hours with AZD1152-hQPA the cells were washed in PBS and re-
suspended in the supplied binding buffer containing calcium chloride and
incubated with annexin V-fluoroscein-isothiocyanate (FITC) and propidium iodide
for 10 minutes in the dark. Data on the annexin V positivity of the cells were
collected on a FACScalibur and analyzed using Cellquest software.
2.13.ii Detection of apoptosis with active Caspase-3 and
Apop2.7 (7A6) antibodies
Active caspase-3 and 7A6 expression was determined in U937 cells treated for 48
hours with 0-300nM AZD1152-hQPA. To measure active caspase-3 expression,
treated cells were harvested by centrifugation, washed in PBSAA and 5x10
5
cells
treated with fixation medium (Abd Serotec) at RT for 15 minutes. Cells were then
washed in PBSAA and re-suspended in permeabilization solution (Abd Serotec)
with 20% Normal Rabbit serum. After 15 minutes at RT, 20µl PE-conjugated
polyclonal Rabbit anti-active caspase-3 (BD Pharmingen) was added and cells
incubated for 1 hour at RT. Cells were washed and data collected on a
FACScalibur using Cellquest software for analysis. Cells for 7A6 analysis were
counted and washed in PBSAA before re-suspending in 25µg/ml Digitonin and
incubation on ice for 20 minutes. The cells were then pelleted and either 20µl of
Anti-APO2.7-PE (Beckman Coulter) or Mouse IgG1 PE isotype control (BD
Pharmingen) was added before incubation for 20 minutes at RT. Cells were
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washed in PBSAA before collection on a FACScalibur and analysis using
Cellquest software.
2.13.iii H2A.X phosphorylation
Measurement of DNA double strand breaks, characteristic of apoptosis, was
determined using the H2A.X phosphorylation kit (Upstate) according to the
manufacturer’s instructions. Briefly, after 24 hours treatment with AZD1152-
hQPA the cells were washed in PBSAA and re-suspended in the supplied fixation
buffer. After further washes cells were permeabilized and incubated with either
anti-phospho-H2A.X (Ser139) FITC or IgG FITC control antibody. Following
further washes in saponin containing buffer, cells were re-suspended in 10µg/ml 7-
AAD and data collected using a FACScalibur.
2.14 p53 Sequencing
Cell line cDNA was prepared using QIAamp blood isolation kits (Qiagen,
Crawley, UK) according to manufacturer’s instructions. Exons 2-11 of p53 were
amplified using 4 over-lapping sets of primers p53; 1F-gacacgcttccctggat tggc, 1R-
gcaaaacatcttgttgagggca, 2F-gtttccg tctgggcttcttgca, 2R-ggtacagtcagagccaacctc, 3F-
tggcccctcctcagcatctta, 3R-caaggcctcattcagctctc, 4F-cggcgcacagaggaagagaatc, 4R-
cgcacacctattgcaa gcaaggg. Approximately 50ng of cDNA was used as template in
each of the PCR amplifications. The 50µl reaction also included 150µM of each
dNTP (Amersham Biosciences, Buckinghamshire, UK), 1µM of each primer,
1.0mM MgCl2 for fragments 1 and 2 or 1.5mM MgCl2 for fragments 3 and 4, and
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2 units of Amplitaq Gold (Applied Biosystems) in the manufacturer’s buffer.
Following an initial heat activation step at 95°C for 10 minutes amplification was
performed in a PTC-100TM Programmemable Thermal Controller (MJ Research)
using the following conditions; denaturation at 95°C for 1 minute, annealing for 1
minute at 55°C for fragments 1 and 2 or 60°C for fragments 3 and 4, extension at
72°C for 1 minute for a total of 35 cycles ending with a final extension at 72°C for
10 minutes. PCR products were purified using a QIAquick PCR purification kit
(Qiagen) prior to sequencing. Sequencing reactions were set up with
approximately 200ng of purified PCR product and 3.2pM primer using BigDye®
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The primers used
for sequencing were the same as those used for the PCR amplifications. The
reactions were electrophoresed using an ABI 3130 Genetic Analyzer (Applied
Biosystems) and results analyzed using the Sequencing Analysis 5.2 software
(Applied Biosystems).
2.15 Cloning assays
2.15.i Bacterial electroporation
The MDR1 gene cloned into the pCMV6-Neo vector (RSPD001-Neo) was
supplied by Origene (Rockville, USA). To amplify stocks RSPD001-Neo or
pCMV6-Neo control was transformed into ElectroTen-Blue electroporation
competent bacteria (XL1-Blue MRF´ strain) (Stratagene, Stockport, UK),
IROORZLQJ WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV%ULHIO\ȝORI563'1HRSODVPLG
was gently added to 30µl of bacteria in a pre-chilled eppendorf tube and then
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transferred to a chilled cuvette which was then incubated on ice for 1 minute. An
electroporation control was included using the pUC18 control plasmid
(Stratagene). Samples were placed into a chilled electroporation chamber and
pulsed once with 2500 applied volts. Immediately following electroporation, 250µl
of SOC (Super optimal broth with catabolic repressor) medium was added to the
cell suspension, before transfer to a 15ml Falcon polypropylene round-bottom
tube. The tubes were then incubated at 37°C for 60 minutes while shaking at
225rpm to allow expression of the antibiotic genes. Agar plates were prepared by
melting powdered LB agar at 35g/L into 200ml distilled water by heating in a
microwave for approximately 4 minutes on medium (with occasional agitation),
until the agar was molten. The agar was cooled slightly, before addition of
100µg/ml ampicillin and then divided between 10-12 sterile Petri dishes and left to
VHWȝORIQHDWDQGDGLOXWLRQRIWKH563'1HRRUS&091HRYHFWRU
transformations and pUC18 electroporation control were spread over the agar
plates, before being incubated overnight at 37ºC. If the transformation experiment
was successful, bacterial colonies would be present. Two bacterial colonies were
selected from each agar plate and grown up overnight at 37ºC in LB Broth (20g/L
in ddH2 PHGLXP FRQWDLQLQJ ȝJPO DPSLFLOOLQ /%$03 ZLWK FRQVWDQW
agitation.
2.15.ii Plasmid preparation
Qiagen plasmid mini and midi kits (Qiagen) were used for plasmid preparation.
Briefly, 3ml (mini) or 25ml (midi) bacteria from the overnight culture were
M.Grundy
60
centrifuged at 6,000g for 15 minutes and re-suspended in 0.3ml or 4ml ‘buffer P1’.
The remaining culture was stored at 4°C for making glycerol stocks if digests
proved to be successful. 0.3ml or 4ml ‘buffer P2’ was added, thoroughly mixed,
and incubated at room temperature for 5 minutes before addition of 0.3ml or 4ml
‘buffer P3’ and incubation on ice for 5 or 15 minutes. Cells were centrifuged at
13,000g for 10 or 30 minutes at 4°C. The cleared lysate was then transferred to a
Qiagen-tip which had been equilibrated with 1ml or 4ml ‘buffer QBT’ and then
washed twice with 2ml or 10ml ‘buffer QC’. The DNA was eluted with 0.8ml or
5ml ‘buffer QF’ before precipitation by addition of 6µl or 350µl 3mM NaAC
(pH5.2) and 1.4ml or 12.5ml ethanol followed by incubation at -70°C for 30
minutes and centrifuging at 8,500 for 30 minutes at 4°C. The DNA pellet was
washed with 1ml or 2ml 70% ethanol, centrifuged at 15,000 for 10 minutes and
then air-dried for 10 minutes before re-suspension in Tris-EDTA (10mM Tris, pH
7.5, 1 mM EDTA) buffer and stored at -20ºC until required.
2.15.iii Restriction digestions
$ ȝO GLJHVWLRQ UHDFWLRQ YROXPH FRQWDLQHG ȝO 1RW, RU ȝO (FR5, IRU S8&
VDPSOHVȝO[EXIIHU'3RPHJDȝO[%6$3URPHJDȝOSODVPLGDQG
ȝO '1DVH51DVHIUHH GLVWLOOHG ZDWHU 7KH UHVWULFWLRQ HQ]\PH WDUJHWV VSHFLILF
sequences in the DNA and is listed in Table 2.3. The DNA was digested overnight,
at 37ºC, with the resulting products run out on a 0.7% agarose gel.
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Table 2.3 – Specification of the NotI restriction endonuclease (cleaved at the
points *).
RESTRICTION ENZYME TARGET SEQUENCE IN DNA
NotI (Promega) 5’-GC*GGCC GC-3’
3’-CG CCGG*CG-5’
2.15.iv Agarose gel purification
A 0.7% agarose gel was prepared by melting 2.1g agarose into 300ml 1x TBE
(Tris Borate EDTA) buffer, which was diluted from a 10x stock. The buffer was
heated in a microwave for approximately 5 minutes, with regular agitation, until
WKH DJDURVH ZDV PROWHQ 7KH DJDURVH ZDV DOORZHG WR FRRO VOLJKWO\ DQG ȝJPO
ethidium bromide was added. The agarose gel was then poured into the gel
electrophoresis casting containing a 16-well gel comb and left to set. Once set, the
agarose gel was placed into an electrophoresis tank, filled with 1x TBE buffer.
ȝO RI '1$ ZDV ORDGHG SHU ZHOO DIWHU EHLQJ GLOXWHG  ZLWK [ *HO ORDGLQJ
solution (Fisher Scientific, Loughborough, UK). The gel was also loaded with
ȝORIDNE'1$ODGGHU1HZ(QJODQG%LRODEV+LWFKLQ8.ZKLFKSURYLGHG
an accurate molecular weight scale, to aid with DNA size quantification. The gel
was run at 150V for approximately 60minutes. The DNA molecules ran towards
the cathode, being separated according to their molecular weight. The mutagen
ethidium bromide intercalated itself into the double-stranded DNA, allowing it to
be visualised under ultra-violet (UV) light, either via the Syngene ChemiGenius
BioImaging system, or a UV lamp. The DNA was purified from the agarose gel
using the Wizard
®
SV Gel Clean-Up System (Promega). Briefly, using a clean
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scalpel, the larger (5838bp) pCMV6-Neo DNA fragments were excised from the
gel into a 1.5ml microcentrifuge tube and weighed. The gel slices were dissolved
at 60ºC in 10µl membrane binding solution per 10mg of gel. The DNA samples
were incubated on minicolumns for 1 minute and then collected onto the filter by
centrifugation at 16,000g for 1 minute. The DNA was then washed by adding
700µl membrane wash solution and centrifuging the samples at 16,000g for 1
minute followed by 500µl membrane wash solution and centrifuging at 16,000g
for 5 minutes. The DNA was eluted into a clean 1.5ml microcentrifuge tube by
addition of 50µl nuclease-free H2O and centrifuging at 16,000g for 1 minute and
its concentration was determined using the CE 7200 spectrophotometer (Cecil
instrument Ltd, Cambridge, UK) according to the manufacturer’s instructions. The
DNA was stored at -20ºC until required.
2.15.v Ligations
$ ȝO OLJDWLRQ UHDFWLRQ YROXPH FRQWDLQHG ȝO [ EXIIHU DQG 7 '1$ OLJDVH
HQ]\PH3URPHJDȝOS&091HRZLWKWKHGLIIHUHQFHPDGHXSXVLQJQXFOHDVH
free H22$VHFRQGOLJDWLRQUHDFWLRQZDVVHWXSZKLFKFRQWDLQHGȝOS&091HR
for comparison. The two ligations were incubated overnight at 15ºC, to allow for
the compatible ends of the pCMV6-Neo vector to combine. Prior to transfection
modifying enzymes were removed from the ligation reactions by addition of 5µl
StrataClean resin (Stratagene) and centrifuging at 2,000g for 1 minute. 10µl of
supernatant was removed to a fresh microcentrifuge tube before repeating the
process.
M.Grundy
63
2.15.vi Plasmid sequencing reactions
The reactions used the forward sequencing primers VP1.5
(5`GGACTTTCCAAAATGTCG-3`) and reverse primers XL39 (5`-
ATTAGGACAAGGCTGGTGGG-3`) as recommended by Origene. Sequencing
reactions were set up using BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) according to manufacturer’s instructions. The sequencing
UHDFWLRQ FRQVLVWHG RI ȝO EXIIHU ȝO VHTXHQFLQJ PL[ ȝO SODVPLG FORQH ȝO
S0SULPHUDQGȝOGLVWLOOHG+ZKLFKZDVUXQRQWKH%LRPHWUD7JUDGLHQW
PCR machine (Biometra, Goettingen, Germany) using the following programme;
96ºC for 1 minute followed by 25 cycles of 96ºC for 10secs (denaturing stage),
50ºC for 5secs (annealing stage) and 60ºC for 4 minutes (extension stage). The
sequencing reaction was then added to 2µl sodium acetate/EDTA followed by
66µl absolute ethanol and incubation on ice for 15 minutes. After centrifuging at
13,000g for 20 minutes the supernatant was removed and 250µl 70% ethanol was
added before centrifuging at 13,000g for 5 minutes and air drying for 20 minutes.
Samples were re-suspended in HiDi buffer and then electrophoresed using an ABI
3130 Genetic Analyzer (Applied Biosystems) and results analyzed using the
Sequencing Analysis 5.2 software (Applied Biosystems).
2.16 UIC2 shift assay
The reactivity of the UIC2 antibody with Pgp is increased by the addition of Pgp
transported compounds and has been described by Park (Park et al., 2003). Briefly,
cells were re-suspended at 5x10
5
/ml in culture medium and incubated for 10
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minutes at 37°C, 5% C02. 1µM AZD1152-hQPA or 5µM of the known Pgp
substrate vinblastine, or both were added to cells in duplicate and incubated at
37°C, 5% C02 for 4 hours. 10µg/ml etoposide +/- vinblastine was also included as
a negative control. Either 0.1µg/ml UIC2 monoclonal antibody (Immunotech) or
IgG2a isotype control (Dako) was added to paired samples and incubated for a
further 15 minutes. Cells were washed twice in PBSAA, re-suspended in 20%
Rabbit serum, and placed on ice for 30 minutes. 5µl FITC-conjugated rabbit anti-
mouse secondary antibody (Dako) was then added to cells, and following 30
minutes incubation on ice, cells were washed twice and analyzed by flow
cytometry. An increase in FL1 fluorescence compared to a drug free control is
taken to indicate the presence of a Pgp substrate.
2.17 Radio-labelled drug accumulation assay
OCI-AML3, OCI-AML3DNR and OCI-AML6.2 cell lines were plated in
duplicate onto 12 well plates and pre-incubated for 30 minutes with or without the
Pgp modulators CSA (Hospital pharmacy) at 2.5µg/ml or PSC833 (Sandoz
pharmaceuticals) at 2µM/ml or the BCRP modulator FTC at 10µM/ml or diluent
control. Medium containing 0.017µCi radio-labelled [
14
C]-AZD1152-hQPA (Astra
Zeneca; Figure 2.2) was then added to give a final drug concentration of 300nM.
The cultures were incubated for 1 hour at 37°C with agitation after 30 minutes.
The radioactive medium was then aspirated and cells washed twice with ice cold
PBS before permeabilization with 1% sodium dodecylsulphate. Cell extracts were
then added to scintillation fluid (Perkin Elmer)
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and radioactivity, recorded as counts per minute (CPM), measured using a TRI-
CARB 2100TR liquid scintillation analyzes (Packard).
2.18 FLT3 mutation analysis
Genomic DNA was extracted from samples using a QIAamp blood DNA isolation
kit (Qiagen, Crawley, UK) according to the manufacturer’s protocol.
Approximately 100ng of genomic DNA was used as template in fluorescent PCR
amplification (24 cycles) to amplify exons 14 and 15 and the intervening intron of
the FLT3 gene using previously described primers with the FOR primer FAM-
labelled (Kiyoi et al., 1999). Analysis was performed on a 3130 Genetic Analyzer
using the GeneMapper ID software v3.2 (Applied Biosystems), this allowed for
determination of length of FLT3-ITD and proportion of DNA containing the
length mutation.
2.19 Detection of pFLT3 – Immunoprecipitation and
immunoblotting
14C
Figure 2.2 The chemical structure of radiolabelled AZD1152-HQPA.
Chemical structure of radiolabelled AZD1152-hQPA
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Cell lines were washed in ice cold PBS and resuspended in lysis buffer (50nM
Tris[pH 7.4], 150mM NaCL [Fisher Scientific, Loughborough, UK], 1% NP-40
[BDH Laboratory supplies, Lutterworth, UK], 0.25% Na-deoxycholate, 1mM
EDTA, 2µg/ml leupeptin, 5µg/ml aprotinin, 1µg/ml pepstatin, 20mM NaF, 1mM
PMSF and 3mM sodium orthovanadate) for 30 minutes. Samples were then
sonicated before addition of 200mM PMSF and incubation for 30 minutes on ice.
The samples were clarified by centrifugation at 100,000g and the supernatant was
assayed for protein content using Bio-Rad dye reagent. Rabbit polyclonal FLT3
(Santa Cruz, CA, USA) was added to the extract and incubated overnight with
mixing. Protein A agarose beads (Upstate) were added for an additional 2 hours.
After sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transfer to nitrocellulose membranes, immunoblotting was performed with
mouse monoclonal anti-phosphotyrosine antibody (Upstate) to detect
phosphorylated FLT3 and then the blots were stripped and re-probed with rabbit
polyclonal Flt-3/Flk-2 (Santa Cruz) antibody to measure total FLT3. Proteins were
visualized using chemiluminescence (Hyperfilm ECL; Amersham), scanned using
a Syngene densitometer and analyzed using GeneSnap software (Syngene,
Cambridge, UK).
2.20 Phosphorylated signal transducer and activator of
transcription factor 5 (pSTAT5) analysis
Cells treated with AZD1152-hQPA or control cells were harvested, washed in
PBSAA, and 5x10
5
cells treated with fixation medium at RT for 15 minutes. Ice
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cold methanol was added and after 10 minutes incubation on ice, cells were
washed in PBSAA, re-suspended in permeabilization medium and 5µg of Mouse
anti-phosphoSTAT5 (Zymed) or mouse isotype control (Dako) was added. After
30 minutes incubation at RT, cells were washed twice in PBSAA, re-suspended in
20% Normal rabbit serum and incubated for 30 minutes on ice. 5µl of secondary
antibody (Rabbit anti-mouse IgG F(ab)2 FITC; Dako), was added and cells
incubated on ice for 30 minutes before washing twice in PBSAA and addition of
5µl CD45 PerCP (Becton Dickinson) and 5µl Normal Mouse serum. Samples were
then washed twice in PBSAA and collected using a FACScalibur.
2.21 Blast cell proliferation assay – 3H-Tdr uptake
To measure stimulated proliferation rate, blast cells were cultured as previously
described in section 2.7. Cells were plated onto 96-microwell plates at a
concentration of 1x10
6
/ml. After 48 hours of culture, cells were exposed to
tritiated thymidine ([
3
H]-Tdr, 5µCi/well; Amersham) for 6 hours. Cells were
harvested onto a 96 well filter plate using a Mash harvester and left overnight to
dry. Incorporation of [
3+@7GU ZDV WKHQ HYDOXDWHG E\ ȕVFLQWLOODWLRQ FRXQWLQJ
Basal proliferation was measured similarly without the 48 hours cytokine
incubation.
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2.22 Real-time PCR for ABCG2 and Aurora kinase B mRNA
message levels
Thawed and rested AML blasts were depleted of CD2
+
cells using Dynabeads (to
deplete NK and T cells some of which express ABCG2 mRNA (Scharenberg et
al., 2002). RNA from CD2 depleted AML blasts, the ABCG2 positive OCI-
AML6.2 and MV4-11 cell lines was prepared using QIAamp RNA kits with
DNase treatment according to the manufacturer’s instructions (Qiagen). Up to 2µg
of RNA was used in a reverse transcription reaction with Moloney murine
leukaemia virus (MMLV) reverse transcriptase (Invitrogen) and random hexamers
(Amersham Pharmacia). Quantitative PCR was performed on an ABI prism 7700
(Applied Biosystems, Warrington, UK) using Excite Real Time Mastermix with
sybr green (Biogene). Each reaction consisted of 1x Excite mastermix, sybr green
(1:60,000 final concentration), 40nM of both forward and reverse primers (for
ABCG2 reactions) or 2µl of aurora kinase B forward and reverse primer mix
(Qiagen: QT00067403), 1.6µl cell line or blast cDNA (or H2O for template
control) and H2O to a final volume of 20µl. Thermal cycler conditions included an
incubation at 95
o
C for 10 minutes followed by 40 cycles of 95
o
C for 15secs and
60
o
C for 1 minute. Following the 40 cycles, the products were heated from 60
o
C to
95oC over 20 minutes during which a melting curve analysis was performed. This
allowed the specificity of the products to be determined (indicated by the presence
of a single melting peak) and confirmed the absence of product generated by
primer-dimer association. To enable the levels of transcripts to be quantified
standard curves were generated using serial dilutions of OCI-AML6.2 or MV4-11
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Table 2.4 – Oligonucleotide primer pairs used during real-time RT-PCR for
ABCG2 mRNA.
PRIMER: SEQUENCE:
ABCG2 Forward: TGCAACATGTACTGGCGAAGA
Reverse: TCTTCCACAAGCCCCAGG
ȕ0 )RUZDUGGAGTATGCCTGCCGTGTG
Reverse: AATCCAAATGCGGCATCT
F'1$ 7KH KRXVHNHHSLQJ JHQH EHWDPLFURJOREXOLQ ȕ0 ZDV XVHG WR
standardize the samples and the relative expression levels of ABCG2 or aurora
kinase B transcripts were therefore calculated as the ratio between the level of
$%&*RUDXURUDNLQDVH%DQG WKH OHYHORIȕ0%RWKVHWVRI UHDO WLPHSULPHUV
used for ABCG2 message levels have been previously published (Pallisgaard et
al., 1999; Abbott et al., 2002) and are shown in table 2.4. Negative controls (no
template) were included in each experiment and all reactions were run in triplicate.
2.23 Primary cell colony formation assay
Freshly isolated mononuclear cells were washed, resuspended in methylcellulose
based medium H4534 (Stem Cell Technologies) containing 0-30nM AZD1152-
hQPA or diluent control (Astra Zeneca, Alderley Edge, UK) and plated in
triplicates onto 96 well plates (100µl containing 2x10
4
cells). The plates were
incubated for 14 days at 37°C in 5% CO2 and the number of colonies formed then
counted under the microscope. Colonies were defined as >20 cells and growth
defined as >12 colonies present in untreated wells.
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2.24 Statistical analysis
Statistical analysis was carried out using the Statistical Package for Social
6FLHQFHV YHUVLRQ  6366 &KLFDJR ,/ 86$ 3 YDOXHV RI  ZHUH
considered to represent significance.
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Chapter Three
BIOMARKER
VALIDATION AND
CHEMOSENSITIVITY
OF AML CELLS TO
AZD1152-hQPA
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3.1 Background
AZD1152-hQPA is a highly potent and selective inhibitor of aurora-B. It is known
that aurora-B phosphorylates Histone H3 at Ser
10
during mitosis (Hsu et al., 2000)
a process thought to be required for correct chromosome condensation (Wei et al.,
1999). We therefore intended to use Histone H3-Ser10 phosphorylation as a
biomarker for AZD1152-hQPA activity in our assays.
3.2 Does AZD1152-hQPA reach its target? Measurement of
pHH3/DNA content and protocol validation
The effects of AZD1152-hQPA were examined in logarithmically growing KG-1a,
U937, M-07e, OCI-AML3, OCI-AML6.2, MV4-11 and MOLM-13 leukaemic cell
lines. This panel of cell lines was selected to represent the heterogeneous nature of
AML. The KG1-a cell line is drug naïve, but positive for Pgp, as are many cases of
untreated AML. There is no known drug naïve BCRP positive AML cell line in
existence, so the BCRP-transfected OCI-AML6.2 cell line was used. The FLT3-
ITD expressing MV4-11 and MOLM-13 cell lines were included as the FLT3 gene
is one of the most commonly mutated genes in AML and is associated with poor
prognosis (Gilliland, 2002). All of the previously mentioned cell lines are cytokine
independent so the cytokine dependent M-07e cell line was included for
comparison (Brizzi et al., 1990).
An in house flow cytometry protocol for measuring phosphorylated proteins was
used to measure pHH3 expression and the fixation and permeabilization technique
M.Grundy
73
previously developed by our group for measuring phosphorylated STAT5 was
employed (Pallis et al., 2003a). The pHH3 antibody stained with extreme
brightness in the FITC (Fluorescein isothiocyanate) channel (Figure 3.1(A)).
Because previous work with aurora kinase inhibitors had shown an increase in
ploidy of treated cells (Ditchfield et al., 2003) we wanted to be able to counter
stain with propidium iodide (PI) to measure cellular DNA content. However,
because of spectral overlap between PI in the PE (PhycoErythrin) channel and the
FITC channel, compensation was impossible to set with any confidence. It was
decided to change the counter-stain to 7-AAD which has minimal spectral overlap
with FITC (Rabinovitch et al., 1986) (Figure 3.1(B)). Back gating solely on the
pHH3 positive population (Figure 3.1(C)) showed pHH3 expression only in the
G2/M phase of the cell cycle as determined by 7-AAD staining. To confirm that
pHH3 was only seen in mitotic cells it was decided to visualize the cells using
immunofluorescence. Cells were treated identically as for Histone H3 flow
cytometric analysis up until the final wash step. Cells were then manually placed
R3 R4
R5
Flow cytometric measurement of pHH3 expression
A CB
R3 R4
R5
pHH3 7AAD (DNA content)
Figure 3.1 Flow cytometric measurement of pHH3 expression (FL1-H)
and 7-AAD (DNA) content (FL3-A) in log phase U937 cell line (A and B).
The histogram in plot (C) is gated solely on the pHH3-positive population
(R3) and confirms 7AAD content/pHH3 expression only in the G2-M
phase of the cell cycle. Representation of three separate experiments.
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onto glass slides, mounted in VECTASHIELD mounting medium containing
DAPI, and visualized with a fluorescent microscope. Immunofluorescence
confirmed that pHH3 was only present in mitotic cells (Figure 3.2).
To be able to use pHH3 as a biomarker for AZD1152-hQPA activity we needed to
demonstrate its inhibition by the drug. U937 cells treated with AZD1152-hQPA at
relatively low concentrations and time periods showed significant inhibition of
percent of total cells expressing pHH3 (Figure 3.3). U937 cells treated with
300nM AZD1152-hQPA for 60 minutes showed almost complete loss of pHH3
(Figure 3.3).
A
C
B
pHH3 and DAPI staining by immunofluorescence
Figure 3.2 pHH3 (FITC) labelled U937 cells counterstained
with DAPI measured on the FISH microscope with (A) DAPI,
(B) DAPI/FITC and (C) FITC fluorescence. Cells with mitotic
DNA are clearly distinguished with DAPI and the pHH3
stained cells were all mitotic.
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3.3 Chemosensitivity of AML cell lines to AZD1152-hQPA
Inhibition of aurora-B activity by AZD1152-hQPA was indicated by a decrease in
the phosphorylation of Histone H3 on Ser10 (Figure 3.3). The basal range of
pHH3 expression in the cell lines was 2.5-4.8% of total cells (Figure 3.4). At
concentrations of 0-1000nM after 24 hours, inhibition of pHH3 was achieved in all
but one of the seven cell lines with complete inhibition achieved at 300nM in all
but two of the lines (Figure 3.4). Seventy-two hours incubation with AZD1152-
hQPA caused loss of viability to a varying degree in the cell lines, with an IC50 of
<60nM achieved in all but two cell lines (Figure 3.5).
The Pgp expressing KG-1a cell line showed high resistance to pHH3 down-
regulation and cell death compared to the Pgp null U937 cell line (Figure 3.4(A)
and 3.5(A)). Almost complete loss of pHH3 was achieved at a concentration of
30nM in U937 cells (p=0.001) with KG-1a resistant at concentrations up to
M1
M1
M1 M1
3.53%
0.02%
0.45%3.3%
1.17%
Inhibition of pHH3 expression by AZD1152-hQPA in U937 cells
pHH3
Figure 3.3 Inhibition of pHH3 expression by AZD1152-hQPA in U937 cells. pHH3
(FITC/FL1-H) labelled U937 cells treated with 30nM AZD1152-hQPA (A) or 300nM
AZD1152-hQPA (B) for 15 or 60 minutes. Percentages are % of total cells expressing
pHH3. Representation of three separate experiments.
pHH3
Untreated control
B
M1
A
15 minutes 15 minutes
60 minutes 60 minutes
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1000nM. Although the KG-1a cells are resistant to 24 hour pHH3 down-regulation
with 1000nM AZD1152-hQPA, the same concentration of drug induced an 80%
loss of viability after 72 hours (Figure 3.5(A)). The p53 wildtype cell line M-07e
was sensitive to AZD1152-hQPA with a significant loss of pHH3 at 100nM
Specificity of AZD1152-hQPA - pHH3 expression
Figure 3.4 Flow cytometric measurement of pHH3 expression
in AML cell lines after 24 hours of AZD1152-hQPA exposure
(*p=0.001/**p=0.019/***p=0.003/****p=0.207/*****p=0.035/******
p=0.013, (analyzed using paired samples t-test), +95%
confidence interval). Columns, mean of three experiments;
bars, SD.
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(p=0.019) and 300nM inducing complete loss with subsequent loss of viability at
72 hours (Figure 3.4(A) and 3.5(A)).
The BCRP transfected OCI-AML6.2 cell line also showed a high degree of
resistance compared to the parental cell line OCI-AML3 (Figure 3.4(B) and 3.5(B)).
There was significant inhibition of pHH3 in the OCI-AML3 (p=0.003) cells at
30nM AZD1152-hQPA before complete inhibition at 100nM. The decrease in
pHH3 seen at 300nM and 1000nM AZD1152-hQPA in the OCI-AML6.2 cells was
Specificity of AZD1152-hQPA – cell viability
Figure 3.5 Flow cytometric measurement of viable cells
after 72 hours of AZD1152-hQPA exposure. Lines, mean
of three experiments; bars, SD.
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not statistically significant (p=0.408/0.207). In terms of viability OCI-AML6.2
cells were the most resistant with no IC50 achieved after 72 hours of high dose
AZD1152-hQPA (Figure 3.4(B)).
Interestingly, the most sensitive of the cell lines tested were the FLT3-ITD
expressing MV4-11 and MOLM-13 cell lines. Both lines showed significant pHH3
inhibition at 10nM AZD1152-hQPA, p=0.035 and p=0.013 respectively (Figure
3.4(C)), before complete inhibition at 30nM and a 72 hour viability IC50 of <10nM
(Figure 3.5(C)).
3.4 AZD1152-hQPA sensitive cells develop a polyploid DNA
content
Cell lines treated with AZD1152-hQPA for 24 hours were dual stained with pHH3
antibody along with 7-AAD to measure cellular DNA content (Figure 3.6A). Cell
lines sensitive to pHH3 inhibition consistently failed to divide and developed a
polyploid (8N) DNA content after treatment with AZD1152-hQPA. U937 cells
exhibit an 8N population after 10nM treatment with the majority of cells having a
polyploid DNA content after 30nM treatment (Figure 3.6A). Likewise, OCI-
AML3 and M-07e cells show >4N DNA content after 24 hour incubation with low
concentrations of AZD1152-hQPA. No polyploid populations were seen in the
KG-1a or OCI-AML6.2 cell lines following 100nM AZD1152-hQPA treatment for
24 hours.
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To confirm whether the AZD1152-hQPA sensitive cells were becoming polyploid
and we were not just seeing a shift in fluorescence in the flow histograms, OCI-
AML3 control (Figure 3.6A(i)) and 24 hour 30nM AZD1152-hQPA treated cells
(Figure 3.6A(iii) were stained with DAPI and visualized on the FISH microscope
(Figure 3.6B). Cells with polyploid DNA can clearly be distinguished in the
AZD1152-hQPA treated cells (Figure 3.6B(ii)).
8N
(ii)
(iii)
(iv)
(i)
OCI-
AML3
OCI-
AML6.2 KG-1a U937 M-07e
DNA content
4N
Figure 3.6 Flow cytometric DNA (7-AAD) content histograms of
AML cell lines exposed to 0nM (i), 10nM (ii), 30nM (iii) and 100nM
(iv) AZD1152-hQPA for 24 hours (A). OCI-AML3 cells exposed to
0nM (i) and 30nM (ii) AZD1152-hQPA for 24 hours stained with
DAPI and viewed on the FISH microscope. Cells with polyploid
DNA (ii) are clearly distinguished with DAPI stain.
DNA content of AZD1152-hQPA treated cell lines
8N
2N
4N
A
B (ii)(i)
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3.5 Chemosensitivity of AML cell lines to AZD1152-hQPA
compared to conventional therapy
The standard induction regimen for newly diagnosed AML consists of three days
of an anthracycline (e.g. DNR, at least 60 mg/m2, idarubicin, 10-12 mg/m2, or the
anthracenidione mitoxantrone, 10-12 mg/m2) intravenously and cytarabine (Ara-
c), 100-200 mg/m
2
by continuous infusion for seven days. With such (“3 + 7”)
regimens 60% to 80% of young adults and 40% to 60% of older adults can achieve
CR (Zhu et al., 2009). Any novel drug for potential use in the treatment of AML
should compare favourably with these standard treatments as a single agent and
possibly enhance their effects when used in combination.
Seven leukaemic cell lines were cultured for 72 hours with either 0-1000nM of
AZD1152-hQPA, DNR or Ara-c (Figure 3.7). 72 hour viability was measured
using 7-AAD and IC50 calculated for each cell line. In terms of concentration of
drug used AZD1152-hQPA compares better than DNR and Ara-c in achieving 72
hour IC50 in all but the KG-1a cell line. Interestingly, the specificity of AZD1152-
hQPA is extremely similar to that seen with DNR (p=<0.0001), with the KG-1a
cell line standing out as the most resistant to the two agents (Figure 3.7(A) and (B)).
The specificity profile of AZD1152-hQPA is significantly different to that of Ara-
c (p=0.533) (Figure 3.7(A) and (C)). To study the effects of AZD1152-hQPA when
used in combination with DNR and Ara-c an IC50 concentration for 72 hour
viability for each drug was selected for MOLM-13 cells (Figure 3.7). MOLM-13
cells were then treated with IC50, ½IC50 and ¼IC50 for each drug alone or a
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combination of AZD1152-hQPA plus DNR or Ara-c (Figure 3.8(A) and (B)) for 72
hours and resulting viability data fed into CalcuSyn software. CalcuSyn is a dose
effect analyzes programme for single and multiple drugs (Chang, 2000). It
quantifies the effects of drug combinations to determine whether they give greater
effects together (synergism) than that expected from their individual effects. The
programmeme automatically plots the data and produces reports of summary
Specificity of AZD1152-hQPA compared to
conventional therapy
Figure 3.7 Flow cytometric IC50 values of leukaemic cell lines
treated for 72 hours with AZD1152-hQPA (A) compared to
DNR (B) or Ara-c (C) (*p<0.0001/**p=0.533, analyzed using
Pearson’s correlation). Columns, mean of three experiments;
bars, SD.
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statistics for all drugs and detailed analysis of drug interactions including the
Combination Index (CI) (Figure 3.8(C)). CalcuSyn gave an IC50 CI value of 1.24
for the combination of AZD1152-hQPA and DNR which is in the “moderate
Specificity of AZD1152-hQPA in combination
with conventional therapy
A
B
Figure 3.8 Flow cytometric measurement of viable MOLM-13
cells after 72 hours exposure of AZD1152-hQPA, DNR or a
combination of both (A) and AZD1152-hQPA, Ara-c or both
(B). Lines, mean of three Experiments. CalcuSyn gives an
IC50 CI value of 1.24 (*) and 0.55 (**). Combination index
(CI) table (C).
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antagonism” range. However, an IC50 CI value of 0.55 was obtained for the
combination of AZD1152-hQPA and Ara-c which is in the “synergism” range.
3.6 Mechanism of cell death following AZD1152-hQPA
treatment
3.6.i Detection of apoptosis with the Annexin V-FITC assay
Apoptosis, or programmemed cell death, is an essential mechanism used by multi-
cellular organisms to negatively select cells that are deemed deleterious to the
host. Typical apoptosis is distinguished from necrosis as the former involves the
activation of specific pathways that result in characteristic morphological features
including DNA fragmentation, chromatin condensation and formation of apoptotic
bodies. Many stimuli can trigger various pathways to apoptosis, but all these
pathways converge to a common process involving the activation of a cascade of
caspases that specifically cleave substrates at aspartic acid residues. One of the
distinct cellular changes during apoptosis is the loss of phospholipid asymmetry,
where during early apoptosis phosphatidylserine is translocated from the internal
to the external portion of the cellular membrane.
Annexin V-FITC is a fluorescent probe which detects early apoptosis by binding
to externalized phosphatidylserine in the presence of calcium using flow cytometry
(Pepper et al., 1998). Dual staining of cellular DNA with propidium iodide (PI)
allows detection of cells where the membrane has been totally compromised. Cells
which are early apoptotic will stain with the Annexin V-FITC alone. Live cells
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show no staining with either Annexin V-FITC or PI while necrotic cells are
stained by both Annexin V-FITC and PI. Annexin staining of AZD1152-hQPA
treated cell lines demonstrates that cell death is by apoptosis (Figure 3.9A). The
FSC-H/SSC-H histogram plot in Figure 3.9B is a measure of cell size (FSC-H) and
granularity (SSC-H) and allows us to distinguish the polyploid (FSC-H/SSC-H
high) population of cells. Gating on the treated cells whole population
R1
(i)
(iii)(ii)
U937 M-07e OCI-AML3
(i)
(ii)
(iii)
(iv)
Annexin V-FITC
P
ro
p
id
iu
m
Io
d
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e
Annexin V-FITC analysis of AZD1152-hQPA treated cell lines
A
B
Figure 3.9 Annexin V-FITC analysis of cell lines after 48 hours exposure
to 0nM (i), 10nM (ii), 30nM (iii) and 100nM (iv) AZD1152-hQPA (A).
Untreated U937 cells (i) with cells treated for 48 hours with 30nM
AZD1152-hQPA gated on the whole cell population (ii) and treated cells
gated on the SSC-H/FSC-H high (polyploid) population (iii) (B).
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(Figure3.9B(ii)) demonstrates a clear apoptotic (FL1 high/FL2 low) and necrotic
(FL1 high/FL2 high) population. By back-gating on the polyploid population
(Figure 3.9B(iii)) it can be seen that this population contains apoptotic cells. This
agrees with previous findings that treatment with aurora-B inhibitors results in the
accumulation of polyploid cells and subsequent apoptosis (Wilkinson et al., 2007;
Yang et al., 2007).
3.6.ii Detection of apoptosis with active Caspase-3 and
Apop2.7 (7A6) antibodies
Annexin staining of AZD1152-hQPA treated cells demonstrates that cell death is
by apoptosis (Figure 3.9). To investigate this further two more markers of
apoptosis were used, namely active caspase-3 and 7A6 antigen.
Caspase-3 is a key protease that is activated in the early stages of apoptosis (Belloc
et al., 2000). It is synthesized as an inactive pro-enzyme, and is mainly located in
the cytoplasm of cells. During apoptosis, caspase-3 is cleaved and activated by
upstream caspases, and is translocated into the nucleus to cleave its nuclear
substrates, resulting in characteristic apoptotic nuclear changes such as DNA
fragmentation, chromatin condensation and nuclear disruption (Belloc et al.,
2000).
7A6 is a 38 kDa mitochondrial membrane protein also expressed in early apoptosis
which is recognized by the Apop2.7 antibody (Nagahara et al., 2007). Active
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caspase-3 and 7A6 expression was measured by flow cytometry in U937 cells after
48 hours culture with 0-300nM AZD1152-hQPA (Figure 3.10A). Both apoptotic
markers were increased in a dose dependent manner to AZD1152-hQPA (p<0.05
for all conditions when compared to untreated controls for both markers) (Figure
AZD1152-hQPA induces active-caspase3 and 7A6 expression
Figure 3.10 Examples of histogram plots showing flow cytometric detection of
active caspase-3 and 7A6 expression in U937 cells after 48 hours exposure
to AZD1152-hQPA (A). Bar charts showing flow cytometric detection of active
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3.10B). Back-gating on the polyploid population of cells showed that active
caspase-3 is only expressed in this population (Figure 3.11). This again supports
the argument that treatment with AZD1152-hQPA results in the accumulation of
polyploid cells that subsequently apoptose.
3.6.iii H2A.X phosphorylation
In the eukaryotic nucleus, the genome is organized into chromatin. Two molecules
each of the core histones (H2A, H2B, H3 and H4) form a single histone octamer,
around which 146 base pairs of DNA are wrapped in repeating units, called
nucleosomes, forming the basic subunit of chromatin (Kornberg, 1974).
Nucleosomes wrap DNA into chromatin, allowing for the compaction and storage
of genetic material. DNA accessibility is regulated via a complex set of post-
AZD1152-hQPA induces active-caspase3 from the polyploid
population of cells
Figure 3.11 Flow cytometric detection of active Caspase-3 (FL2-H) in U937
cells after 48 hours culture (A). The solid line is the untreated control and the
hollow grey line shows cells treated with 100nM AZD1152-hQPA. Plots B and
C are cells treated with 100nM AZD1152-hQPA with plot B gated on
FSC/SSC low cells and plot C gated on the FSC/SSC high (polyploid) cells.
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translational modifications of histones, which are of great importance to their
function as governors of genome access, as they mediate rapid and reversible
responses to changing cellular signals. Histones therefore play a central role in
transcription regulation, DNA repair, DNA replication and chromosomal stability
(Ismail, 2008). Agents that cause DNA damage and double-stranded DNA breaks
(DSBs) include ionizing radiation, topoisomerase inhibitors, or DNA binding
drugs. One of the principal responses to DSBs is the activation of the ATM-
initiated signalling cascade to arrest cell division until repairs can be made. A
major substrate of the kinases in this cascade is H2A.X which becomes
SKRVSKRU\ODWHGRQVHULQHDQGLVVXEVHTXHQWO\WHUPHGȖ+$;5RJDNRX et al.,
2000). These phosphorylation events are important for recruitment and
maintenance of the DNA repair machinery to the site of the break. When the DNA
damage is severe enough, the cell will undergo apoptosis, which involves
processing of the genome into small fragments and creating more DSBs. Thus
H2A.X phosphorylation at serine 139 can be used as an early marker for apoptosis.
Anti-phospho-H2A.X and 7-AAD staining was used to assess whether cells treated
with AZD1152-hQPA undergo DNA double strand breaks, characteristic of early
apoptosis, and at which point in the cell cycle these breaks occur. MOLM-13,
OCI-AML3 and U937 cells treated with AZD1152-hQPA for 24 hours all express
DNA double strand breaks shown by positive H2A.X staining (Figure 3.12).
Furthermore, all the cell lines exhibit double strand breaks in pre-polyploid cells
(R6 and R7 gates in H2A.X plots, Figure 3.12) as well as in cells with 8N DNA
content (R8 gates in H2A.X plots, Figure 3.12).
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AZD1152-hQPA therefore appears to induce a damage response in all phases of
the cell cycle with the phase affected more dependent on variability between AML
cell types than on drug.
3.7 Does cellular p53 status affect response to AZD1152-
hQPA?
A research group has recently published data suggesting that p53 is critical for
aurora-B kinase inhibitor mediated apoptosis in AML cells (Ikezoe et al., 2009).
Also, VX-680 is an aurora kinase inhibitor that is selective for aurora-A, B and C
and has been shown to preferentially induce endoreduplication in cells with
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compromised p53 (Gizatullin et al., 2006).
With this in mind it was decided to sequence our cell lines for p53 status (Figure
3.13 and Table 3.1). By measuring cellular DNA content, the effect of p53 status
on the cell lines response to AZD1152-hQPA, was then investigated (Figure
3.14A). p53 compromised HL60 and U937 cells acquired 8N DNA 24 hours after
AZD1152-hQPA treatment and continued DNA synthesis to a point where, at 48
hours, 8N peaks are not detected. The p53wt cell lines also acquire 8N at 24 hours
at which point DNA synthesis appears to be partially checked because the 8N
peaks remain visible for up to 72 hours. This seems to agree with results seen with
VX-680 where differences in cellular DNA content after AZD1152-hQPA
treatment depends on p53 status (Gizatullin et al., 2006). However if we look at
Example of p53 sequencing in AML cell lines
Figure 3.13 Example of a wild-type p53 sequence in OCI-
AML3 (A) and a mutation in KG-1a (B) cell lines. The black
box in B highlights a 5 base pair insertion (ATCTG)
between codons 224 and 225 in the KG-1a cell line.
A
B
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Table 3.1 – Cell line p53 status.
CELL LINE P53 STATUS
OCI-AML3 WT
MOLM-13 WT
MV4-11 WT
M-07e WT
HL-60 Null
U937 Mut (46 bp deletion)
KG-1a Mut (5 bp insertion)
the same AZD1152-hQPA treated p53wt MOLM-13, M-07e and OCI-AML3 cells
and analyze by flow cytometry with decreased voltage in the FL-2 channel a
further 16N peak can be detected (Figure 3.14B).
So although the p53wt cells are checked in comparison to p53 compromised cells,
p53 is not saving them from massive endoreduplication and subsequent loss of
viability. A 16N peak was not detected in the p53 compromised HL60 and U937
cells lines after decreasing the FL2 voltage (Figure 3.14B) indicating that these
cells apoptose before reaching this ploidy. Also, by revisiting figure 3.12 with
regard to cellular p53 status it should be noted that it is the p53 compromised
U937 cells which display more DNA damage (6.1%) in the G1/S phase of the cell
cycle (R6 gate in H2A.X plots, Figure 3.12) when compared to the p53wt MV4-11
(2.0%) and OCI-AML3 (0.7%) cells.
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Figure 3.14 Flow cytometric DNA content histograms (measured using 7-
AAD) after treatment with 30nM AZD1152-hQPA (A). Cell line DNA content
after 72 hours treatment with 30nM AZD1152-hQPA (B). In plot B(ii), the
cells were acquired at a lower voltage in the FL-2 channel, which allows us
to see a further 16N peak in p53 wt cells compared with the plots in B(i).
AZD1152-hQPA induced endoreduplication is paused but not
stopped in p53wt cell lines
A
B MOLM-13 M-07e OCI-AML3
16N
(i)
(ii)
HL60 U937
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Chapter Four
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4.1 Background
The effects of AZD1152-hQPA were examined in logarithmically growing OCI-
AML3, OCI-AML6.2, KG-1a, U937, M-07e, MOLM-13 and MV4-11 leukaemic
cell lines. The ABCG2 transfected OCI-AML6.2 along with the Pgp expressing
KG-1a cells, were the most resistant cell lines to both pHH3 inhibition and loss of
viability (Figure 4.1). Elevated expressions of Pgp and BCRP have both been
associated with poor prognosis and worse complete remission rates in AML (Leith
et al., 1997; Damiani et al., 2007). Because of this it was decided to measure Pgp
and BCRP transporter status in all of our cell lines and compare it to sensitivity to
AZD1152-hQPA.
pHH3 expression and cell viability
Figure 4.1 Flow cytometric measurement of pHH3 expression in AML cell lines after
24 hours of AZD1152-hQPA exposure (A) and flow cytometric measurement of
viable cells after 72 hours of AZD1152-hQPA exposure (B). Columns/lines, mean of
three experiments; bars, SD.
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4.2 Cell line Pgp and BCRP transporter status
Functional Pgp was determined using R123 retention and the known Pgp
modulator CSA as a positive control modulator (Pallis, 2005; Pallis et al., 2005).
The KG-1a cell line showed more than eleven times as much functional Pgp
expression compared to the other cell lines (p=0.002) (Figure 4.2). Functional
BCRP was measured using BODIPY retention and FTC as a modulator
(Rabindran et al., 2000). The OCI-AML6.2 cell line was the only one to show any
functional BCRP activity; more than six times that of their parent OCI-AML3 cells
(p=0.015) (Figure 4.2). High KG-1a Pgp levels (p=0.006) were also observed
when Pgp protein was measured using the MRK-16 monoclonal antibody (Figure
4.3(A)). High BCRP expression in the OCI-AML6.2 cell line was confirmed using
real-time PCR to measure ABCG2 message levels (Figure 4.3(B)). Clearly then, the
Pgp and BCRP functional expression in
AML cell lines
Figure 4.2 Flow cytometric measurement of Pgp and BCRP
function in AML cell lines. Pgp function was measured using
R123 accumulation and CSA as a positive control modulator.
BCRP was measured similarly with BODIPY-prazosin
accumulation and FTC as the modulator (*p=0.015/**p=0.002
(analyzed using paired samples t-test), +95% confidence
interval).
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only two cell lines which have elevated ABC transporter levels are the cell lines
which are most resistant to AZD1152-hQPA, both at the level of the biomarker
and cell viability.
An “isogenic” model for BCRP expression in our cell lines was available in our
lab, with the stably transfected OCI-AML6.2, and the parent OCI-AML3 cells. To
create a similar model for Pgp expression it was decided to stably transfect the
Pgp protein expression and ABCG2 message
levels in AML cell lines
Figure 4.3 Pgp protein expression and ABCG2 message levels
in AML cell lines. Pgp protein expression was determined flow
cytometrically using the MRK-16 monoclonal antibody
(*p=0.006 (analyzed using paired samples t-test), +95%
confidence interval) (A). Columns, mean of three experiments;
bars, SD. ABCG2 message levels were determined by real-
time PCR (B).
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MDR1 gene, coding for Pgp, into the OCI-AML3 cell line. It has been reported
that leukaemia and lymphoma cells are resistant to most non-viral gene transfer
methods (Schakowski et al., 2004). A novel electroporation based technique called
nucleofection has recently become available. This technique uses a combination of
special electrical parameters and cell type specific solutions to deliver the DNA
directly to the cell nucleus under mild conditions thus giving high efficiency and
low cell death rates (Schakowski et al., 2004).
4.3 Stable transfection of MDR1 into the OCI-AML3 cell line
4.3.i Optimization of cell viability and GFP expression
Initially the nucleofection protocol needed to be optimized for the OCI-AML3 cell
line. Logarithmically growing OCI-AML3 cells cultured for one week without
penicillin/streptomycin and with low passage number were used for transfection
experiments. Nucleofector solution was prepared by mixing nucleofector
supplement and nucleofector solution T (Amaxa Biosystems, Cologne, Germany)
(1:4.5). Cells were then counted, centrifuged for 10 minutes and re-suspended in
O SUHZDUPHG QXFOHRIHFWRU VROXWLRQ EHIRUH DGGLWLRQ RI ȝJ RI SPD[*)3
(green fluorescent protein) in a 2mm nucleofection cuvette (Amaxa) and
nucleofection using programme X-001. Use of solution T and programme X-001
was recommended by Amaxa Biosystems for optimal transfection efficiency and
YLDELOLW\ LQ 2&,$0/ FHOOV ,PPHGLDWHO\ DIWHU QXFOHRIHFWLRQ ȝO RI SUH
warmed RPMI containing 10% FCS was added to the nucleofection mixture, and
the cells were transferred to six-well plates containing RPMI supplemented with
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Table 4.1 – OCI-AML3 nucleofection conditions.
CELL
CONC
SOL.
T
GFP PROGRAMME GFP (%
GATED)
VIABILITY
(%)
1x10
6
- - - 0.75 99.34
1x10
6
+ + - 0.94 99.3
1x10
6
+ - X-001 2.59 78.06
1x10
6 + + X-001 60.4 70.4
2x10
6
+ + X-001 56.2 69.7
3x10
6
+ + X-001 54.2 68.4
4x10
6
+ + X-001 57.8 70.2
5x10
6
+ + X-001 53.2 67.1
10% FCS and 2mM L-glutamine. Cells were cultured for 24 hours, harvested and
counted, before addition of 50µg/ml 7-AAD for 15 minutes. Cell viability and
GFP expression (a measure of transfection efficiency) were determined flow
cytometrically. Controls consisted of cells alone and cells processed through the
nucleofection procedure +/- DNA or +/- programme X-001 (Table 4.1). A cell
concentration of 1x106 was deemed to be optimal giving a transfection efficiency
of 60.4% and a viability of 70.4%.
4.3.ii Expression vector for MDR1
The pCMV6-Neo vector contains a cytomegalovirus (CMV) immediate-early
promoter sequence (suitable for protein over-expression), a simian virus (SV)-40
and colicin E1 (ColE1) replication site and genes for neomycin and ampicillin
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resistance along with restriction sites for subcloning genes of interest (Figure 4.4).
Neomycin is a natural product that binds to ribosomal subunits inhibiting protein
synthesis and elongation resulting in cell death. G418 is a synthetic analogue that
mimics this inhibition, but whose action on mammalian cells is blocked by the
presence of the neomycin resistance gene product. Culturing transfected cells in
the presence of G418 effectively permits only those containing the pCMV6-Neo
gene construct to survive. Continued growth under antibiotic pressure allows
clonal selection of stable cell lines perpetually over-expressing the protein of
interest at 100% transfection efficiency. The MDR1 gene cloned into the pCMV6-
Neo vector (RSPD001-Neo) was supplied by Origene.
Figure 4.4 A plasmid map of pCMV6-Neo expression plasmid
detailing key constructs and restriction enzyme sites. The neomycin
/ampicillin resistance genes and SV40/ColE1 origins allow positive
selection and replication in mammalian and bacterial cells
respectively.
Physical map of pCMV6-Neo
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4.3.iii Limiting dilution of cells and G418 dosing
Optimization of the G418 concentration with the OCI-AML3 cell line was first
established before attempting positive selection. A limiting dilution procedure to
assess whether OCI-AML3 cells were able to produce colonies from isolated cells
also needed to be performed as some cell lines only grow if they have contact with
one another. Logarithmically growing OCI-AML3 cells cultured for one week
without penicillin/streptomycin and with low passage number were counted and
re-suspended in RPMI supplemented with 10% FCS and 2mM L-glutamine at a
concentration of 4x10
4
/ml. 100µl media was added to each well of a 96wp
followed by 100µl cell suspension to the first column of the well. After mixing,
100µl was carried over to the next and subsequent columns, discarding 100µl from
the last column. 100µl G418 containing media at 2.8mg/ml was then added to row
A followed by decreasing concentrations in the subsequent rows (Figure 4.5).
After 10 days cell growth was observed in wells without G418 and initially less
Figure 4.5 Plate set up for limiting dilution assay to determination
G418 and plating concentrations for OCI-AML3 cells.
Determination of G418 and plating concentrations
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than 4 cells so it was assumed that the OCI-AML3 cells could grow from isolation.
Complete cell death measured by trypan blue exclusion was observed in row F
(0.4mg/ml G418) after 10 days culture so a concentration of 0.6mg/ml G418 was
chosen for later positive selection experiments.
4.3.iv Preparation of control plasmid
To create a negative control for our nucleofection assays a plasmid without the
MDR1 gene insert needed to be prepared. To amplify stocks RSPD001-Neo was
transformed into ElectroTen-Blue electroporation competent bacteria as described
in the methods. Initially, the DNA plasmids were prepared using the Promega
PureYield plasmid miniprep and midiprep systems (Promega, Southampton, UK).
However, although DNA was obtained with these systems, when the NotI
digestions were run (as described later) we did not see the expected bands. We
thought the problem could be the amount of residual ethanol that was consistently
left-over in the binding column after processing with the Promega midiprep
system and that this was interfering with the digest. Because of this it was decided
to switch to Qiagen plasmid mini and midi kits (Qiagen) for plasmid preparation.
Prior to ligation and bacterial transformation, the DNA was digested using a
sequence-specific restriction enzyme. The object of the digestion was to cut out
the MDR1 insert from the RSPD001-Neo plasmid to produce pCMV6-Neo DNA
molecules with compatible ends for ligation. RSPD001-Neo plasmid was digested
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using NotI restriction enzyme. Two bands (at 4700bp and 5838bp) of the correct
size were present in the RSPD001-Neo digest (Figure 4.6) and the larger band was
then gel purified as described in the methods. Following ligation, the pCMV6-Neo
vector was then transformed into ElectroTen-Blue electroporation competent
bacteria as previously described to amplify stocks. The ligation reactions were
added to the bacteria and two different concentrations of each transformation were
plated onto agar in an attempt to obtain colonies. A control transformation
containing pUC18 was included to act as an electroporation control. Two bacterial
colonies were selected from each agar plate and grown up overnight. DNA
plasmids were prepared using the Qiagen plasmid miniprep kit and NotI digestions
performed as previously described before running on a 0.7% agarose gel. Two
bands (at 4700bp and 5838bp) were present in the RSPD001-Neo digest and just
one band (at 5838bp) in the pCMV6-Neo digest (Figure 4.7). 500µl of RSPD001-
Neo and pCMV6-Neo cultures were then taken to 19.5ml LB+AMP and grown up
-NotI +NotI
Figure 4.6 An agarose gel image of RSPD001-Neo NotI
digestion. The larger (5838bp) pCMV6-Neo plasmid can
be distinguished from the smaller (4700bp) MDR1
plasmid. A reaction without NotI was included as a
digestion control.
Agarose gel purification of pCMV6-Neo vector
1KB
ladder
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overnight at 37ºC. Cultures were then centrifuged at 6,000g for 10 minutes and re-
suspended in 1ml 15% glycerol in LB before storage at -80°C. To amplify DNA
for transfection a small amount of each glycerol stock was transferred in to 10ml
LB+AMP and incubated overnight. Plasmids were prepared with Qiagen plasmid
midiprep kits as previously described before digestion and running on a
0.7%agarose gel to confirm bands.
Sequencing reactions were electrophoresed using an ABI 3130 Genetic Analyzer
and results analyzed using the Sequencing Analysis 5.2 software as described in
the methods. The MDR1 and control pCMV6-Neo sequences matched those in the
literature and the control vector did not contain the MDR1 insert (NCBI Reference
Sequence: NM_000927.4 and www.origene.com).
Figure 4.7 An agarose gel image of RSPD001-Neo
(MDR1) and pCMV6-Neo NotI midiprep digestions. A
digestion without NotI was included as an enzyme
control.
NotI plasmid miniprep digestions
1KB
ladder MDR1 pCMV6-Neo
Undigested
control
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4.3.v Nucleofection and phenotyping for Pgp expression
Logarithmically growing OCI-AML3 cells cultured for one week without
penicillin/streptomycin and with low passage number were used for transfection
experiments. Nucleofector solution was prepared as previously described and
1x106 cells were then counted, centrifuged for 10 minutes, and re-suspended in
100µl pre-warmed nucleofector solution before addition of either 2µg MDR1
(RSPD001-Neo) or pCMV6-Neo in a 2mm electroporation cuvette and
electroporation using programme X-001. A nucleofection control condition was
LQFOXGHG ZLWK QR '1$ ,PPHGLDWHO\ DIWHU HOHFWURSRUDWLRQ ȝO RI SUHZDUPHG
RPMI containing 10% FCS was added to the electroporation mixture, and the cells
were transferred to six-well plates containing RPMI supplemented with 10% FCS
and 2mM L-glutamine. Six hours post nucleofection an additional 1ml of growth
medium was added to each well to avoid overcrowding of cells. Cells were then
allowed to express the protein for G418 resistance under non-selective conditions
for 48 hours before being transferred to 25cm
2
culture flasks and the addition of
0.6mg/ml G418. Cells were incubated for 72 hours, counted by trypan blue
exclusion, and plated out in three 96wps per condition at 4x10
4
/ml. After 9 days
cells were fed with fresh growth medium containing 0.6mg/ml G418. At day 16
cellular outgrowths were seen in the RSPD001-Neo and pCMV6-Neo plates whilst
all of the control cells were dead. Cells were then expanded further before another
round of serial dilution (as previously described) under G418 selection to assure
that cell populations represented clones from a single cell. After further expansion,
13 RSPD001-Neo clones were present, where outgrowth appeared to be from a
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Table 4.2 – Pgp protein expression and function in RSPD001-Neo and pCMV6-
Neo clones.
CLONE/CELL LINE MRK-16 MFI (T/C) R123 MODULATION RATIO
RSPD001-Neo (1) 1.01 0.97
RSPD001-Neo (2) 1.0 -
RSPD001-Neo (3) 1.02 1.01
RSPD001-Neo (4) 1.03 1.02
RSPD001-Neo (5) 1.06 0.97
RSPD001-Neo (6) 0.96 -
RSPD001-Neo (7) 1.03 1.06
RSPD001-Neo (8) 1.03 1.04
RSPD001-Neo (9) 0.98 -
RSPD001-Neo (10) 0.99 -
RSPD001-Neo (11) 0.98 -
RSPD001-Neo (12) 0.97 -
RSPD001-Neo (13) 0.96 0.95
KG-1a 6.65 14.99
OCI-AML3 0.97 0.91
pCMV6-Neo 0.94 0.98
single cell. Pgp protein expression was measured in all 13 clones using the MRK-
16 monoclonal antibody with KG-1a and OCI-AML3 cells included for positive
and negative controls along with the pCMV6-Neo clone (Table 4.2). Pgp function
was determined by modulation of R123 efflux by the Pgp modulator PSC833 in 7
of the clones (Table 4.2). Pgp protein level was recorded as positive when the
05. WHVWFRQWUROYDOXHZDVEDVHGRQGDWDJDWKHUHGGXULQJ WKH$0/
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and AML15 trials carried out in our lab). Pgp was recorded as functional when the
36&5PRGXODWLRQUDWLRZDVEDVHGRQDSUHYLRXVVWXG\3DOOLV et al.,
1999b). None of the G418 resistant RSPD001-Neo clones were positive for Pgp
expression or function.
4.4 Selection of Daunorubicin resistant OCI-AML3 cells
Because the RSPD001-Neo clones failed to show any increase in Pgp it was
decided to try and select for Pgp expression in the OCI-AML3 cell line using the
known Pgp substrate DNR (Legrand et al., 1999; Borg et al., 2000) and a method
adapted from (Randle et al., 2007). OCI-AML3 cells were initially exposed to
DNR at a concentration of 10nM, which represented the IC50 concentration. Cells
were seeded at 5x105/ml in 50ml of complete medium containing 10nM DNR. At
days 3, 10 and 14, 50ml of fresh culture medium without DNR was added. At day
18 cells were pelleted and re-suspended in 160ml medium containing 10nM DNR.
From day 26 to day 35 the DNR containing medium was changed once per week.
At day 35 there were very few remaining viable cells, so cells were separated over
histopaque to exclude dead cells and cell debris. The remaining cells were re-
suspended in 10ml of medium containing 10nM DNR up until day 45 when cell
growth was seen. Cells were maintained at this drug concentration until their
growth rate approached that of untreated OCI-AML3 cells.
Over the next 10 weeks cells were exposed to gradually increasing concentrations
of DNR up to a final concentration of 15nM. By using the R123 accumulation
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assay these cells were confirmed to have increased levels of Pgp function and were
subsequently cloned by limiting dilution. Cells were serially diluted in 96 well
plates down to a concentration of 1 cell/well in medium containing 15nM DNR.
Any cells showing outgrowth were then gradually cultured in medium containing
15nM DNR up to sufficient numbers to be able to assay for Pgp protein and
function. One clone, which was named OCI-AML3DNR, showed an increase in
both Pgp expression and function. These cells were then cryo-preserved for future
use.
4.4.i OCI-AML3/OCI-AML3DNR genetic analysis
DNA was prepared using a QIAamp DNA blood mini kit (Qiagen, Crawley, UK)
and 5ng DNA was amplified using the Powerplex 16 System (Promega,
Southampton, UK) to assess short tandem repeats (STR). The products were run
on a 3130 Genetic Analyzer and the data analyzed using GeneMapper ID v3.2
software. The STR analysis of the OCI-AML3DNR cell line was shown to be
identical to the parent OCI-AML3 cell line indicating that there were no
significant genetic changes.
4.4.ii OCI-AML3 DNR cell line validation using monoclonal
antibodies and FLT3 analysis
Continued testing to authenticate the OCI-AML3DNR cell line was performed
using a panel of monoclonal antibodies and FLT3 mutational analysis towards the
final passage of each batch thawed. CD38 FITC, CD33 PE, CD34 Percp (BD
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Table 4.3 – OCI-AML3 cell line family: phenotype and FLT3 status.
Cell line CD13 CD33 CD38 CD34 CD42 FLT3
OCI-AML3 Positive Positive Positive Negative Negative WT
OCI-AML6.2 Positive Positive Positive Negative Negative
WT
OCI-AML3DNR Positive Positive Positive Negative Negative
WT
Biosciences), CD13 FITC (Dako) and CD42 PE (Pharmingen) mouse monoclonal
antibodies along with their isotype control were used to validate the cell lines
phenotype. 2x10
5
cells were incubated with 2.5µl normal mouse serum and 2.5µl
monoclonal antibody or the isotype control followed by washing in PBSAA and
analysis by flow cytometry. Cell line FLT3-ITD status was confirmed using the
protocol described in 2.16. The phenotype and FLT3 status of the OCI-
AML3DNR cell line is consistent with that of the parent OCI-AML3 and OCI-
AML6.2 cell lines as shown in table 4.3.
4.5 ABC transporter status of the OCI-AML3DNR cell line
Experiments were carried out on logarithmically growing OCI-AML3DNR cells
cultured with 15nM DNR until seven days before the assay. Pgp expression was
determined by modulation of R123 efflux by PSC833. Functional BCRP was
measured using BODIPY-prazosin retention and the BCRP modulator FTC
(Rabindran et al., 2000). A six fold increase in Pgp functional activity (p=0.039)
was seen in the OCI-AML3DNR cells compared to the OCI-AML3 parent cell line
(Figure 4.8(A)). No increase in BCRP function was seen in the OCI-AML3DNR
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cells (Figure 4.8(A)). More than twice as much Pgp protein (p=0.003) was observed
in the OCI-AMLDNR cells compared to the OCI-AML3 cells (Figure 4.8(B)).
MRP1 has been associated with efflux and in vitro resistance to DNR in AML
cells (Legrand et al., 1999; Borg et al., 2000). To determine whether MRP1
expression had also been elevated in our DNR selected cell line a calcein-AM
Pgp and BCRP expression in the OCI-AML3DNR cell line
Figure 4.8 Pgp function was measured using R123 accumulation and
PSC833 as a positive control modulator. BCRP was measured
similarly with BODIPY-prazosin accumulation and FTC as the
modulator (*p=0.039/**p=0.015 (analyzed using paired samples t-test),
+95% confidence interval) (A). Pgp protein expression was determined
using the MRK-16 monoclonal antibody (***p=0.003) (B). Columns,
mean of three experiments; bars, SD.
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retention assay was used with the MRP1 modulator MK-571 (Gekeler et al., 1995;
Dogan et al., 2004) and MRP function was compared to the adriamycin selected,
MRP1 positive, HL-60ADR cell line (Krishnamachary et al., 1994) (Figure 4.9).
No significant increase in MRP1 function was detected in the OCI-AML3DNR
cells (p=0.358) in contrast to that seen in the HL-60ADR cells (p=0.004)
whencompared to the parent cell lines.
MRP1 functional expression in AML cell lines
Functional MRP1 expression measured using Calcein-AM
accumulation and MK-571 as a modulator (*p=0.358/**p=0.004
(analyzed using paired samples t-test), +95% confidence interval).
Columns, mean of three experiments; bars, SD.
**
*
0
0.5
1
1.5
2
2.5
3
3.5
4
OCI-AML3 OCI-AML3DNR HL-60 HL-60ADR
M
o
d
u
la
ti
o
n
ra
ti
o
(G
e
o
-m
e
a
n
fl
u
o
re
sc
e
n
ce
)
M.Grundy
111
Chapter Five
EFFECT OF ATP-
BINDING
CASSETTE
TRANSPORTERS
ON AZD1152-hQPA
SENSITIVITY
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5.1 Background
We have previously shown that the ABCG2 transfected OCI-AML6.2 along with
the Pgp expressing KG-1a cells, were the most resistant cell lines to both pHH3
inhibition and loss of viability (Figure 4.1). By selecting the OCI-AML3 cell line
for resistance to DNR, a cell line which expressed elevated Pgp protein and
function was created, with no increase in BCRP or MRP expression (Figure 4.7
and 4.8). We now had two cell lines, OCI-AML3DNR and OCI-AML6.2, with
respective elevated Pgp and BCRP levels compared to the parent OCI-AML3
cells. We intended to investigate the effect of ABC transporter status on the
specificity of AZD1152-hQPA in these cell lines.
5.2 Specificity of AZD1152-hQPA in OCI-AML3DNR cells
Initially, it was decided to measure the specificity of AZD1152-hQPA in our new
model for elevated Pgp expression, the OCI-AML3DNR cell line. The OCI-
AML3DNR cells were much more resistant to pHH3 inhibition by AZD1152-
hQPA compared to the OCI-AML3 parent cell line, with no inhibition at 1000nM
AZD1152-hQPA (Figure 5.1). The OCI-AML3DNR cell line was also much more
resistant to seventy-two hour AZD1152-hQPA induced loss of viability compared
to the parent cell line (Figure 5.1). There was a significant (p=0.001) loss of
viability at 30nM AZD1152-hQPA in the OCI-AML3 cells whilst there was only
significant (p=0.011) loss of viability at 1000nM in the OCI-AML3DNR cells.
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5.3 Is AZD1152-hQPA a substrate or modulator of drug
efflux molecules in AML cells?
5.3.i UIC2 shift assay
An indirect way of measuring unlabelled Pgp substrates has recently become
available due to the development of the UIC2 shift assay (Park et al., 2003). The
Specificity of AZD1152-hQPA in the OCI-AML3DNR
cell line
Figure 5.1 Flow cytometric measurement of pHH3 expression
in AML cell lines after 24 hours AZD1152-hQPA exposure (A)
(*p=0.003 (analyzed using paired samples t-test), +95%
confidence interval) and flow cytometric measurement of
viable cells after 72 hours AZD1152-hQPA exposure
(**p=0.011/***p=0.001) (B). Columns/lines, mean of three
experiments; bars, SD.
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reactivity of the UIC2 antibody with Pgp is increased by the addition of Pgp
transported compounds. AZD1152-hQPA was tested in the UIC2 shift assay using
the Pgp positive KG-1a cell line and the known Pgp substrate vinblastine (Park et
al., 2003) as a positive control (Figure 5.2A). No shift in UIC2 binding was seen
with AZD1152-hQPA treatment up to 24 hours. Also, co-incubation of AZD1152-
hQPA and vinblastine failed to affect any shift seen with vinblastine alone.
Is AZD1152-hQPA a Pgp substrate?: UIC2 shift assay
Figure 5.2 Flow cytometric histogram plots showing UIC2 binding
in KG-1a cells in the presence or absence of 5µM vinblastine (i),
1µM AZD1152-hQPA (ii) or both (iii) (A). UIC2 binding in KG-1a
cells in the presence of vinblastine, AZD1152-hQPA or 10µg/ml
etoposide. The dark line is the diluent control and the green line
indicates any shift. Plots are representative of a single experiment
which was done in triplicate.
A
B
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Etop. + Vin.Etoposide
AZD + Vin.AZD1152-hQPA
1 hour 4 hours 24 hours
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M.Grundy
115
This assay failed to show that AZD1152-hQPA is a Pgp substrate. However it did
not prove the converse as a few Pgp substrates such as etoposide fail to alter UIC2
binding depending on their stoichiometry and Pgp ATPase activity (Mechetner et
al., 1997). This is demonstrated in figure 5.2B which shows that AZD1152-hQPA
and etoposide both fail to produce a shift in UIC2 binding and that both fail to
affect any shift seen with vinblastine alone.
5.3.ii Rhodamine 123 and Bodipy-prazosin accumulation
assays
An additional possibility is that AZD1152-hQPA can modulate Pgp function
without itself being a substrate. To determine whether AZD1152-hQPA is able to
modulate Pgp or BCRP function it was compared to known modulators using
fluorescent dye retention assays. AZD1152-hQPA had no effect on R123 retention
in the Pgp positive OCI-AML3DNR cell line (Figure 5.3A(i)) in contrast to the
marked increase in retention seen with CSA (Figure 5.3A(ii)). Likewise AZD1152-
hQPA had no effect on BODIPY retention in the BCRP positive OCI-AML6.2 cell
line (Figure 5.3B(i)) in contrast to the increase in retention seen with FTC (Figure
5.3B(ii)). In these assays AZD1152-hQPA did not appear to be a modulator of Pgp
or BCRP function.
5.3.iii Radio-labelled drug accumulation assay
To categorically determine if AZD1152-hQPA was being effluxed by Pgp and
BCRP, radio-labelled AZD1152-hQPA was used to measure the cellular retention
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of the drug (Figure 5.4). In this assay CSA and FTC increased retention of [
14
C]-
AZD1152-hQPA in both OCI-AMLDNR (p=0.004) and OCI-AML6.2 (p=0.005)
cells respectively. The modulators increased retention of [14C]-AZD1152-hQPA to
at least the concentration seen in the ABC transporter negative/AZD1152-hQPA
sensitive OCI-AML3 cell line. This suggests that AZD1152-hQPA is being
effluxed by Pgp and BCRP and explains why cell lines over-expressing these
transporters are less sensitive to the drug.
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Figure 5.3 R123 accumulation in OCI-AML3DNR cells +/- 300nM AZD1152-hQPA (i)
or 2.5µg/ml CSA (ii). The dotted lines are the 4°C R123 control. The solid black line
is R123 + diluent control and the solid grey line R123 + AZD1152-hQPA (i) and
R123 + CSA (ii) (A). BODIPY-prazosin accumulation in OCI-AML6.2 cells +/- 300nM
AZD1152-hQPA (i) or 10µM FTC (ii). The dotted lines are the 4°C BODIPY control.
The solid black line is BODIPY + diluent control and the solid grey line BODIPY +
AZD1152-hQPA (i) and BODIPY + FTC (ii) (B). Plots are representative of a single
experiment which was done in triplicate.
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5.4 Does culture with known drug efflux inhibitors enhance
sensitivity to AZD1152-hQPA?
Sub-toxic doses of the Pgp inhibitor CSA or the BCRP inhibitor FTC were added
to cell culture with 10-1000nM AZD1152-hQPA (Figure 5.5). Addition of CSA
sensitizes the Pgp positive cell lines OCI-AML3DNR and KG-1a to pHH3 down-
regulation with complete loss of pHH3 seen at 24 hours with 100nM AZD1152-
hQPA (Figure 5.5A(i)). There is no statistical significance in the decrease in pHH3
at 10nM AZD1152-hQPA plus CSA in the OCI-AML3
Modulation of [14C]-AZD1152-hQPA uptake in the
OCI-AML3DNR and OCI-AML6.2 cell lines
Figure 5.4 300nM [14C]-AZD1152-hQPA uptake in Pgp
expressing OCI-AML3DNR cells +/- the Pgp modulator CSA
and in OCI-AML6.2 cells +/- the BCRP modulator FTC.
Pgp/BCRP negative OCI-AML3 cells have been used as a
positive control (*p=0.004/**p=0.005) (analyzed using paired
samples t-test), +95% confidence interval). Diluent controls
were included for each modulator. Columns, mean of three
experiments; bars, SD.
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cells, or in the increase in pHH3 in KG-1a cells with the same treatment, both
p=0.145. The same effect is seen in 72 hour cell viability with a marked decrease
in viability at 10nM and complete loss of cell viability at 100nM AZD1152-hQPA
with the addition of CSA (Figure 5.5A(ii)). PSC-833 is a cyclosporine analogue
with greater specificity for Pgp than CSA (Twentyman, 1991). CSA is a broad-
spectrum MDR modulator, with effects on MDR-associated proteins including
Pgp, MRP, and BCRP (Qadir et al., 2005). In contrast, whereas PSC-833
Reversal of AZD1152-hQPA resistance in AML cell lines
Figure 5.5 Effect of 24 hours AZD1152-hQPA exposure +/- 2.5µg/ml CSA on pHH3
expression in OCI-AML3, OCI-AML3DNR and KG-1a cells (*p=0.145/**p=0.145)
(analyzed using paired samples t-test), +95% confidence interval) (i) and 72 hours
viable cell count (ii) (A). Effect of 24 hours AZD1152-hQPA exposure +/- 1µM PSC-
833 on pHH3 expression in OCI-AML3DNR cells (***p=0.021) (i) and 72 hours viable
cell count (ii) (B) Effect of 24 hours AZD1152-hQPA exposure +/- 5µM FTC on pHH3
expression in OCI-AML3 and OCI-AML6.2 cells (****p=0.021) (i) and 72 hours viable
cell count (ii) (C). Columns/lines, mean of three experiments; bars, SD.
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effectively modulates Pgp, it has no effects on BCRP or MRP modulation (Qadir
et al., 2005). Addition of PSC-833 to the OCI-AML3DNR cells results in
complete inhibition of pHH3 at 100nM AZD1152-hQPA (Figure 5.5B(i)), with
significant (p=0.021) loss of viability seen at 10nM AZD1152-hQPA with the
addition of PSC-833 (Figure 5.5B(ii)).
Addition of FTC also sensitizes the BCRP positive cell line OCI-AML6.2 to
pHH3 down-regulation at AZD1152-hQPA concentrations as low as 10nM
(p=0.021) with complete down-regulation of pHH3 seen at 100nM AZD1152-
hQPA with the addition of FTC (Figure 5.5C(i)). Complete loss of cell viability at
72 hours was achieved at 100nM AZD1152-hQPA with the addition of FTC
(Figure 5.5C(ii)).
The MRP inhibitor MK-571 did not sensitize OCI-AML3DNR cells to AZD1152-
MK-571 does not reverse resistance to AZD1152-hQPA
in the OCI-AML3DNR cells
Figure 5.6 Flow cytometric measurement of pHH3 expression in
OCI-AML3DNR cells after 24 hours AZD1152-hQPA exposure +/-
40µM MK-571. (n=1 for MK-571 addition) Columns/lines, mean of
three experiments; bars, SD.
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hQPA induced pHH3 inhibition confirming that resistance in the OCI-AML3DNR
cells is not due to any elevated MRP expression (Figure 5.6).
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Chapter Six
THE FLT3-ITD
MUTATION IS A
SECONDARY
TARGET OF
AZD1152-hQPA IN
AML CELLS
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6.1 Background
FLT3 mutations can be found in approximately 30% of AML patients, either as
FLT3-ITD (24%) or FLT3 activation loop mutations (7%), making FLT3 one of
the most commonly mutated genes in AML (Gilliland, 2002). Younger patients
with AML have a high complete remission rate, but relapses occur in
approximately 50% of cases overall and this figure rises to 70% in patients with
FLT3-ITDs making the FLT3-ITD gene mutation a poor prognostic factor in AML
(Grimwade et al., 1998; Gale et al., 2005).
6.2 AML cell lines with the FLT3-ITD mutation are
particularly sensitive to AZD1152-hQPA
During the course of this study, it was noticed that the FLT3-ITD expressing
MV4-11 and MOLM-13 cell lines were particularly sensitive to AZD1152-hQPA,
with viability and pHH3 IC50s below 10nM (Figure 6.1). Interestingly, VX-680 a
selective inhibitor of all three aurora kinases also exhibits cross-inhibitory activity
against the receptor tyrosine kinase FLT3 and ablated colony formation in primary
AML cells with FLT3-ITD (Harrington et al., 2004; Carvajal et al., 2006). ITD
mutation of FLT3 induces activating phosphorylation of the receptor in the
absence of FL (Gilliland, 2002). With this in mind, it was decided to measure
pFLT3 levels in the ITD cell lines after treatment with AZD1152-hQPA.
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6.3 pFLT3 inhibition by AZD1152-hQPA
The phosphorylated form of FLT3 was measured by immunoprecipitation in
FLT3-ITD expressing cell lines initially treated for 24 hours with AZD1152-
hQPA. A 77.7% and 86.9% decrease in phosphorylated FLT3 was seen in
MOLM-13 and MV4-11 cells respectively (Figure 6.2). Data was obtained using
Sensitivity of FLT3-ITD cell lines to AZD1152-hQPA
Figure 6.1 Flow cytometric measurement of pHH3 expression
in AML cell lines after 24 hours AZD1152-hQPA exposure (A).
Flow cytometric measurement of viable cells after 72 hours
AZD1152-hQPA exposure (B). Columns, mean of three
experiments; bars, SD.
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Genesnap software attached to a syngene spectrometer but the image itself was
fairly messy and difficult to visualize (a clearer immunoblot is presented in a later
section in Figure 6.5). The data was normalized to total FLT3 expression which
was unaffected by the drug.
Encouraged by this result it was decided to measure the effect of phosphorylated
signal transducer and activator of transcription 5 (pSTAT5) in the same FLT3-ITD
cell lines. Oncogenic activation by FLT3-ITD mutation is known to activate
aberrant signalling, including direct STAT5 activation (Choudhary et al., 2007).
pSTAT5 was measured by flow cytometry in the FLT3-ITD cell lines using an
antibody specific for activated (tyrosine-phosphorylated) STAT5 (Figure 6.3).
This assay is fairly rapid and requires far less material than for immunoblotting,
which makes it potentially useful for patient material. Experiments confirmed the
down-regulation of pSTAT5 after 24 hours of treatment with AZD1152-hQPA in
Effect of 24 hours AZD1152-hQPA exposure on
pFLT3 expression in FLT3-ITD cell lines
Figure 6.2 Effect of 24 hours AZD1152-hQPA exposure on
pFLT3 expression measured by immunoblotting and normalized
to total FLT3 expression. (n=1)
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the FLT3-ITD cell lines. 10nM AZD1152-hQPA induced a 68.7% (p=0.008) and
66.5% (p=0.007) decrease in pSTAT5 expression in MV4-11 and MOLM-13
FLT3-ITD cell lines respectively (Figure 6.3).
6.4 Is AZD1152-hQPA targeting FLT3 directly or is it a result
of Aurora B inhibition?
To determine whether AZD1152-hQPA is directly targeting pFLT3 and
subsequently pSTAT5 in our FLT3-ITD cell lines it was decided to decrease the
Effect of 24 hours AZD1152-hQPA exposure on
pSTAT5 expression in FLT3-ITD cell lines
Figure 6.3 Flow cytometric histograms of 24 hour pSTAT5
expression in MV4-11 control cells (i) and 10nM AZD1152-
hQPA exposure (ii) (A). The light line indicates the isotype
control. Flow cytometric measurement of pSTAT5 expression in
FLT3-ITD cell lines (*p=0.008/**p=0.007 (analyzed using paired
samples t-test), +95% confidence interval) (B). Columns, mean
of three experiments; bars, SD.
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incubation times with the drug. Because of the convenience of the assay in terms
of time and material needed pSTAT5 expression was measured first in the cell
lines. Experiments confirmed the down-regulation of pSTAT5 after 30 minutes
and 1 hour treatment with AZD1152-hQPA in the FLT3-ITD cell lines in a dose
dependent manner (Figure 6.4). Down-regulation of pFLT3 was confirmed using
immunoblotting with down-regulation seen in the FLT3-ITD cell lines at
concentrations as low as 30nM AZD1152-hQPA after 1 hour incubation (Figure
Effect of short term AZD1152-hQPA exposure on
pSTAT5 expression in FLT3-ITD cell lines
Figure 6.4 Effect of short term AZD1152-hQPA exposure on
pSTAT5 expression measured by flow cytometry (*p<0.05
(analyzed using paired samples t-test), +95% confidence
interval) . Columns, mean of three experiments; bars, SD.
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6.5). 300nM AZD1152-hQPA induced a 71% (p=0.005) and 65.3% (p=0.006)
decrease in pFLT3 expression in MV4-11 and MOLM-13 FLT3-ITD cell lines
respectively (Figure 6.5).
The FLT3-ITD MV4-11 cell line is cytokine independent, but growth is enhanced
in the presence of IL-3 (Santoli et al., 1987). We therefore investigated whether
sensitivity to AZD1152-hQPA is abrogated when alternative cytokine pathways
Effect of 1 hour AZD1152-hQPA exposure on
pFLT3 expression in FLT3-ITD cell lines
Figure 6.5 Immunoblots showing pFLT3 down-regulation in FLT3-
ITD cells treated for 1 hour with 0-300nM AZD1152-hQPA. Data
represents one of three independent experiments (A). Effect of 1
hour exposure on pFLT3 expression measured by immunoblotting
and normalized to total FLT3 expression (*p<0.05/**p=0.005/
p=0.006 (analyzed using paired samples t-test), +95% confidence
interval) (B). Columns, mean of three experiments; bars, SD.
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are stimulated (Figure 6.6). Here we demonstrate that IL-3 does not protect MV4-
11 cells from AZD1152-hQPA induced loss of viability.
Effect of IL-3 on MV4-11 cell viability after
AZD1152-hQPA exposure
Figure 6.6 Effect of 72 hours AZD1152-hQPA exposure on MV4-11
viable cell count plus/minus incubation with 100u/ml IL-3. Columns,
mean of three experiments; bars, SD.
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Chapter Seven
SPECIFICITY OF
AZD1152-hQPA IN
PRIMARY AML
CELLS
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7.1 Background
We have established that specificity of AZD1152-hQPA in AML cell lines is
dependent on the Pgp, BCRP and FLT3 status of the cells. Our next aim was to
investigate the specificity of AZD1152-hQPA in primary samples and determine
whether the same predictors of response that were found in the cell lines are
observed in these samples.
7.2 Establishment of proliferating primary AML cell cultures
The level of pHH3 detectable in untreated cell lines was low (2.5-4.8% of total
cells; Figure 3.4) and expression in primary cells was expected to be even lower,
as a very small population of cells are actively dividing at the time of sampling.
Because of this we wanted to pre-incubate primary samples with a cytokine
cocktail to drive the cells into cycle, allowing us to measure pHH3, and determine
specificity of AZD1152-hQPA in the samples. The combination of cytokines used
(20ng/ml IL-3, SCF, IL-6, and 25ng/ml G-CSF) for optimal 48 hour culture of
leukaemic blasts has been previously reported by our lab (Mony et al., 2008).
Cellular proliferation was measured in 65 primary AML samples using [
3
H]-Tdr
uptake with or without 48 hours pre-incubation with cytokine cocktail (Figure
7.1). Proliferation was confirmed in 51 (78.5%) of the samples when treated with
cytokine cocktail for 48 hours and all proliferating samples showed increased
[
3
H]-Tdr uptake at 48 hours compared to basal proliferation measured at 6 hours
(Figure 7.1(A)).
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7.3 Can pHH3 be measured in primary samples and
inhibited with AZD1152-hQPA?
Proliferation of primary AML samples – [3H]-Tdr uptake
and pHH3 expression
Figure 7.1 [3H]-Tdr uptake in 65 primary AML samples after 6 hours
without and 48 hours with cytokine cocktail pre-incubation (A). pHH3
expression in 43 primary samples after 48 hours pre-incubation with
cytokine cocktail (B).
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Confident with the amount of proliferation seen at 48 hours we then went on to
measure pHH3 under the same conditions and were able to measure pHH3
expression in 43 primary samples (Figure 7.1(B)). Mean basal pHH3 expression in
the primary samples was 3.01% (range, 0.04-13.14%) of total cells which was
comparable to the expression seen in cell lines. Basal pHH3 expression and the
amount of proliferation shown by [
3
H]-Tdr uptake was measured in 3 primary
samples and corresponding values were seen (Figure 7.2).
Aurora-B mRNA levels were measured in 88 primary samples (Figure 7.3(A)) and
as expected pHH3 expression in untreated primary samples correlated well with
aurora-B mRNA levels (p=0.015, R2=0.2098; Figure 7.3(B)). Our next aim was to
try to inhibit pHH3 with AZD1152-hQPA in these primary samples. Significant
pHH3 inhibition was achieved in cytokine-primed primary samples at short time
periods with 300nM AZD1152-hQPA (Figure 7.4(A)). pHH3 expression was
measured in 37 primary samples after 1 hours treatment with 300nM AZD1152-
Proliferation of primary AML samples – [3H]-Tdr uptake
and corresponding pHH3 expression
Figure 7.2 [3H]-Tdr uptake in 3 primary AML samples after 6 hours and
after 48 hours of pre-incubation with cytokine cocktail. The histograms
show pHH3 expression in the corresponding samples after 48 hours
cytokine cocktail pre-incubation.
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hQPA (Figure 7.4(B)). IC50 was achieved in all but 2 samples (94.6%) with a mean
down-regulation of 78% (Range, 32.7-100%).
7.4 Pgp and BCRP positive primary AML samples are less
sensitive to AZD1152-hQPA induced pHH3 inhibition
Pgp and BCRP expression was measured in 37 primary AML samples. A study in
Aurora-B mRNA expression in primary AML samples
Figure 7.3 Aurora-B mRNA expression in 88 primary AML samples (A).
Scatter plot demonstrating basal pHH3 expression and aurora-B mRNA
levels in 35 primary AML samples (p=0.015;Mann-Whitney) (B).
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2001 compared MRK-16, UIC2 and 15D3 monoclonal antibody staining in
leukaemic blasts (Taylor et al., 2001). They concluded that when assaying patient
samples for Pgp expression and function using flow cytometry, the R123
functional assay should be performed in concert with MRK-16 antibody staining
(Taylor et al., 2001). Mean MRK-16 test/control mean fluorescence intensity
(MFI) in the primary samples was 1.13 (range, 0.72-2.92). Pgp protein level was
Inhibition of pHH3 by AZD1152-hQPA in primary
AML samples
Figure 7.4 Example of two primary AML samples cultured for 48 hours
with cytokine cocktail and treated with 300nM AZD1152-hQPA followed
by pHH3 measurement by flow cytometry. % total pHH3 expression
is shown (A). 37 primary samples cultured for 48 hours with cytokine
cocktail and then treated with 300nM AZD1152-hQPA for 60 min. pHH3
expression was calculated as a percentage of non-treated controls (B).
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UHFRUGHGDVSRVLWLYHZKHQWKH05.WHVWFRQWUROYDOXHZDVEDVHGRQGDWD
gathered during the AML14 and AML15 trials carried out in our lab). Mean
CSA/R123 modulation ratio in the primary samples was 1.74 (range, 0.91-9.16).
3JS ZDV UHFRUGHG DV IXQFWLRQDO ZKHQ WKH &6$5 PRGXODWLRQ UDWLR ZDV 
based on a previous study (Pallis et al., 1999b). There was a significant correlation
between Pgp protein expression and functional activity in our samples (p=0.001)
(Figure 7.5(A)). ABCG2 message levels were measured in 35 patient samples using
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Pgp and BCRP expression in primary AML samples
Figure 7.5 Scatter plot demonstrating Pgp protein expression and Pgp
functionality in 37 primary AML samples (p=0.001;Mann-Whitney) (A).
ABCG2 message levels in 35 primary AML samples measured using
real-time PCR.
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real-time PCR (in 2 samples the cDNA was not amplified) (Figure 7.5(B)). The
ABCG2 expression levels data was normally distributed, so for statistical
purposes, values above and below the mean were used to classify samples as
ABCG2 positive and negative respectively. Of the primary samples tested 9/37
(24.3%) were positive for Pgp and 9/35 (25.7%) were positive for BCRP. The 2
samples where an IC50 for pHH3 expression was not achieved were positive for
both Pgp and BCRP expression (Figure 7.6). Five samples co-expressed Pgp and
BCRP such that a significant correlation was found (p=0.008, R
2
=0.238) between
Pgp and BCRP expression in our primary samples. The percentage of Pgp and
BCRP positive samples and the co-expression correlation agrees with previously
published data (Damiani et al., 2006).
Pgp positive samples were significantly (p=<0.001) less sensitive to AZD1152-
Figure 7.6 Flow cytometric pHH3 expression in 37 primary AML samples
pre-incubated with cytokine cocktail for 48 hours and then treated with
300nM AZD1152-hQPA for 60 minutes.
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hQPA induced pHH3 inhibition than Pgp negative samples (Figure 7.7(A)). BCRP
positive primary samples were also significantly (p=<0.001) less sensitive to
AZD1152-hQPA induced pHH3 inhibition compared to BCRP negative samples
(Figure 7.7(B)). However, a sharp distinction between cell lines and primary
samples was noted. The transporter-expressing cell lines were insensitive to down-
Pgp and BCRP positive primary AML samples are less
sensitive to AZD1152-hQPA induced pHH3 inhibition
Figure 7.7 Scatter plot showing that Pgp positive primary samples are
less sensitive to AZD1152-hQPA induced pHH3 inhibition than Pgp
negative samples (p=<0.001;Mann-Whitney) (A). Scatter plot showing
that BCRP positive primary samples are less sensitive to AZD1152-hQPA
induced pHH3 inhibition than BCRP negative samples (p=<0.001) (B).
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regulation of pHH3 at concentrations of up to 1000nM AZD1152-hQPA even after
24 hours. In contrast 50% pHH3 inhibition was achieved in 94.6% of total primary
samples at 300nM AZD1152-hQPA after only one hour incubation. Importantly,
IC50 was also achieved in 77.78% (7/9) of Pgp positive samples and 77.78% (7/9)
of BCRP positive samples. The two samples where an IC50 was not achieved co-
Primary FLT3-ITD samples are more sensitive than FLT3-WT
samples to AZD1152-hQPA induced pHH3 inhibition and
pSTAT5 down-regulation
Figure 7.8 Scatter plot showing that FLT3-ITD samples are more sensitive
to AZD1152-hQPA induced pHH3 inhibition than FLT3-WT samples
(p=0.022;Mann-Whitney) (A). Scatter plot showing that FLT3-ITD primary
samples are more sensitive to AZD1152-hQPA induced pSTAT5 down-
regulation than FLT3-WT samples (p=0.007) (B).
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expressed both Pgp and BCRP, although it should be noted that IC50 was achieved
in 3/5 (60%) samples that co-expressed Pgp and BCRP.
7.5 Primary FLT3-ITD samples are more sensitive to
AZD1152-hQPA induced pHH3 down-regulation and
pSTAT5 down-regulation compared to FLT3-WT samples
It was found that the FLT3-ITD mutation is a secondary target of AZD1152-
hQPA, and because of the sensitivity of the FLT3-ITD cell lines to the drug, it was
decided to screen our primary samples for FLT3 status. Forty two primary samples
were screened for FLT3 mutation using genomic DNA fluorescent PCR
amplification and analysis on a 3130 Genetic Analyzer. Seventeen (40.5%) of the
samples had a FLT3-ITD mutation. Samples were pre-incubated with cytokine
cocktail for 48 hours and then treated with 300nM AZD1152-hQPA for 1 hour.
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Primary FLT3-ITD samples have higher basal pHH3
expression than FLT3-WT samples
Figure 7.9 Scatter plot comparing basal pHH3 expression and FLT3
status in 42 primary AML samples (p=0.011;Mann-Whitney).
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pHH3 expression was measured by flow cytometry and inhibition was calculated
as a percentage of total pHH3 in untreated controls. The FLT3-ITD samples were
more sensitive to AZD1152-hQPA induced pHH3 inhibition (p=0.022; Figure
7.8(A)).
Thirty-one primary AML samples were pre-incubated with cytokine cocktail for
48 hours and then treated with 300nM AZD1152-hQPA for 1 hour. pSTAT5
expression was measured by flow cytometry and inhibition was calculated as a
percentage of total pSTAT5 in untreated controls. The FLT3-ITD samples were
significantly more sensitive to AZD1152-hQPA induced pSTAT5 down-regulation
(p=0.007; Figure 7.8(B)).
The presence of a FLT3-ITD results in an increased auto-phosphorylation of the
FLT3 receptor tyrosine kinase and thereby increased cellular proliferation
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FLT3-ITDs are inversely associated with functional
Pgp activity
Figure 7.10 Scatter plot comparing FLT3 status and functional Pgp
activity in 46 primary AML samples (p=0.038;Mann-Whitney).
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(Gilliland, 2002). Expression of pHH3 is limited to mitosis and hence proliferating
cells. We can demonstrate that our primary FLT3-ITD samples have higher basal
pHH3 expression than FLT3-WT samples (p=0.011) (Figure 7.9). Previous work
by our group has shown that FLT3-ITDs are inversely associated with functional
Pgp activity (Pallis et al., 2003b). The same was found in this sample population.
3JSZDV UHFRUGHGDV IXQFWLRQDOZKHQ WKH&6$PRGXODWLRQ UDWLRZDV+HUH
the mean modulation ratio in FLT3 wild-type samples was 2.13, and in ITD
samples it was 1.27 (p=0.038) (Figure 7.10). Also, Pgp protein level was recorded
DV SRVLWLYH ZKHQ WKH 05. WHVWFRQWURO YDOXH ZDV  7KH PHDQ 05.
test/control value in FLT3 wild-type samples was 1.18, and in ITD samples it was
1.06, although this was not statistically significant (p=0.137). Out of our fourteen
FLT3-ITD samples only two samples (14.3%) were positive for Pgp expression
and there was no statistical significance in terms of sensitivity to AZD1152-hQPA
induced pHH3 inhibition in these samples (p=0.1) (Figure 7.11). There was also
Effect of Pgp expression on AZD1152-hQPA response
in FLT3-ITD primary samples
Figure 7.11 Scatter plot comparing Pgp status and AZD1152-hQPA
induced pHH3 inhibition in 14 FLT3-ITD primary AML samples (p=0.1;
Mann-Whitney).
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no correlation between FLT3 and BCRP status in this sample group (p=0.586).
7.6 Primary FLT3-ITD samples are more sensitive to
AZD1152-hQPA induced growth inhibition compared to
FLT3-WT samples
Initial experiments to examine the effects of AZD1152-hQPA on cell viability in
primary samples were carried out in suspension culture. As previously described,
samples were cultured for 48 hours in cytokine medium, and then cultured for a
further 72 hours with 300nM AZD1152-hQPA. Cell viability was determined by
Effect of 300nM AZD1152-hQPA on primary cell viability
in suspension culture
Figure 7.12 Twenty primary AML samples cultured for 48 hours with
cytokine cocktail followed by 72 hours culture with 300nM AZD1152-hQPA.
There is no significance between Pgp (p=0.589; Mann-Whitney), BCRP
(p=0.791) or FLT3 (p=0.643) status of primary samples and viability in
response to AZD1152-hQPA in this assay.
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flow cytometry using 7AAD to detect viable cells (Figure 7.12). There was no
statistical significance between FLT3 (p=0.643), Pgp (p=0.589), or BCRP
(p=0.791) status of primary samples and viability in response to AZD1152-hQPA
in suspension culture. In this assay a reference to an internal standard of fixed and
stained mononuclear cells is used. This allows us to determine the absolute
number rather than the proportion of viable cells remaining at the end of the
culture period. When control cell viability count as a percent of the starting
concentration was examined and compared to the percent of control viability of
cells treated with AZD1152-hQPA a statistical significance (p=0.009) was seen
(Figure 7.13). The % untreated cells surviving data was normally distributed, so
for statistical purposes, values above and below the mean were used to classify
samples as high (viable/proliferating) or low (non-proliferating) respectively.
Clearly then, a response to AZD1152-hQPA in suspension culture was seen
predominantly in those primary samples that were viable/proliferating, regardless
Effect of control cell count on response
to AZD1152-hQPA
Figure 7.13 Effect of AZD1152-hQPA on viable/proliferating (High) and
non-proliferating (Low) primary AML cells (p=0.009;Mann-Whitney).
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of the FLT3, Pgp or BCRP status of the cells. There is no “gold standard” assay
for primary AML cellular response to a drug in culture. It was decided to switch to
a methylcellulose based colony forming assay to determine growth inhibition in
response to AZD1152-hQPA in primary cells. This assay has the disadvantage that
fresh samples are needed for optimal colony growth and these are in limited
supply.
Consecutive fresh primary AML samples (20 FLT3-WT and 8 FLT3-ITD) were
grown for 14 days in methylcellulose based medium containing 0-30nM
AZD1152-hQPA. Colonies were counted under the microscope and growth was
defined as greater than 12 colonies present in untreated wells. Colonies were
detected in untreated samples from 11 FLT3-WT but only 2 FLT3-ITD cases. IC50
was calculated compared to untreated controls. The two FLT3-ITD samples were
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AZD1152-hQPA inhibits the clonogenic potential of primary
AML samples – sensitivity of FLT3-ITD samples
Figure 7.14 Scatter plot comparing FLT3 status to AZD1152-hQPA IC 50
concentrations in 13 primary AML samples grown for 14 days in
methylcellulose based medium (p=<0.029;Mann-Whitney).
p=0.029
M.Grundy
145
both more sensitive to AZD1152-hQPA induced growth inhibition than any of the
wild type samples (p=0.029) (Figure 7.14).
In this chapter the ability to measure the pHH3 biomarker and to target it in
primary AML cells is demonstrated. Pgp and ABCG2 expressing primary samples
are less sensitive to AZD1152-hQPA induced pHH3 inhibition although 50%
inhibition of pHH3 was achieved in nearly 95% of these samples in contrast to the
resistance seen in cell lines. FLT3-ITD primary samples are more sensitive to
AZD1152-hQPA in terms of pHH3 and pSTAT5 inhibition and colony forming
potential.
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Chapter Eight
DISCUSSION
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8.1 Study aims and objectives
The aurora kinase family members are essential for normal mitotic progression
and have attracted great interest as potential new therapeutic targets (Kollareddy et
al., 2012). The aim of this study was to investigate the efficacy of the novel
aurora-B kinase inhibitor AZD1152-hQPA in a panel of AML cell lines and
primary samples. Initially, particular attention was paid to the ABC transporter
status of AML cell lines and its effect on the sensitivity of AZD1152-hQPA, by
measuring the biomarker pHH3. Our studies showed that AML cell lines with
elevated ABC transporter expression were relatively resistant to AZD1152-hQPA
(Chapter 3). The mode of cell death following treatment with AZD1152-hQPA in
our cell lines was investigated and also whether p53 status affects cellular response
to the drug (Chapter 3). With the development of the OCI-AML3DNR cell line we
were able to demonstrate that AZD1152-hQPA is effluxed by Pgp along with
BCRP in our cell lines (Chapters 4 and 5). Subsequent investigations revealed that
mutant FLT3 was a secondary target of AZD1152-hQPA in our cell lines (Chapter
6). Response to AZD1152-hQPA in primary AML samples was subsequently
investigated with particular emphasis on their ABC transporter and FLT3 status
(Chapter 7).
8.2 Biomarker assay optimization and chemosensitivity of
AML cells to AZD1152-hQPA
Aurora-B is known to phosphorylate Histone H3 (pHH3) at the Ser10 position
during mitosis (Giet, 2001; Bhaumik et al., 2007) and previous reports have shown
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inhibition of pHH3 following treatment with aurora kinase inhibitors (Ditchfield et
al., 2003; Keen, 2004). Inhibition of pHH3 reflects aurora-B inhibition and as such
can be considered a biomarker for aurora-B activity. A clinical marker for aurora-
A inhibition is currently not available (Kitzen et al., 2010). To be able to use
pHH3 as a biomarker for AZD1152-hQPA activity in our cell lines and patient
samples, we needed to develop a method to measure its expression, and its
inhibition by the drug. The development and technical validation of a biomarker
assay, particularly in clinical samples, is important as it allows an early indication
of drug efficacy and gives a rapid and valid endpoint for our cell based assays.
A flow cytometric method was subsequently developed to simultaneously measure
pHH3 expression, and DNA content, in our cell lines (Figure 3.1). Initially PI was
used to counter-stain for DNA content. However because of spectral overlap
between PI in the PE and the pHH3 antibody in the FITC channel, the counter-
stain was changed to 7-AAD which has minimal spectral overlap with FITC
(Rabinovitch et al., 1986). The level of pHH3 detectable in untreated cell lines was
low and expression in primary cells was expected to be even lower as a very small
population of cells is actively dividing at the time of sampling. With this in mind,
it was decided to pre-incubate the AML blasts with a cytokine cocktail to drive the
cells into cycle before treatment with AZD1152-hQPA. Proliferation was seen in
51 out of 65 primary samples as measured by [
3
H]-Tdr uptake and levels of pHH3
were comparable to those found in cell lines (Figure 7.1). The pHH3 antibody
stained with extreme brightness (Figure 3.1) and an initial publication of this
method seems to have missed the pHH3 positive population entirely, reporting a
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shift in autofluorescence as evidence of biomarker targeting (Yang et al., 2007). A
detailed protocol of the optimized assay is included in the appendix of this thesis.
Real-time PCR confirmed that aurora-B mRNA levels correlated to basal pHH3
expression in primary AML blasts (Figure 7.3). This was to be expected as aurora-
B is known to phosphorylate Histone H3 and both are indicative of cells in G2/M
(Giet, 2001; Bhaumik et al., 2007). pHH3 inhibition was seen at short time periods
after treatment with AZD1152-HQPA in all of the primary samples tested (Figure
7.4).
Treatment with AZD1152-hQPA resulted in inhibition of pHH3, accumulation of
cells with >4N DNA content, and subsequent loss of viability in a panel of
leukaemic cell lines (Figures 3.4-3.6). To determine mode of cell death, Annexin
binding, along with active caspase-3 and 7A6 antigen expression were used, and it
was shown that AZD1152-hQPA treated cell lines undergo apoptosis and that the
polyploid population contained apoptotic cells (Figures 3.9-3.11). This agrees with
previous studies which reported that aurora-B disruption in tumour cells forces
cells through a catastrophic mitotic exit leading to polyploid cells that
subsequently lose viability (Ditchfield et al., 2003).
The way that AML is treated has changed little over the last thirty years and
current chemotherapy is not cancer specific resulting in numerous unwanted side
effects caused by damage to normal tissues, such as those of the bone marrow, gut
mucosa and hair follicles. It is hoped that these toxic side effects can be minimized
by using a drug with a specific target, such as aurora-B. Also it may be possible to
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use a lower dose of current chemotherapy when used in combination with targeted
drugs such as AZD1152-hQPA, again reducing toxicity. AZD1152-hQPA was
compared in our cell lines to the standard chemotherapeutic agents used in AML,
DNR and Ara-c, and a 72 hour IC50 was achieved in all but one cell line at lower
concentrations of AZD1152-hQPA (Figure 3.7). The specificity of AZD1152-
hQPA was significantly similar to that of DNR with the KG-1a cell line standing
out as the most resistant to the two agents. DNR is known to be effluxed by Pgp in
AML cells (Borg et al., 2000) and the elevated expression of Pgp in the KG-1a
cell line has been demonstrated. One group has published data suggesting that
AZD1152-hQPA synergistically enhanced the anti-proliferative capacity of DNR
in MOLM-13 cells (Ikezoe et al., 2007). However, we found the opposite, in the
same cell line using IC50 concentrations and calcusyn software to calculate a CI
value; we found that there was moderate antagonism between the two agents
(Figure 3.8). The cell line specificity profile of AZD1152-hQPA was significantly
different to that of Ara-c. Promisingly, there was synergism between these two
agents in the MOLM-13 cell line. One explanation for this could be the different
modes of action of DNR and Ara-c. The anthracycline DNR forms a stable
complex with DNA and interferes with nucleic acid synthesis but its cytotoxic
effects are not cell cycle phase specific (Come et al., 1999). The nucleoside
analogue Ara-c is incorporated into newly synthesized DNA leading to chain
termination and inhibition of DNA synthesis (Ravandi et al., 2004). As such it
exhibits cell cycle phase specificity and primarily kills cells undergoing DNA
synthesis (S-phase). AZD1152-hQPA targets cells specifically in the G2/M phase
of the cell cycle so it is reasonable to presume that drugs that induce S-phase
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inhibition should not necessarily be synergistic in combination with AZD1152-
hQPA. However it may be this two pronged targeting of either ends of the cell
cycle that accounts for the synergy between these two drugs. Also, this synergy
was found in cell lines, which tend to be much more synchronized than cells in
vivo, where this dual targeting of the cell cycle may be enhanced. Because of the
small number of cells in G2/M phase at any one time, as demonstrated by the
amount of baseline cells expressing pHH3 (Figure 3.4 and Figure 7.1B), the drug
should be administered as a continuous infusion over long time periods for
maximal benefit. A phase II clinical trial in AML patients combining AZD1152-
hQPA over 7 days continuous infusion with low dose Ara-c is currently ongoing
(Clinicaltrials.Gov, April 2012).
8.3 p53 mutation and AZD1152-hQPA sensitivity in AML
The non-specific aurora kinase inhibitor, VX-680, has been shown to
preferentially induce endoreduplication in cells with compromised p53 (Gizatullin
et al., 2006). The p53 tumour suppressor gene is mutated and/or deleted in more
than 50% of solid tumours (Levine, 1997). It is possible then, that cells lacking
functional p53 might be selectively sensitive to aurora kinase inhibition, providing
a benefit for normal cells over tumour cells. However, haematological
malignancies do not contain frequent alterations in the p53 gene, with one study
detecting loss of p53 in only 5% of over two thousand adult AML patients (Fenaux
et al., 1992; Seifert et al., 2009). Our cell lines were sequenced for p53 expression
and their DNA content measured after treatment with AZD1152-hQPA (Figure
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3.14). AZD1152-hQPA preferentially induced endoreduplication in the p53
compromised HL-60 and U937 cells in comparison to p53wt cells, findings that
agree with reported data on VX-680 (Gizatullin et al., 2006). However, although
the p53wt cell lines were checked in comparison with p53-compromised cells,
p53wt did not save our AZD1152-hQPA treated AML cell lines from massive
endoreduplication and ultimate loss of viability. It appears then that p53 restrains
endoreduplication after aurora-B inhibition by AZD152-hQPA. These findings are
consistant with Ditchfield et al and their investigations with the dual aurora
inhibitor ZM447439 in HeLa cells (Ditchfield et al., 2003). Also, p53
compromised U937 cells acquired DNA damage quicker (in the G1/S phase of the
cell cycle) when compared to the p53wt MV4-11 and OCI-AML3 (Figure 3.12)
cells indicating a role for p53 in DNA damage response to AZD1152-hQPA.
Recently published data suggests a direct link to aurora-B and p53 via NIR (novel
INHAT repressor), a transcriptional co-repressor with inhibitor of histone
acetyltransferase activity, which is known to suppress p53 transcriptional activity
and function (Wu et al., 2011). This group demonstrate that aurora-B, NIR and
p53 exist in a protein complex in which aurora-B binds to NIR and also
phosphorylates p53 suppressing its activity (Wu et al., 2011) (Figure 8.1). They
also report that inhibition of aurora-B causes p53-dependent apoptosis and cell
growth arrest, due to the up-regulation of p21 and Bax. This suggests a possible
mechanism for the apoptosis seen in response to AZD1152-hQPA in our p53wt
AML cell lines. Interestingly, VX-680 has been shown to act synergistically to
induce apoptosis in p53wt AML cell lines with Nutlin-3, which is a small
molecule antagonist of the p53 regulator Mdm2 (Kojima et al., 2008). This
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suggests a rationale for the dual targeting of aurora kinases and Mdm2 in AML
where p53 mutations are rare and downstream p53 signalling is mostly intact.
8.4 The effect of ABC transporters on the efficacy of
AZD1152-hQPA
Elevated expression of the MDR1 gene coding for the drug efflux pump Pgp and
the ABCG2 gene encoding BCRP are both associated with worse remission rates
in AML (Leith et al., 1997; Damiani et al., 2006). Any potential new drug for the
treatment of AML should therefore be screened for its efficacy in patients
expressing high levels of these drug transporters. Initial experiments showed that
our Pgp positive (KG-1a) and BCRP positive (OCI-AML6.2) cell lines were much
less sensitive to AZD1152-hQPA in comparison to transporter negative cell lines.
This was seen at both the biomarker and subsequent viability level (Figure 4.1).
Because there was no parental Pgp negative comparison for the KG-1a cell line, it
was decided to create a Pgp expressing cell line from the OCI-AML3 cells. No
increase in Pgp expression or function after our nucleofection MDR1 transfection
assays was detected. Although the transfected cells grew in the presence of G418
(in contrast to the control cells), indicating that the cells retained the neomycin
resistance gene, no increase in Pgp protein was observed, suggesting that the
MDR1 gene may have been ejected by the cells. One explanation could be a
problem with the pCMV promoter region and it has also been reported that viral
gene transfer methods are more efficient in leukaemia and lymphoma cells
(Schakowski et al., 2004). Along with this a literature search reveals a paucity of
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data where the MDR1 gene has been successfully transfected into AML cells. As
such it was decided to try and select for elevated Pgp expression in the OCI-AML3
cell line using the known Pgp substrate DNR (Legrand et al., 1999; Borg et al.,
2000). The subsequently developed OCI-AML3DNR cell line expressed
significantly more Pgp both at the protein and functional level (Figures 4.7) and
importantly no increase in BCRP or MRP expression was seen (Figures 4.7 and
4.8). Also, STR analysis of the OCI-AML3DNR cell line was identical to the
parent cell line and the cell line phenotype and FLT3 status matched that of the
parent cell line (Table 4.1). Therefore the OCI-AMLDNR cell line is a relatively
clean model for measuring Pgp related MDR. The OCI-AMLDNR cell line was
significantly more resistant to AZD1152-hQPA, in terms of biomarker inhibition
and loss of viability, compared to the sensitive OCI-AML3 parent cells (Figure
5.1). Using the UIC2 shift assay and fluorescent dye accumulation assays it was
shown that AZD1152-hQPA is neither a substrate of Pgp or modulates the
function of Pgp or BCRP in the resistant cell lines (Figure 5.2 and 5.3). By using
radioabelled
14
[C]-AZD1152-hQPA in combination with known Pgp and BCRP
inhibitors it was shown definitively that the drug is being effluxed by these
transporters in the OCI-AML3DNR and OCI-AML6.2 cells accounting for the
resistance seen in both cell lines (Figure 5.4). The resistance to AZD1152-hQPA
in the transporter positive cell lines was reversed when known inhibitors of Pgp
and BCRP were co-cultured with AZD1152-hQPA (Figure 5.5).
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8.5 The FLT3-ITD mutation is a secondary target of
AZD1152-hQPA
Through the course of our studies, the particular sensitivity of the FLT3-ITD
expressing MV4-11, and MOLM-13 cell lines, to AZD1152-hQPA was noticed.
Both had IC50 values for viability and pHH3 inhibition of <10nM and were
therefore the most sensitive of any of the lines tested (Figure 6.1). The FLT3 gene
is one of the most commonly mutated genes in AML either as FLT3-ITD (24%) or
FLT3 activation loop mutation (7%), and is associated with poor prognosis
(Gilliland, 2002; Hunter et al., 2004). Interestingly, VX-680, a selective inhibitor
of all three aurora kinases, also exhibits cross-inhibitory activity against the
receptor tyrosine kinase FLT3 and ablated colony formation in primary AML cells
with FLT3-ITD (Harrington et al., 2004; Carvajal et al., 2006).
Because AZD1152-hQPA has been designed to specifically target aurora-B kinase,
one of the questions that needed to be addressed was whether AZD1152-hQPA is
also targeting FLT3 in the sensitive FLT3-ITD cell lines. AZD1152-hQPA has
shown > 100-fold specificity for aurora B kinase in a panel of 50 other
serine/threonine and tyrosine kinases, including FLT3, but its action against
mutated FLT3 had not been reported (Keen et al., 2005). ITD mutation of FLT3
induces activating phosphorylation of the receptor in the absence of ligand
(Gilliland, 2002). Oncogenic activation by ITD mutation is also known to activate
aberrant signalling, including direct STAT5 activation (Choudhary et al., 2007),
whilst ligand-induced FLT3-WT does not directly activate STAT5 (Mizuki et al.,
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2000; Spiekermann et al., 2003). Measurement of pSTAT5 can be performed by
flow cytometry and requires relatively small amounts of cellular material so it was
deemed important to optimize this assay for potential use with patient samples.
One hour incubation at low doses of AZD1152-hQPA resulted in down-regulation
of pSTAT5 in both the FLT3-ITD cell lines (Figure 6.4). Encouraged by this,
pFLT3 expression was measured in the ITD cell lines by immunoblotting. FLT3
dephosphorylation is shown after 1 hour incubation at doses as low as 30nM
AZD1152-HQPA (Figure 6.5). This was the first demonstration that AZD1152-
hQPA inhibits pFLT3 in ITD cell lines along with its down-stream target pSTAT5.
The FLT3-ITD MV4-11 cell line is cytokine independent, but growth is enhanced
in the presence of IL-3 (Santoli et al., 1987). Also, the addition of IL-3 has been
shown to rescue the growth of BaF3/ITD cells in the presence of the FLT3
inhibitor CEP-701 (Levis et al., 2002). Activation of the IL-3 receptor induces the
activity of the JAK/STAT (leading to STAT5 phosphorylation), Raf/MEK/ERK
and PI3K/Akt pathways, which results in cell proliferation and prevention of
apoptosis (Steelman et al., 2004). It was demonstrated that IL-3 does not protect
MV4-11 cells from AZD1152-hQPA induced loss of viability (Figure 6.6). So
introducing pSTAT5 via an alternative pathway does not protect MV4-11 cells
from the effects of AZD1152-hQPA suggesting it is the dual targeting of FLT3-
ITD and aurora-B that is responsible for the enhanced sensitivity in these cells.
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8.6 Effect of AZD1152-hQPA on primary AML cells
In our viability assays, a response was seen to AZD1152-hQPA in suspension
culture predominantly in those primary samples that were viable and proliferating
regardless of the Pgp, BCRP or FLT3 status of the cells (Figure 7.12 and 7.13).
This demonstrates that cells need to go through the G2/M phase to elicit a response
from AZD1152-hQPA as only the proliferating cells were responding. Also, the
quality of the sample in terms of its age and the effect of freeze/thawing could well
have an effect on its ability to proliferate in suspension culture. Because of this
priority was given to the pHH3 biomarker, over cell death, as a measure of
response to AZD1152-hQPA in primary samples.
pHH3 expression was measured in 37 primary AML samples cultured for one hour
with or without AZD1152-hQPA. 9/37 (24.3%) were positive for Pgp and 9/35
(25.7%) were positive for BCRP with a significant correlation (p=0.008,
R
2
=0.238) seen for co-expression. This data agrees with results seen previously
(Damiani et al., 2006). Pgp positive samples were significantly less sensitive to
AZD1152-hQPA induced pHH3 inhibition compared to Pgp negative samples
(p=0.001) as were BCRP positive samples compared to BCRP negative samples
(p=0.001) (Figure 7.6 and 7.7). Importantly though, >50% inhibition of pHH3 was
still seen in all but 2 primary samples (94.6%). So certainly at the level of the
biomarker a much better response was seen in ABC transporter positive primary
samples than in transporter positive cell lines at the corresponding dose of
AZD1152-hQPA. Whereas in the transporter positive cell lines efflux of
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AZD1152-hQPA using radio-labelled AZD1152-hQPA was demonstrated it is
clear that all of our primary samples retained enough drug to target the pHH3
biomarker. This difference in response may be explained by the ‘artificially’ high
transporter expression seen in the cell lines. For example, if we look at our
measure of Pgp function, the mean CSA modulation ratio in our primary samples
was 1.74. Four times this was seen in the Pgp expressing OCI-AML3DNR cell
line and greater than seven times seen in the Pgp expressing KG-1a cell line.
Likewise the amount of Pgp protein measured using the MRK-16 antibody was 2-
fold higher in the OCI-AML3DNR cells and 7-fold higher in the KG-1a cells
compared to the mean value of 1.13 seen in primary samples. A study of 149 AML
patient samples reported that Pgp and BCRP expression was a prognostic factor
and patients who co-expressed Pgp and BCRP had the poorest prognosis
(Benderra et al., 2004). It is demonstrated here that primary samples with high Pgp
and/or BCRP expression, are less sensitive to AZD1152-hQPA, although an IC50
for pHH3 inhibition was achieved in 3/5 (60%) samples that co-expressed Pgp and
BCRP. Clearly then, AZD1152-hQPA is able to enter these cells and target aurora-
B and pHH3 in these primary samples, even when they express high levels of both
Pgp and BCRP.
Results to support our findings have recently been reported in data from solid
tumours. Using whole-genome microarray techniques to analyse two AZD1152-
hQPA resistant colon and pancreatic cell lines it was discovered that it was
amplification of genes that encode for Pgp and BCRP that conferred resistance to
the drug (Guo et al., 2009). Inhibiting Pgp as a way of reversing MDR has been
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intensively studied for many years. Pharmacological inhibition of Pgp by small-
molecule antagonists has been studied in several AML trials with various agents
but only yielding little clinical success (Mahadevan, 2004; Szakacs et al., 2006).
Many of these agents are substrates for other transporters and enzyme systems
resulting in unpredictable pharmacokinetic interactions in the presence of
chemotherapy agents. Recently more specific so called third generation inhibitors
of MDR, such as zosuquidar, have been developed that have the potential to
minimize any drug-drug interactions (Lancet et al., 2009). A combination of these
inhibitors with AZD1152-hQPA could circumvent any problem of drug efflux by
ABC transporters seen with this drug. Another strategy to overcome susceptibility
to the effects of MDR would be to design a novel aurora kinase inhibitor whose
activity is not influenced by drug efflux mediated by ABC transporters. One such
inhibitor, AMG-900, is discussed later.
It was demonstrated that AZD1152-hQPA inhibits pFLT3 in ITD cell lines along
with its down-stream target pSTAT5. AZD1152-hQPA caused growth inhibition
of primary AML blasts in our colony formation assays and again the FLT3-ITD
samples were the most sensitive of those tested (Figure 7.14). FLT3-ITD primary
samples were also particularly sensitive to pSTAT5 down-regulation after
treatment with AZD1152-hQPA, compared to FLT3-WT samples (Figure 7.8).
FLT3-ITD primary samples were also found to be the most sensitive to AZD1152-
hQPA induced pHH3 inhibition (Figure 7.8) which is intriguing as pHH3 is widely
reported to be a direct substrate of aurora kinase B. One possible explanation for
this could be the role of survivin, a member of the inhibitors-of-apoptosis protein
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(IAPs) family, which has recently been demonstrated to lie downstream of FLT3-
ITD signalling (Fukuda et al., 2009). Survivin along with aurora-B, INCENP and
borealin makes up the chromosomal passenger complex which plays a key role in
mitotic progression. One study reported that treatment of FLT3-ITD MV4-11
leukaemia cells with the FLT3-ITD inhibitor SU5416 resulted in reduced survivin
expression and inhibited cell proliferation (Fukuda et al., 2009). Survivin is highly
expressed in various malignant cells, including leukaemic cells, and small
molecule (YM155), and antisense (SPC3042) inhibitors of survivin are currently
in phase I and phase II clinical trials (Hansen et al., 2008; Lewis et al., 2009). It
has recently been reported that survivin expression levels are prognostic in AML
and that survivin is over-expressed in CD34+/CD38- AML stem/progenitor cells
when compared to bulk AML blasts (Carter et al., 2012). Survivin may therefore
be an important target in AML therapy. Interestingly, AZD1152-hQPA has also
been reported to inhibit survivin expression along with pHH3 and Rb protein in
Burkitt’s and Hodgkin’s lymphoma cell lines (Mori et al., 2011). This group
demonstrated survivin inhibition in these cells followed by caspase-9 and caspase-
3 activation with subsequent apoptosis (Figure 8.1). They also concluded that Rb
inhibition in these cells resulted in the polyploid phenotype associated with aurora-
B inhibition.
An important problem with the current crop of small molecule FLT3 inhibitors
being tested in AML is mechanisms of acquired resistance. These include the
development of secondary mutations in the FLT3 gene, elevated levels of FL after
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chemotherapy and also over-expression of survivin (Zhou et al., 2009; Sato et al.,
2011). An interesting study recently reported the effect of CCT241736 on MOLM-
13 and MV4-11 AML cell lines selected for resistance against the FLT3 inhibitor
MLN518 (tandutinib) (Moore et al., 2011). Like AZD1152-hQPA, CCT241736 is
a dual aurora kinase and FLT3-ITD inhibitor. Unlike the selective FLT3 inhibitors
MLN518 and AC220, the in vitro cellular efficacy of CCT241736 was not affected
by high levels of FL in AML cell lines. Furthermore, CCT241736 inhibited a wide
range of FLT3 mutants, including FLT3-ITD, -D835Y, -D835H, -K663Q and –
N841I.
The presence of a FLT3-ITD results in an increased auto-phosphorylation of the
FLT3 receptor tyrosine kinase and thereby increased cellular proliferation
Figure 8.1 Interactions of aurora-B and the CPC. Adapted
from Mori et al Biochem Pharmacol 2011.
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(Gilliland, 2002). pHH3 expression is limited to mitosis and therefore proliferating
cells. It is demonstrated here that primary FLT3-ITD samples have statistically
higher basal pHH3 expression than FLT3-WT samples thus rendering them more
susceptible to AZD1152-hQPA (Figure 7.9). Of our primary samples, 40.5% had
the FLT3-ITD mutation. This is more than the 24% expected and described in the
literature (Gilliland, 2002). Occurrence of FTL3-ITD has been strongly associated
with higher peripheral leukocyte count and higher blast percentages (Kottaridis et
al., 2001; Schnittger et al., 2002). This means that in samples with a FLT3-ITD,
we would expect a larger blast percentage available after separation over
Histopaque, to be cryo-preserved for future use. So in effect we are selecting for
FLT3-ITD samples in the lab giving a false positive percentage of these samples
occurring in our frozen primary sample pool and hence the slightly higher than
expected value of 37.8% in our primary samples. No FLT3-ALMs were detected
in our primary sample group. This is not particularly surprising as only 7% of
AML patients are reported to have this mutation (Gilliland, 2002) and in contrast
to FLT3-ITD mutations, FLT3-ALMs are not associated with higher diagnostic
white cell counts (Meshinchi et al., 2006). The same argument applies to the
percentage of Pgp positive samples that were seen (24.3%). Pgp has been reported
to be expressed in 47% of elderly AML cases (Burnett et al., 2009) compared to
34% in younger patients (Pallis et al., 2011). High Pgp protein expression is
associated with low WBC count (Seedhouse et al., 2007) so it would be expected
that there would be fewer cryo-preserved Pgp positive samples.
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A recent study found that out of 171 AML patients, 2% had clones that co-
expressed FLT3-ITDs and Pgp, and these patients had a very poor prognosis
(Marzac et al., 2006). In our sample group 5% (2/37) of the samples co-expressed
a FLT3-ITD and Pgp. It should be noted that an IC50 for pHH3 inhibition was
achieved in both these samples. It was also found that FLT3-ITDs are inversely
associated with functional Pgp activity (Figure 7.10). The mean modulation ratio
in FLT3 wild-type samples was 2.13, and in ITD samples it was 1.27 (p=0.038).
These results agree with previous findings from our group (Pallis et al., 2003b). In
the two samples where FLT3-ITD was associated with high Pgp expression there
was no statistical significance in terms of pHH3 response to AZD1152-hQPA.
FLT3-ITD mutations are associated with higher proliferation and a higher
diagnostic WBC, in contrast to the low WBC count associated with high Pgp
expression (Kottaridis et al., 2001; Seedhouse et al., 2007). One explanation for
this could be a loss of Pgp phenotype under increased proliferative capacity as
reported by Smeets et al (Smeets et al., 1999). The authors report that non-cycling
progenitor cells, both normal and leukaemic, have a relatively high MDR
functionality. A direct link between FLT3-ITD tyrosine kinase activity and Pgp
expression has been suggested. Our group has recently identified FOXO1 as a
gene co-expressed with ABCB1, and determined that manipulation of FOXO1
expression levels, leads to corresponding changes in Pgp expression (Seedhouse et
al., 2009). FOXO1 is a transcription factor that mediates a cellular stress response
by inhibiting cell growth and up-regulating expression of molecules involved in
apoptosis and antioxidant defences (Tothova, 2007). Seedhouse et al suggest that
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FOXO1 acts on an axis with Pgp and FLT3, where FOXO1 up-regulates Pgp, and
FLT3-ITDs suppress FOXO1 (Seedhouse et al., 2009).
Tiribelli et al found a significant correlation between over-expression of FLT3-
ITD and ABCG2 and that this subgroup of AML patients had a significantly worse
prognosis (Tiribelli et al., 2010). This group measured BCRP by flow cytometry
using the BXP-34 antibody and they reported that 70% of their FLT3-ITD samples
were associated with high BCRP expression. Four out of fourteen (26.6%) of our
FLT3-ITD samples expressed high levels of ABCG2 such that no correlation
between FLT3 and BCRP status was found in our sample group (p=0.586). This
may be explained by our relatively small number (n=35) of patient samples
compared to the 166 sampled by Tiribelli’s group and also by the different
methods of measuring BCRP/ABCG2 expression.
8.7 Aurora kinase inhibitors in clinical development
There are currently more than 30 aurora kinase inhibitors in various stages of pre-
clinical and clinical studies and those in clinical development are listed in table 8.1
(Kollareddy et al., 2012). Because of their diverse chemical structures many of
these inhibitors have off-target activities, as has been demonstrated with
AZD1152, and its activity against pFLT3. One of the most interesting and
advanced of the aurora kinase inhibitors is PHA-739358 (Danusertib) which has
been shown to have good pharmacokinetics and anticancer activity in patients with
advanced solid tumours (Cohen et al., 2009). Danusertib exhibits inhibitory
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Table 8.1 – Aurora kinase inhibitors in clinical trials. (Adapted from (Kollareddy
et al., 2012)).
COMPOUND IN VITRO POTENCY CLINICAL DEVELOPMENT
PAN-AURORA KINASE INHIBITORS
PHA-739358 Aurora A(IC50) - 13nM
Aurora B(IC50) - 79nM
Aurora C(IC50) - 61nM
Phase II – Advanced solid tumours and leukaemias.
CYC116 Aurora A(IC50) - 44nM
Aurora B(IC50) - 19nM
Aurora C(IC50) - 65nM
Phase I – Advanced solid tumours.
SNS-314 Aurora A(IC50) - 9nM
Aurora B(IC50) - 31nM
Aurora C(IC50) - 3nM
Phase I – Advanced solid tumours.
VX-680 Aurora A(IC50) - 0.7nM
Aurora B(IC50) - 18nM
Aurora C(IC50) - 4.6nM
Terminated due to severe toxicities.
R763 Aurora A(IC50) - 4nM
Aurora B(IC50) - 4.8nM
Aurora C(IC50) - 6.8nM
Phase I – Advanced solid tumours.
AT9283 Aurora A(IC50) - 3nM
Aurora B(IC50) - 3nM
Phase II – Refractory solid tumours and leukaemias.
PF-03814375 Aurora A(IC50) - 5nM
Aurora B(IC50) – 0.8nM
Phase I – Advanced solid tumours.
GSK1070916 Aurora B(IC50) – 3.5nM
Aurora C(IC50) – 6.5nM
Phase I – Advanced solid tumours and leukaemias.
AMG-900 Aurora A(IC50) - 5nM
Aurora B(IC50) - 4nM
Aurora C(IC50) - 1nM
Phase I – Advanced solid tumours and acute
leukaemias.
SPECIFIC AURORA KINASE INHIBITORS
MLN8237 Aurora A(IC50) - 1nM Phase II – Advanced solid tumours, AML and MDS.
ENMD-2076 Aurora A(IC50) - 14nM Phase II – Refractory ovarian cancers.
MK-5108 Aurora A(IC50) – 0.064nM Phase I – Advanced and refractory solid tumours.
AZD1152 Aurora B(IC50) – 0.37nM Phase II – Advanced solid tumours, acute leukaemia
and B-cell lymphoma.
activity against all three aurora kinases as well as other off-target oncogenic
kinases such as Ret, FGFR-1 and Bcr-Abl tyrosine kinase including its multidrug
resistant T315I mutant (Gontarewicz, 2010). This mutation is responsible for up to
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25% of all clinically observed resistances in CML patients undergoing imatinib
therapy and danusertib is currently in phase II studies in this group of CML
patients (Paquette et al., 2007). Along with all three aurora kinases CYC116 has
been shown to inhibit VEGFR-2 which directly promotes angiogenesis
(Kollareddy et al., 2012). Inhibition of angiogenesis is a novel approach for
suppressing metastasis in the treatment of solid tumours and this has encouraged
further clinical development of CYC116. AT9283 is a multikinase inhibitor with
activity against aurora-A and B and also JAK2 (janus kinase 2), JAK3 and Abl.
Like Danusertib the compound was found to inhibit proliferation of cells with both
wild type BCR-ABL and T315I BCR-ABL (Tanaka et al., 2010). The pan-aurora
kinase inhibitor AMG-900 has been shown to be broadly active in taxane resistant
Pgp and BCRP expressing cell lines along with 3 multidrug resistant xenograft
models (Payton et al., 2010). This compound may therefore have an advantage
over AZD1152 in its ability to negate any MDR conferred by high ABC
transporter expression. Interestingly AMG-900 was more potent than AZD1152,
VX-680 and danusertib when tested in P-gp expressing cell lines (Payton et al.,
2010). Two phase I studies are currently recruiting patients to study AMG-900 in
AML and advanced solid tumours.
8.8 The future of AZD1152 (Barasertib)
AZD1152 (AZD1152-hQPA) has recently been given the international
nonproprietary name of Barasertib (Barasertib-hQPA). A phase I/II study of
AZD1152 was undertaken in a Western population of patients with advanced
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AML or newly diagnosed patients for whom no standard therapies were
anticipated to result in durable remission (Lowenberg et al., 2009). AZD1152 had
acceptable tolerability with the most commonly reported adverse effect being
febrile neutropenia and stomatitis/mucosal inflammation which were generally
manageable. The maximum tolerated dose (MTD) of AZD1152 given as a
continuous intravenous infusion over 7 days was established as 1200mg with an
overall haematological response rate of 25%. A similarly designed study in
Japanese patients with advanced AML found a similar pharmacokinetic profile and
minimal adverse effects with a 19% overall haematological response (Tsuboi et
al., 2011). The findings in both these studies are in contrast to previous studies of
AZD1152 and other aurora kinase inhibitors in patients with solid tumours where
only stable disease has generally been reported (Boss et al., 2006; Steeghs et al.,
2009; Traynor et al., 2011). A major topic of current research is the combination
of other cytotoxic agents and radiotherapy with aurora kinase inhibitors. Two
studies have reported that AZD1152 sensitizes cancer cells to ionizing radiation in
prostate cancer (Niermann et al., 2011) and colorectal and lung cancer cell lines
(Tao et al., 2008). There is pre-clinical data suggesting synergy between AZD1152
and the topoisomerase I poison CPT-11 (Irinotecan) in colon cancer xenograft
models (Nair et al., 2009). Another group found that AZD1152 enhanced the
effectiveness of the alkylating agent oxaliplatin, and the nucleoside analogue
gemcitabine, in colon and pancreatic cancer xenografts respectively (Azzariti et
al., 2011). Both studies state that the administration schedule of drug
administration is crucial when combining AZD1152-hQPA with another
chemotherapeutic agent. A further study, reported enhanced tumour growth
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inhibition in human xenograft models, when AZD1152-hQPA was combined with
the MEK1/2 inhibitor selumetinib compared with monotherapies (Holt et al.,
2012). This group also reported the importance of scheduling as AZD1152-hQPA
before selumetinib was more beneficial than when selumetinib was dosed before
AZD1152-hQPA. Synergism was found between AZD1152-hQPA and Ara-c in
our cell lines. A multi-centre phase II clinical trial in patients aged over 60 with
newly diagnosed AML is currently ongoing. Its aims are to assess the efficacy,
safety, and tolerability of AZD1152 alone, and in combination with low dose Ara-
c, in comparison with low dose Ara-c alone. Another phase II trial is similarly
investigating the effects of AZD1152 in relapsed/refractory diffuse large B-cell
lymphoma.
8.9 Conclusions and future work
It is commonly accepted that the AML phenotype results from multiple
genetic/epigenetic lesions affecting differentiation, proliferation, and apoptosis.
Consequently, targeting of a single aberrant protein is unlikely to eradicate the
leukaemic clone. Furthermore, although several molecularly targeted therapies
have been shown to be active in AML, it is clear from early clinical studies that
most of these novel agents will need to be used in combination with conventional
cytotoxic therapy. AZD1152 appears to be a promising new agent for treatment of
individuals with AML because of its dual targeting of aurora-B and the FLT3-ITD.
In particular, those patients who have an ITD mutation in the FLT3 gene should
benefit, as we have demonstrated that these samples have high levels of pHH3
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compared to FLT3-WT samples, and are less likely to have high levels of
functional Pgp. MDR AML cell lines are a useful tool to model transporter
mediated drug resistance but their efflux activity is extreme compared to that
found in primary AML samples. Most clinical trials with Pgp modulators have
been unsuccessful and thus the importance of efflux pumps in AML
chemoresistance is unclear. Clinical trials with AZD1152 may help to resolve this
issue, since pHH3 is such a clear-cut biomarker at the cellular level. In conclusion,
Pgp and BCRP expression levels, and pHH3 down-regulation in patients treated
with AZD1152 should be monitored in order to establish whether transporter-
mediated efflux is sufficient to adversely impact on the efficacy of the agent.
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Appendix
Protocol for measuring phospho-Histone H3 expression and DNA content in primary AML cells
and cell lines
Reagents:
PBSAA buffer (PBS with 1%BSA and 0.1% sodium azide)
Cell permeabilization kit (Abd Serotec) containing reagent A and reagent B.
Anti-phospho-Histone H3 (Ser 10) clone 3H10 mouse monoclonal IgG1k (Upstate) 1mg/ml
Mouse IgG1 (Dako) 100µg/ml
Polyclonal Goat anti-mouse IgG FITC F(ab`)2 (Dako) 1mg/ml
1. Prepare primary samples or cell lines as described.
2. Re-suspend cells at 3x10
6
/ml in 1ml PBSAA, put 100µl (3x10
5
cells) into each of two tubes.
3. Add 20µl reagent A to each tube.
4. Incubate 15 for minutes at room temperature in the dark.
5. Whilst vortexing add 3ml of ice cold methanol to each tube and incubate for 10 minutes on ice.
6. Pellet and then wash once in 3ml PBSAA. Tip off supernatant and re-suspend.
7. Add 20µl Reagent B to each tube.
8. Add 1
st
layer abs:
Add 200µl Anti-phospho-Histone H3 Ab (Diluted 1:290 in PBSAA) to Tube 1.
Add 200µl Mouse IgG1 control (Diluted 1:24) to Tube 2.
Vortex 1-2 seconds.
9. Incubate for 2 hours at room temperature.
10. Wash twice in PBSAA. Tip off supernatant and re-suspend.
11. Add 3µl Polyclonal Goat anti-mouse IgG FITC F(ab`)2 to each tube.
12. Vortex and incubate for one hour at room temperature in the dark.
13. Wash twice in PBSAA. Tip off supernatant and follow protocol A or B.
A Re-suspend the pellet in 20µl PBSAA and add to a slide to air dry. Add 10µl
DAPI stain to a cover-slip, add the slide and seal with varnish. View under the
fluorescence microscope to asses the percentage of cells positive for pHH3.
B Add 300ul of 25µg/ml 7AAD.
Incubate at room temperature in the dark for 15 minutes and FACS (collecting
25000 events).
